var title_f23_43_24240="Pulmonary hypertension MCTD";
var content_f23_43_24240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary hypertension in mixed connective tissue disease (MCTD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph of a MCTD patient with severe pulmonary hypertension associated with MCTD, showing enlargement of both pulmonary arteries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bull TM, Fagain KA, Badesch DB. Pulmonary Vascular Manifestations of Mixed Connective Tissue Disease. Rheum Dis Clin N Am 2005; 31:451. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24240=[""].join("\n");
var outline_f23_43_24240=null;
var title_f23_43_24241="Primary ciliary dyskinesia";
var content_f23_43_24241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary ciliary dyskinesia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross-sectioned axoneme from a man with immotile-cilia syndrome. The dynein arms are lacking from the axoneme, resulting in immotile cilia and sperm tails.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Afzelius, BA, et al. Tissue &amp; Cell 1995; 27:241.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24241=[""].join("\n");
var outline_f23_43_24241=null;
var title_f23_43_24242="Vaginal tubal sterilization A";
var content_f23_43_24242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vaginal tubal sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 412px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGcAVkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqnpeoRajDNJCGAinkgbd/eRyp/lVygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAxRRRQAUUUUAFFFFABRRRQBWsr62vWuVtZRIbaUwSgZ+VwASPyI/OrNc94WUR6l4kQcf8THdj6wxGuhoAKKKKACgZxz1oPNFABRRRQAVjpqFwfF82nNt+yrYpcLxzvMjKefoBWxXPn5fiAn+3pjf+Oyj/wCKoAi8DSq8Gsopz5WrXSH2y+7/ANmrpa5rwbH5N74mjxgf2q74/wB6KM/1rpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKzvEOsWmgaLd6pqL7LW2Te5xnvgD8SQPxrO1XXUXQbHX9Nl+06XlJ5TEN2+3cYLjv8oIb6KaAOiopEZXRWRgysMgg5BFLQByFjqK6dqXje4ZPMWzkS4KA8kfZkP/ALLXWxuJI0cdGAIrzSe7tpdd+KtrA+6aCwt2nXbjazW0mOe/ygV6LprB9OtXGMNEh4+goAsUUUUAFFFFABRRRQAVz1+DF460mUH5ZrO4hP4NGw/ka6Guf1ogeLfDhPU/aVH/AH7B/pQA3w42PEXiiLJ+W7if87eP/CuiriPD14sXxW8XabISJJbWyvoxyQV2vGx9jlBXb0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSMdqknOAM8DNLRQB8mftA6trPiC80x7PULqXwtrlgt/p0ayiKLcqqXjkUEFnU4cbjgFuh216L+zR4kGr+Erjw7qMaloI/tcAY7hNbTs5I9MLIJE9MbRWX4p8NyN4e8W+DraJhfaBcL4i8PMgAIgkZnKJ2+V/PjwexT0zXAfCTVJNKudI1HTLnbHpupzaRcsI9ym1ulE0O4BQSPOEh+XGAOM7hQB9IfDW8njsb/w/qUgfUdDuDbMR/HA3zQN+MZUfVTXUapf22l6bdX9/KIrS1iaaaQgnaijJOByeB2rz+81FdO8X+HvFJjFvaa0o0a+G4MvmZLWzhh1G7egPH+sGRnp1PixBqJstDA3C+kD3A9LeMhnz7Mdqf8AA6APHPhM+qahrnxeudWt3trjU7a2vY7aRcPFHLFcGJWHZhHsyOxyK9t8IT/avCei3Gc+bZQSZ9cxqa4bw2Cnx18fWki4W90zT5h7hRIn8ya6/wCHo2+AvDaj+HTbdfyiUUAdBRRRQAUUUUAFFFFABXNeKV2eIPCdzlvlv5ISAeu+3l6/98iulrnfF2Bd+G2JA26qn6xSj+tAHHarqDWHx/tEJ2w3Ol28TEdWLSXQAPsGVPxavU68T+KLyaT8VbfW/M22sWh/vwTtA8udijFuwDSAn6DFeueHtUh1zQdN1a0z9nvraO5jz12uoYfzoA0KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDg/iGw0PxD4a8U4It4Jzpl+w6C3uCFVj7LKIj9Ca8bbwhcaT8VfGXhffMLLXNPa+0t0cl45YXE0aICQPlJk2j29K+jvE2j2/iDw9qOkXozb3sDwP6jcMZHuDz+FeL67cXElv8MPGtyM6joup/2PqbHkqJSbaRmxx94A/wDA6ANLwzMnjvwDPbi7IfVbQbZ4k2rHejBDyJ1jkEiZyvyvjPBrsfhZqE/iLR28RanGsWp3Ba0lgB/49/JZkZPYlw7H/eHXGa4zQ7Kbwn481XSYQiwef9tsEgXZMIpWLSIpPyyLvyfLOCM5XpXT+FLiHSfiJq9jbPGNL15P7UtAFK4uVwlyhz/F/q3x15bpigDQfTY4/jHFqalvNn0F7Zh2wlwrA/8AkQ1f+G77/Amidfktlj5GPu/L/SsnVNbEXxn0LR44TJJLpF1NI4bHlr5ke0kd8lSK1/h8nleFoYs58ue5T8p5KAOjooooAKKKKACiiigArlviA5itdEm4Aj1i0yfZpNnH/fVdTXN/EIKPDXmyFQsN3aS5boNtxGaAOL+McMF1rNpY3FtNMbvTLko0SBiGikhk2gHgsyhgueAee1dJ8H4/sfgWy0vz2uBpjPZpM2MvGpzGeOP9WUrK+KImTxN4ZkEZksniu4bjHVciNkb3+ZcEejVa+H8cmlfYI5VkWHUbcgBgBtkiJAxjjBjIx7IKAO/ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvL/EOmRi58aeHnVhDqlmdYs9vVZ1wH2/7QdY347tmvUK8u8QatNPrsfiiKRBouiX66fu2j98kh8qds91V2QDHeM0AYPxD1aGGLwJ4slR0ttWjjsLvfB5w/ex741dR83Dg4KkFSSR6VoeI2vbjwrF4ht43uLjw3dJqFu6kvJLGMieMPxvBjLD5sEEDcOMmLS7O18RfBLVNH0yZLu60e4uIo/NG/99bzs6Ajrg4UY7g1s/C2ay1WGO9sBJb29zAJJLcN5kLZA4V/QZ+6+HXp92gDnrK3vJvjL4M8TXyKlxrllfKEibcsNsscbwxsehPLMSO7ccCvTPBLA6beIMZj1C6Q4/67Mf61wng7zNJ1HS/Dl0W3aJrE9pbk/wAdtJbySQnPsp29f4a7XwSpjfxDGcfLq054/wBoI3/s1AHTUUUUAFFFFABRRRQAVS1rTrXVtLuLHUF3Wsq4cZxwCD1/CrtZXisZ8L6x1/485un+4aAOJ+LRvB4g8JNA+2xD3ZuhjPmDyeE/EbiB3Kiuih0/7f4UgjsW8q8tJPNhYnIWZGP/AI63P4NXB/HrU3sPCPgjU4WQRLrVp5jucKsbxSAkn0BINei+Cbg3GiJmLbsYoHwMOBx1HcY2n/doA1NH1CPVNOhuogV3gh0brG4OGU+4IIq5XN3G3w7rE167FdJv3Uzk/dt5ugf2VuAT2IB7mukHI4oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMHx5ra+HPBus6uzANa2zvHnoZMYRfxYqPxqlpvhSJfhtB4Zuh96xEEzE7j5hXLPnud5LZ9axvH9vP4unGkaepltNLuLe6uyvSSZZUZIfcAZdvTCDvXolAHgGjXHiK5WbxTotssut2sj6bq9vaxgsJoTsdXjyPNQ43ggh13cZyRVT9njxPqdvLBpviPTp7fM82mrevHsUzL+9SJgSHB2H5fMXOBgNzis/wCOura78MPihYeIfDqCbTtb23N3ZjIEktsuHOeduYnGSOuCSDiun8OanB8Ro7u9sXNi/ifT1vrNHkDG0vbKbYcEAE9YT9B70AYem3mra3468I+Kk1a4lhutdudM1GxnCRRWzwiUQqqZJDbC5PJLFh7CvbvDBC6x4njBHy6grHH+1bwmvnrR9Qn3fEKe1tZIfs93aeMLOAxhsSIQ12gz/ECDGfTnpXuvg6+hu/Fniw2ziSGR7O5jdTlXR7ZQGHsdlAHY0UUUAFFFFABRRRQAVX1GH7Tp91B/z1iZPzBFJe31pYqjXtxFbq52q0rhQT6ZNMi1TT5ioivrVy3ACzKc/rQB5R8V7ezv/g14c/tdTLYm50z7RjJ+RmRGPr0YmpP2cXubTR/EOi6hctLeafqciur9cN0deT8rYyPxPejxrG1/8CdHVPNWTzdNUGIgMrC5iXgngHPrS+E2TS9SttbDeVGsa2d/EVxtibhJeeysqA+inNAHrc8Uc8MkM6LJFIpV0cZDA8EEelYGlOdCv00e5djZS/8AIPlbnAAyYCfVQMrnqvH8NdFWfr+nf2ppU1sr+XNw8Mo6xyqcow+jAUAaFFZ3h3Uv7X0W1vShildSssZGPLkUlXX8GDD8K0aACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxfFeoXFlp8cGn4/tK+lFra5GQrsCS5HoihmP+7jvW1XPWeNT8X3dyfmg0tPskXHHnOA8jD6L5a/i1AGpoumW+j6ZBY2akRRD7zHLOx5LMe7E5JPcmrU0scEMkszrHFGpZ3Y4Cgckk9hT647U7SfxR4neykuB/wAI1YIFurdBg3VySGEbN3jVcEqOpYA5wRQBxPxKHn6TZ/EW4M0MeiahbXFmm0kmxMgjmJU8jzEkZsdcInuKxra3i8IeM/EcdhGsNro+q22vW8aH5Wsr1PJugq9kQhnwOAVX6V6/8QYbK58Da9bamoa0msZo3XIBIKEDb75Ix74rwyO6M1j8O9Y1ZJIXnhn8EeIFlG5gxGxd5HAxKm7Po4oAu69ZL4X+PlpBcweZo2tb42BBK+VdZSSPsAPtGxj1J85fQ1sfs4XFwmoeJtFv5PMvdCitNLlO0rkQvcxoQOwMaIf1rD+OWn3+tfBbR/EVvvXXfDNwv2gxnlTG3lS5A54ZQ3XgZNb/AMMNTtD8Zdbu7MD7H4v0Sy1u3YA43R5jdP8AeyxJHagD2yiiq91NNDt8m1ecHrsdQR+ZFAE0jFEZgrOQM7V6ms59XEYJew1AY9IN38iaf/aiqMzWl7GAMk+SWA/75zTP7d00D95dLD7TK0Z/8eAoAUa1a/xR3icZ+a0l/wDiap3muW7oPsWq2EDjORdof5blIrWt760uTi2uoJTjOEkDfyqweaAOPure/urhpItR04yPgfuLqaHOPYMy/oafp2h6jFqEEt8sU8St8wM6ydjzzCpP59q6ObTrKYYms7aQf7USn+lVZtA0qXbusYQV6FBtI/LFAHm/jtJV+BOrMshtXsblpkcrnYIL/cCR3GEHHpWr8Mr6DUl1jTdSiikuSSzH7yTwOOoPcH17grTfG8dpd/B/xzBZR+UUt76KRGlZwHQMM5JOMgKce9Hwatt2i2d+8Bglls445I+QEZQFZB/uOHX/AHQhFAHTWN1JoE6abqkhaxdgljeNzwekUh7MOgY/eHv16OsnxbaT3/hbV7SzVGuprSVIQ4BBcqdvX3xS+E57e58M6VLZPM9u1tHsMzl5MbQPmJ5Lep9c0Aea+BfEmo6Z8U/G+haqgOiNqcf2S5wAIp5olkER9nHIP97I6uK9frnb/wAI6detr7SBw2spEs5H8LRrhHX/AGh8pz6qPSrXhPUZtS0SF70Kt/CzW10qngSxsVY/Qkbh7EUAbFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6/q0ej2QmaN555HEVvbx43zSHoozx6kk8AAntWP8MGuZ/BlnfagiR31+8t5cIhyFeSRm2577QQuf9mn6Eo13Wptek3G1g32mnoc4wGxJL9WIwD/AHV9zW5Z21ppGmpBbqsFnbJwCeEUckkmgCl4su7u00Sb+y2jXUpytvatIu5RK5wCR3Azk+wq3oumxaTpkFnCzOIx80jnLSOTlnY+pJJP1rLSZNa8SwmB1kstNQSllOQ80i/L/wB8oSf+BiuhoA5fxNpdnqvinw4l8jSeR51wibiFLL5ZG4fxANtIB7gHtXl/xX8Ptc6P8RvD0CBTc28fiWwCfeMqYEwAHJJMSn6y16+p+0+LXOQUsrQL05DyNnr9EHH0rE+IMK2moeH9c2ZS2uvsV2cHBtrj5GzjsH8s+2DQBl+EWsvENpq1jMEk03xHp8Wpqu0AMs8flzDHruAJ/wB+vN9K8Oar8NdL+GF94g279K1i40yQxS5C2t5uCmQjg7XwfQcfhv8Aw1lk0Hy9IlY7vC2sS6RJnOTZ3GHhY/iYwPYV6D8XtAbxL8Nte02EH7U1uZrcg4ImjIkj5/3lFAHS3Gm2dxKZJ4Fdz1LZqF9F09hg2wxjH3m/xrm/D2v6vqvhbQ9Wt44pV1CziuGXyWJjZkBKkhuuSe3arkvie4ttouLOJWP8LytCf/H1A/WgDaXSbRE2xLLGOvyTOp/Q0xNLaM/utQvQM5Ku4kB9vmBqvaa6Z4Q5sLkjuYWSYD/vls/pVg63ZIQJ2lgJ5/fQun6kYoAqzaROeqaZdc5/f2u1sfUH+lVRpTwyHbpEKDHLWd68WfwAX+dbdtqdjdHFte20p9ElUn+dW6AOaMcqH/j31+Eei3CSAf8Aj5qKSeRI1K3PiJB1I+yK5/H5DXVUUAeZwW/9oeAvH9n5lxukmvULyRiN23QqeRtA746Vj/BTxHJAtjo+qo0M1/bCaJnff5kyKA43dyUCt74J713Gm7TeeMraU5Tzw7KTwFe3T+eDXiPw2sbnUdA0NNNLx3AtY57KTdv8uRF9epVgMH0wB2NAH01XN6SRo3iO60kqVtLzde2Z/hVif3sY/E7wP9o+lXPCOsHXdAtr6SMRTNlJUByFdThsfiKm8QWMt7p5NmUW+gYTWzt0WQdAfYjKn2JoA0q5/R0+yeLNdtgAEuFgvVAPdgY24/7ZCtTR9Qi1TTobuEMocEMjDDIwOGUj1BBFZk2I/HdoQOZ9PlUn12SIR/6GfzoA36KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKQEEZBBHtVS4vTBfW8DW07RzAgTou5Fb0bHIz69KzL+K40W6n1KxjmubOU77u0T5mBx/rIx6+q9+o56gG/WV4qvG0/w1qd0hIkjt3KY67sYX9SKk8P63p3iHSLfU9Guo7qynBKSJ6g4II6gg5BB5BrO8fSpF4bYzyJFC9zbRyO5wArTop/nigDW0WzXT9IsrNBgQQpH+QArK+Im7/hAfEixttdtOuFU4zhjGwH6kV0NYPjLM2lJp0ZPm6hMlsMdQpOXP0CBqAK/w50Obw/4K0qwu5fNvxArXU2PvykDcf6D2Aro5ZEhheSVgsaKWZmPQDkmngYAA6Cud8RytqF/baBCrFbhfOvJB0jgU/dz6ufl+m40AS6G4t9JudVu9wN2zXbjbllTACLgckhQvHrTvFuljxF4Q1LTwpVru1ZYw+VKvjK57jDYq9HehtXksI0BEMCyuwP3SxIVcfRWP4CrvegDwLeb7xbZ3m3yx428PtAQ67SupWnzLnnjjdx6qK9r8N6j/a+gaff4KtcQq7KRja2PmGPY5FeL/EGKTRl1pIA4l8NanbeKrNYsbmtZGK3CAYxwfO4PqOleneCJkt73V9KikR7ZJVvrNlIwYJ8uAPYOHH0xQBS+HM8OmDxJoTssMOj6i4i3gIqwTATJj2G9hn/ZNdXDqmm3bGKC+s526FEmVj+QNeXeP/h14e1z4raTfeIoJ7qz1W3Ns1v9oaOI3EI3xswUgtlPMGCcce9dPbfCbwHbc2/hbTYz/eWM5/POaAOpuNH0655msbdj6+WAfzFQnQbQDED3dv8A9cbl1/rWO/gHSo2DaXc6rpbryPsd9Iqj/gBJX9KdbWPivS5P3eqWmtWv/PO8i8iYD2kQFT+K0AW7zw4Z3DfbFmIPS8tYpx+e0N+tUm8OXUUjGGDTSuOBC81qfzVjj8BWTd/FjRtEuY7bxnZal4anlfZE17AXglP+zLHuX/vrB9q62HxFpUtvFOt0FhlXdG8iMgYeoLAcUAZKWWqwFVEWop/tQaks+P8Av8opputVilZTcaqEHAMmnJIPzQ810VtqlhclRb3ttKW6BJVJP61coA4nw9a30/ifxBLNeK9tc29ufKa1MTElGXLZORjHTFeLfsqvNFG2n3UiPJp17NBFv6BWByFPoWDsD6hxX0TZJt8S6o+MboLfn1wZK+fvhx5vhDxjo0jyQvp15dXel3odNpikNzK8Gc9wzEBu4kPpwAep3EEngrxmb22Pk+GNSGLqIjMcE/aRMfcz3HQ9Rgjn0MEMAQQQeQRWb4g059SsGiikVXGTskGY5QQQUkHdSD9R1HSsbwDqaPayaNIjwXWmhY/IlbLrH0UEnrjpnuMHvQA/wQrSXfiO881jHPqciJCBhI/LAQkD1YqST61heK9X1PSviz4fk+zmXQTYyQXUnT7PJLKio+e+SFXHYEntW94P8211fxNp1xGE8u+N3CRnDxTKGB/77Eg/CtfxJpw1fQNQsDgG4hZFJGdrY+U/gcH8KANGis3w3fNqWgafeScSywq0gxjD4ww/A5FaVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMniSeGSGZQ8cilWU9CCMEVy63T+EClvqMjP4fJCQXjkk2hJwI5SednQBz06N2NdXUV1bw3dtNb3UUc1vMhjkjkUMrqRggg9QR2oA8k8Q2eveCfFl1r+hpDcWGoT+ZcWaARRXWeNp7JP/dl4WThXwQpMnjnWYvHGm+Hl8ONJdW8V0NUurYJiQi2kQGCRDyrb3GVIz8tbwVvBx/srWiLzwZdAW9vPOu7+zwQFEE5P3oj0WQ9CdrdjWD4g8NX3gzxIfEvhWKJ5ZkS3nSd8R3EYPEcrnlX4ASYnHRX4wwAO78faxd6B4XudUsY0ka1kiklVunk+YolP4IWP4VFo8y674jutTjKyWFhus7V1ORJIcea49hgID7NSWWoaZ4/8IahBbvNFFdRS2N3BIuye1dlKujqfuuM/ToRkEGj4X2UOnfDjw1aWygRRafAvAxuOwZY+5OSfc0Abuq30Omabc3tyT5UCF2A6nHYe56D61neGrO4trW4v9VbGoXpE067vlhAHyxj2Ud+5ye9QeJD9t1jRdIHKSSm9nA/55Q4IB+sjR/gDT/GM7mwg022Yrc6pMLRSp5VCCZHH0QMfrigC5oUVpJHNqdpHKraiVndpCckbQq8HoMAcD1qh4n8RS6fcQ6Xo9p/aGvXSlobbdtSJM4M0zfwxg/ix4UE9LHiXVhoWmRLaQLNfXDra2NqDtEkpHA9lABYnsqmk8LaENGt5pbmb7Xq14wlvbwrgzP2AH8KKOFXoB7kkgHmXizw7LoPijwxr3iLUpNVl1ad9A1YsojhNvcowSNI84SNZFX1YluSarfCvVTp15ZabrN15GpeHnk8O3AlVv9LhMii1lTGRj7qknpuPTIrO+N17L430/UrDSJm8uxtvtunso+aS6izLvjx1/dBlB/6aDqa80uNdh1r9oCC9tJTZt4q0m3V03q5hnkt0aBcrnH7yOBjnB69uoB9I/Gpruy8DT65pkayX2hTR6nGrcbljP7xc9sxl64bwv8ZYb+S3S6vrdHkEZiTfnzCOqZx951JI/wBpCM816xZTQ+LvBSOy+XFqliVkRl3bN6YZSD1wSQR7V8z/AAY+GPh/xhpNxY6xf39vq2mzSQutqywZCOADgDO5WTPOfvZ6k0AfR0HjjQpFyL+JgA5yGHJVQ2AM9SpyPoR1GK6G0uoby2huLeRXimQSIw/iUjIP614nqXwFeIzS+H/FV7DLI5k8u9iWaPdyRjaVK/Md3fnJ7nPK6xL8Uvh2tsz6N/aGj2T70n0yY3OzJO/KuPMCNwSvAB5BFAH0pqFjaalZy2mo2sF1ayjbJDPGHRx6EHg15pq/wtudJiln+GWuXXhyZm8xtOMjSWEzZyRsOTFnoWT8qf4A+Nvg7xbaxp/aQsdRVFM1vdoYtpPXDHKkZ75+uK9NgmiuIVlgkSWJxlXRgykexFAHlFj4k3Xy6V4jhubHxAi5exvbe3nW4THMsMo2ean0+Yd1FaYmt4wG+zxRZ5Crb3Voc/8AANwFdZ4v8LaR4v0eTTNes0ubduUbo8TdnRuqsPUV47NBqHgjW7fSvE4+0WEn7vTNbjjjjE7HpBOFCkTejFgH+uRQB2vhyZ7r4jcXUwQaYziJbt5EJEoGWVlBH3q898IWn/CYSaxaarDPDLFqVxYalAHA2sJtyTwsem1nxz0yOxrsfDVzE3xG0eaP7U81xaXUEnmMSFVfKbkF2A5HauA8Eaklr+0B450oSSrcNqH2xY87lliOBKAndgGVuOqhv7ooA938Kay95Lf6VqGV1XTJBFNuGPOjIzHMPZh+TBh2rm9Xhbwt4ntdYui8tsEa3W7bJYRMwYwSHvg/MjH0Knkgnb8YafNBeWfiPTEY31h8k8ajJntifnTHcj7w9wfWrfi6zbXvCV3DYmOdbiHcqZG2ZCM7c9sjoexwaAH6kVtNd03Ulb91cD7FKQeCG+aNv++ht/4HW5XIeHLpPFngmS2eZftMYNtJInG2RcFXx2P3Wx2OR2rd8OagdU0W1u5AqzspSZFOdkqkrIv4MGH4UAUPBLqLLUbVCcWeoXEIU9VG8uB+Tj8DXQ1z/hvaNb8UouBjUIyQPU2sBroKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAI7mCG6tpbe6ijmglQpJHIoZXUjBBB4II7V5dY+JtN8HeLpvBOr6hHcaQ8KyWzXbfPZpISFgkLf6yI4wr5O3hG/hJ9Vryr4p+A7Dxf4lii1CATC50144wpCNujfJ2v1Vtspx2OCGBHQAl8Q+Gr/w/rMOseH7sWzJhBJMSYpE6Lb3I6lOfkl5aPocrW38JtWiuvCVjpNwzRa5pFvFa6lZyjbJBKFAOR3U4yrDgjpXA/D3xbf+Br+18HeOpprjSbh/I0fW7hNobj/j2uM/ckHQZPP0wa67xr4Ykjni1PT75tNvLQk2mpKu77PnrDMv/LS3J7H7vUY7AHQ6Nm+8X65fsD5dqsWnQkj0HmSEfUyKv1jpmig6v4q1DV35tbIHTrL0JyDPIPqwVP8AtmfWsCx+Im/TtUsNUtl03xfZQgnTy25Jyx2Rywt/y0iZiORyOhANamsCXw14JstG0qUf2rchLC1c8kzOPnlP0G+Q/SgCbw//AMT/AMSXmvSHdY2Zex00djg4mmH+8w2A/wB1Dj7xql8WNdgsvDd9pyXy2l7cWzsJCygRxhWZsliNu5Y5Ap9R7V1Vja22haJDa26stpZQBFAGTtRfbqePzr5j8Utd/FH42J4aeeQ6fGEuJ4Y96Ytwd8bMRwdqMrLn+K4I7YoAf8MvBuufEPVxrcGu6vpfhSBgiXEOLae+dTlvLwM+UGyNzE8Kq4yp2+X3HhG20Dx54i0vSJAde8M3Z1HT/wB8c3sMREhjx/z1VBv+XH3XGDwV+8NPsrbTrG3srGFILW3QRxRIMKigYAFfPv7QXhOEeLrXxJpMdxHrEMSyE2ybWkwccFcMWx1yGyCRxQB6b8IdXh1LStRW2fNsbr7daKRhhb3SLcICPZpJE44yhHavObGx/wCEQ+MfibyY/llvk1Zd748yO4X58HttdZcj0wf4TVH9n/UptG8avospDWd1C8cHl52Qjm4ijPJxhZJgATnt2rqf2hbafRrjQPGVku9LWZdN1GIkAPbSsNrZPQpIAQfVvTNAHtAIIBByD3orE8FX1vqPhbTZ7SRJE8lUO0n5WHBU55BBGMVt0AcN4w+GWgeIZWvYrdNO1lT5kV9bLtZZOzEDGT78HHeuSm1TT/BOoW9l4k0m88PyzEJFrmlOHtLlgB80q44ckcqyN3OSMkezVS1rSrDW9Mn07VrSG7sp12yQyrlT3H0IPIPUHkUAN0f7b9l/0+4trrJBimgQrvTAwSMkZ+hxTfEOi2HiHRrvStXgW4srlNkiE4PsQRyCDggjkEAivOtIl1H4Y6pFpWq3NzqHhS7mb7Jfyq0j2ZONsMhyeM9CFAP14r1YEEAggg8gigDwTwpYan4U+L3h3wxqL3d1bxJeSWV5IcrPbmJcZwf9YpAVs4zkHvXI6/ZpYfGn4gaxDbxtfaZf6ZcW1xkh4WeBmIOOsbjKN1+8p7V7n8WNLvZ/Do1rQDt8QaEWvrI84lwP3kLDusiArj1we1eEaT4psPFPxK8RavZ27PpmtWlhJI+3Jt5BA0bRsRz1LIwHXr1C0AfTugapDrejWepWwZY7mMPsYYZD3U+4OQfpWdpn/Ek1o6TjFhd757I9kYcyRfTnevsWHRaxfBFvP4dsrQXMhbT9Qb5d3WCTomT3DKAM/wB4D+9XYarBJNZSG1SBryNWe2My5VZdpCk9++OOxNAGZplouj6/eQQhVs9SZrxF6bZ+PNH/AALh/rvqj4HPlav4vs1KmODVi647ebBFIw/76dvzro7JnuLS2nurfybgoGaNsExsRyM/mKw/CEITUvFEwPMuqEn8IYl/pQBD4Wdv+Ez8aRGZWAurZxFtwUzbRjJOeQdvp2NdXXG+Grm3HxF8Y2vnp9rP2SbyDw3l+SF3j1GQR9RXZUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVa4luI7mARQLJbtu819+GT0IGOR1qzWZr1zqFlZm6020F80QJe1Vgsko/2GJxu68Hr6igCfT9StNQ3C1lDOnDxsCrp9VPIq5XJaXrXh/wAaxulrNLBqVsdrwyA295at6FT8w/VT70CfxVokqrcww6/p+4AzQAQXUYz1ZPuSY/2dp9qAOtrA8W/6OumakB/x5XiM59I3zG36Pn8K1rG+tb6Nns545gjbX2Nko3ow6g+xpNWs01HTLuzl+5cRNGfxGKAOb+Ivh6DVvD+oObWG5JhPn20q5S5jXkqfR8Z2uOQcdq4bwJ4vk8OXNt4d8U3TXOhXuE0nUro/OgYZW1us9Hx91jww75r1DwpfNqfh2yuJgPOMflzDrh1JVh+YNedeO9Ai1nwL4k03Cfb7WU2MT8ZaKRkMavkHgCQAHsVyKANvxR8M9I1fTrbdfXVlNptyL7Tb2Nl32BUA7VZgcxZGSp4+mBXm99468RWHxv8AAem+MIbO1sfKmiW/t2329+8qFVlTP3MnyxjJI3HnBrU+GPji+8L65H4B8el/+eWlajPj96gHEEp/vgcBv4vyz0HxF+Hmlaho89lfWzy+HpGMo8oZm0uX/ntB/sf3k6dwMZFAGn8ZPFMvh7RIIbKCS5vruRY4IIWAeSQkBEz1QE87+g2YPWsL9nzwSvh611nVr4RS63e3LQXNxG+5XMbHeU9FLlhgAcKtZfhzV7nQPESW3xBmt7nUdP0t00LVVX93qcfLuwY5xNhYwUJ55IzmvXfCVkdP8NabbN/rFhVpOc5dvmY/mTQBrVwPxIzJcRRy2sk9mYsSPGA4jJP8aHKkdCCQvs1d9XE+Mmgj1a3mm2qw2xrI6vEVyeQk8YJB5+6/BoA4CSystO8VaHFp8gjUHTrxl5BY+fNEDkkkja5HJOABzXSfHDxv4N03wNrml69qNpcz3Vq8SWEUoaZ3I+XgZK4bB3HgYrwT9p2yfxF8XRYaU8YbTdMhtiqyRqTIzO4UBmXOQ4zjOPSsbwb8KFuLCBr+0ke7nJQJOrRjnGCCCVwCFy2ekntQB6f+zX8TC3h9LLVtrRRTCG4nB5idvuSP/ssAAW/vKSepr6WBBAIOQa+RLvRL/wAFala+IfDumRQyWoKS2At9qahbs3zxNgfM4YEAgHHy1734J8RwXeh2+q6C01/4cl3B4SCbnT3H3oyp5YKeNvUdsjFAHoFFVtPvrXUbVLmxnjuIG6PG2R9Pr7VZoAq6rp1nq2nXFhqdtFdWVwhjlhlXcrqexFM0TTk0nSbawikaSO3Ty0ZgAdo6ZwAOnFXaydU16ysIm2sbq4BwLe2IeRj6AZ/nigA8UXs2n6PJNamP7SXjSJHHEjM4Gz8c49utfE3gKxl0H4xa1BbOsVkt9c6bAZciK5kEuUg8zorsFypP8QFfS/xG8Xy6BpUHiPUtFu4pITtsrPIaWWZsogY52r1zgbmwKw/hx4C0mb4WxRamo1CDxJuk1W5Yc+eWPlyRk9FRuFI9Q3egD0bTBbpp8VjcCR9Jvl8tPOG17eb+KJvQ5BII6MMelbGh3khebTr5s39oBuY8edGfuyD64wfQg1wnwm1TULyz1XwP40H2jWdFxE9wxyL23OfLlHfOMAnrnBzXS3EN7Hcxwh0OrWoY2M8hwt1F/FG59cYz7gMO9AHSWlnFaNcGHf8Av5TKwZywDEDOM9Bx06VkeFF23Gv9edTkPP8A1zjrV0y8F/ZpOIpIWJKvHIuGRgcEH8e/esDwLdXF3L4le5tzAE1ieKP/AKaIqooYfXB/KgA8SfuPGfhS4RV3yyXFq7d9jRF8e/zRrXU1z/ilM3/hyXjMeojt6xSD+tdBQAUUUUAFFFFABRRRQAUUUxpollWJpEErDIQsMn8KAH0UUUAFFFIGBYgEEjqM9KAFooooAKKKKAOe8W+ENM8T2xW7WW2vAP3V9aP5VxEexVx/I5FcVFca/wDDe2lbW76XVNCVuLuXdJ5Q7mQ4LRD3+def4RXq1NJDZUjIPB44oA5CD+wPFDxXUW6x1SRD5VxDIsc7L6pIhKyL9Cy+tXfO1/RgouYxrdmOssKiO5UepT7r/wDAcH2rmdf+GEcMlzfeBbuPQr6Z/Nms3hEun3T+rwn7jHGN8ZVh71BYeM9Q0G8i07xRZvpE7fLELycSWlwfSC77H0SUBvegDtvC8mlGC6GjzbhLO88sTfK0bscsChAK89iO9c1ryxzN47WFgHiht5mx2dELj9FWt7y9H8SSK5R4tQiUSB1JinjB6EMOq/QlT71h3Oi6xpNpr8XOsW2qh2ecALcxEoEAKDCuoAGMYPXg0AR/GDS4rrwLqusx21pNdWenzSmO4j3JNGIySp7gjqrDoRXLfAjxtfL4W8PaZ4rfet1bxx2OoMCN7bciCXPR9uCrfxj3yK9KtLuw1/w3PYxSLM8lq0MsEqFH5XadyNyAa8m+H1vY3/hqw0PUkjKi2itbuGRyVckDHzHkEkbkfswZc0Adv428L2P9k3dlqNh9v8J3RLXNsq5ksXP/AC3h7hQSSQOV6jjIpfCXiW60fUbXw34qu47k3Azo+srgRajH2RiPlE4HUDhhyO4q94f1a70HVYPDXiadpnmyNM1Fx/x9qOfKkPQTKB/wIDI5zVXxb4dsrbTLq1u7JrvwpdEvdWyZ32L5yJ4cchQfmIXlT8y9xQB3ksixRPJIcIgLMeuAK4aCWPVfEf21o4YrWLMrXVvNneE5GXjYZHqsi1zya1rujS22g63qRvYp0/4lmpJAzjUouCAXiIKTqOSRkOo3AdRXN/F3VbHw98N9Vl0yaA6/4gb7AlytyHcIB+83OyqVAUEHPOWGTQB5Ra3EvjD4n6zqDQ3UtrcXjXBEdmJJlhO2NCUzjG1YmyR3Jr3HRvhjpFta299qc+prEzB4Ut2kXZwc7lUcDODg5HA9K4z9nz4fx39zb+KmutUjbcreXNcLLlRgoGO0NjadoGSOPpXu2oa9E1xt0/V9LRI8iUSAyMG9trCgDlNQ8Jwa7bR239uQaikchmRLj5JQzDDkMuCuevQ815bqSeK/hv4rn1TS4orb7RMi3sTKTZXS44kkI/1bYH3wBznINe4tei9AE8mg3+T91iYmI7Y3Z5qC802wkbNzHfaU+wxklvNt2U4OO64yAR93GKAKng/XPDfjUy3WkyyabrKkC5jglCuWA68ZSVeeG5HTp0rrLK31iC4Rbi/trq1GdzNblJT6DIbb+OB9K8d8S/DB7if+0NBvF0q6lLCOVSWtWl4IOFPyq/qOVPHTAPBz+MvjH4QFxpGqO8122Wt3mhikbg/wMcCRCM87iw7gdKAPpq6sdXkunVNRhNjIwJUxFJYx6K6sM/iPzrE8YavpXhTS57q5n1O+uOkdhaztJPMx4CqgOfx6AV47HN498caTEdQ1fV7KSUANpqSx6Zv7EpJ5e519gxHSuo8OfDu5jSSzuE/sppV8tnhgmleXI5MkoYK31NAGJPpepeOtZs9T1q6+zix/d/ZPMMNtZoRkoHPzSykDaxXoCRnmva9N0lR4amtBOZhcqzKdpRI9w+VUX+FBxgVQ8CeErDw5aSRW80N3+8JL+WMo44bnJx0HAxitnxNJJFos0kEjxujRtuTrgOuR+IyKAPLvFeqr4f8AiD4C8Uecos9YRtK1B9uNzFd0bY7YYHPsK9Y1SzF9agIwSdGEkEuM7HHQ/TsfYmvFf2irFJPhdobw20t1e2msQta28OcysGcFcAZ+7n8s12Pwm8WDV7CwsXnM6tZi4tZnG1pIcjaW/wBsKwBA6Fc9xQB3Gk34voX3KY7mF/KniPVHH8weCD3BrE8N6hbQeJ9d0Dc4vI5P7QCMvBilx8wP+/vH4Vf1dP7PvYtXiQ4+WC6C/wAUZOA2O5UnP0LVha80dj8T9Bv1BzNZy2M5HTa8iGMn/gYx/wADoA2vFWQ2isO2pRfqGH9a3a5zxpPFCuiLJIqPLqtukYJwWOScD14BP0Bro6ACiiigAooooAKKKKACvP8AxD4Zudd8bamNkMFo+m2CfbJLYu6sk9yxEL5AVxlTnnG5Tjpn0Cse/wDEdhY3F3BcGUT23kZjCZL+c5SPaO+WBX6g0AcQz6/ILlUudZtr1orsX0jW0ssUZ8wCEwLjDfL08vnbkt8wFN06HUJ9W8PXt3aavAlvJdwIxe5lDMxhMZfeokWNirA+YMDHXGDXUz+N9JtdTvbG9MtvNaxSTkMUcyIjBWIVGLDllwGCls8Z5qSLxVDNdQ232We2uDfLZSw3IAZGaEyjBQsD8oHfv68UAcRpzeKW0ebzL3Vk1KSO3W5jFnNujmM8YkdHcGPhTJxHlMDOMDnVv7fUrLWriKQ6u+jfaIFuLi3SRp5I/s8nIaNd7DzPLBKcjjoM1vad41sdQsmube1vghs47+ESKiGeF+Ay5bAweu4r69OabpHjC31rU9Kj0wK1rdJdeaWIZo5IWjG0FSVI+c8gkHjBoAz/AAxDrt3rNo2rXOpxW0FikioQEWVzNKB5h2/f8sR7lBHJ5HSu6rj7zxbNa+Kb+xktJPsVoIYhsi3vcTS/dVDvAXqOoI4YkqBV2PxfYSXNlbJb37Xd0ZlEC25ZojE6JJ5mMhQDIvOcEcgnIyAdHRXIP46spdKuru2guIwtk19A1ym1JowQCw2ktgEgHIB5GMjmtW28S2FzrLaTF5x1FHdZYDHholUA+Y3YIdy7T3zx0OADaopBnJzjHasrVPEmj6TqNtY6pfw2dxcqWhE5KLJzjAc/Ln2znpxQBrVBf2VrqNnLaX9tDc2sq7ZIZkDo49CDwanBDAEHIPQiigD5vitfF/gu+11PB866voqalPB/wj107RvHD8jAWknGNof7oPGB8pNd14A+Kmm67ILOG4llu0JWSwvAIr6EjqAv3ZgPVefUV1fhm1hvJ/FUF3EksJ1ZvlYZ/wCWEJ/A5PWvKvEvhHTItS8YG4t0ujDdG6hkcnzoz9nid23DnA3A7h8wHPNAHtb2+l67HHcJsleM/JNGSskZ9MjlT7GvNNU8B6hompRXWnxHVNNCSRzFSPtSoXLgbDhZQCzDHBweOQDWPr3iY/Dy20+/1XUZL7TJ4t0NyZV+04G0bUkHyzjnIV+cKcGvQfCfj/Tta05LuK5S7stqsbuFCvlgjI86I/NHkEHPKnrnFAFprzw3400uXR5bgGTAzbSFoLqBl+66q2HVgcEMPzqr4W8TfZdZHhXxDqNtPqyhjZ3QZV+3ov3vlB4lX+Jf+BDjIGx4m8L6D4x05I9Ws4LyPG6G4RsSR+jRyLyp9wa8C+MHw1+IllpDf8Izqra3pOnyx3dsJju1SEoOivt+fHUbSGPTB7gHsPibRLXTrG5iubd5/C1w3mTwx58zTpM58+HHIUHkgcqfmHGRXg/j/wAJ+J/EXxBgtfFMkd/p0Nsp06+tpzFJd2q5LuAuVeTG1nA5+VSoIr1T4CfE3UfGMV7ofi62Ww8UaYi+dBKjRSzp3kMZA29QCB3IOACBWz4z8MW1tpskT/aF0Ay/aFe2OJ9HnBJFxAeuzJ5UdMngqWFAFjwbcyf2Na6b4bltblNvmSX4cyRwqfujBALSY/hOMY59K6aDRGQhn1K9aTOSUKIpP+6FxWDpGt3Vjdx6TPYw3WpzoZ47yApDFfxgD94p6b8EblGcdRwRXT2F5dXDAT2LQKRneJldfpwc/pQBGLK6EirLcRXcBOGW4hG7HsRgfmKtWtjb2rubePyw4GVUnb+C9B+FWaqahZm8VNl1c2zochoHA/MEEH8RQAw6XaeYzpH5YcESInCSAjoy9D169ay9agtbi0k0nUtAuNR04KoXISZWwP8AabcCPU/nWhHa6nFnGoxzennW4/8AZSKhk/4SAHEf9lEf3m8wfp/9egDmtE8PWWkXl1Jp2i6o1tOmDaXLo8Ybjld7nHA6VduNFvHEghK6Rp5yZEW4wOmMkIAen+2K21ttYljAuNQtoW7/AGa2OR9C7EfpSx6HaFxJeGa9lHO65cuAfZPuj8BQBH4aa0jsEs9P3SW9uoH2gRhUkY5ztx1PqR69TXL+OdVbUIobXTtxkttT8idM8OFQHt2zJH+Nd7I8cELSSMscUalmJ4CgD+VedWUcQvbC7kn+zSyXbzeWEy88s8gkMIB7hEj3H+Hn3wAVvFMc58c/DfRLyRXlM13qDtGDt3xIOo/u4lYDPfFc3Bat4M8crp8bDzEvpLjTYx/y0t5Y3b7Pz7q4DDuij0ru/D2lXuofEvW/FF8qrYw2y6XpSlSH2Bt07kH1kAAPdVB71wPxjhW51jRtcvJoY5tE12WxjkdvLG2W0EkYLdiH2gN/CWzQB654Z1v/AISDQ4ruAeXJNbpMrbDtw65UgHn8DVPSXupte09tTSNb3+zGE6xkFRIsihse2elcj8DrkQPqukszgxpBPGjMf3eVxLGARkYkBYg9PMA7Cuq0K0n07xRqC35jC3NxPJYkHJeNlhZs+mHDcUAU/ijbea/g+5BINp4htJOO+8PF/wC1K7iuS+JS50nSmzjZrWnN/wCTUY/rXW0AFFFFABRRRQAUUUUAFY+p+HbLUdd0zVrgyi5sN2xVbCSZ6bx/FtPK+hOa2K8/8UNrp8WsIrm8tbNEga0aC1nnRjuPmBxH8uTwP3nABBXByaALdz4Asvs06xXF5OBDcpb20sqRxo0zBz86x787lXDHcRjvT9B8LXCXUl3r140t+9+t+gjkVvuQCEBiI0DDBJOEXGQOepxJrnxR5uti3/tY2ywznSCYMO5DDf5mf4l5EQfAZeTk807U0uWniOhza9FbCwvFa6urO4lljkMtlhRvXzcMok6c8MV+6MAG8/gLTG03T7MXF6q2Nnb2UL7kLBYXV0YgqVLZQZyNp9Ks6d4bsNJ1G2vJL+5lujLOVa4eMea82wuMBQM/ugQBjv8AhxVxN4jns7FSuq6bZBLgLKqXd0/miQbHIAE23bkqsgK9Q2flzdMWpXfiXSn1KPVZLyDVlcFYZVtVtvsrgPgfuwdxOcncCcdMUAdff+GLS8uL24M1zFcXMsEwljZcwvF9xkypH1BBByRjFGl+GbTTtQtr5J7ma6ijuUaSUrmUzyRu7vhQM5iUDGABkY6YxfFlper4xtL6wS887+yrqG3aNXaL7RujZFk2ggA88tgHb7VY8EPeNe3WTqrWH2WAk6mkiyfacv5u3eAcY8vOPkz93vQBM/gjTX0yGxM955MWnPpgIdd3lMykk/L975Bz068VctfDNtba9JrCXV4b6Vm852dSJYyPliYYxsTGVxgg7jk7m3cS8nidZ9ake41FL9UvwlulpO8bqFc2/lvzECAIyNvzEkhsnOF1nTtS85Ypzrc1hb3Wn3hkXzZJAxEqzFMAsQDsJVfu5zgUAepVQ1rRtN1y1+zavY295D1CzIG2n1B6g+4rz+OTxH/bOoNLc6jHMr3gjhFpcPHJAEk8ja/+qVv9U2fvltynrXceFbW4ttBtBfXN3c3UkaSytdkbw5UZGAABg9scUAce/wAPtS0E+Z4B8QXOmxjkabefv7Q/7IB5Qe454601fiBq/h/CePPDk9nEDj+0NOzPbn3Kj5l9h8x9q9JpCAwIYAg8EGgDjPhrrOn60fEd1pl1FPHJqjuNp+bHlRLkqeRyp6iuY+Oxj8NeDdZ1iKZlkvZmMit0J+yPGEz1AbYmfepdC+HOha1pR1W3hn0jUpru7mhurGQwuqtcOV6dBjHTFeZ/E+38XWHg3xO1/e2+t6PBqSI88w2zqIlTPGQpG0lSOT3znqAZ37VGjw3V1ocdg32aWVEjFsG2wvNIHb5V6BjsVSeOXUmvVfh1b6Dr/wAOfAkkbTWmpy6VHbW+pWx2SrJAgR0Ld+VbCtkEKeK8c/aA8Zad4ourS5ihurO5s9OYLaXsRUq0hz8oTJydqENkfdGcZNeqeGdNj8BeFPD2jXkVyujalbwTLqEKlxp2oeWmSR1CO4LA9NxYHhqANy8vtW8EjzdYBFpuw2qWduXtWGOtxbqd0J9XTK+uK7LRvFFjqK24eWFHn4hkjlEsFwf+mUo+Vvpw3tTI/EIgtWTVraRLq3YJdpGu4KnP74DqYz6jOM89DXL6z8ObaZLjUvAV9b6RNeESz2vlLPp18c5zJD0UnGN8ZVu/JoAxv2lbXZ4ZttVtIDFqliJp7XUbdzHc2siRtIMOOsZVXVlOc7l9M1rfAz4p2XxK8O5kCwa9Zoq31t0BOP8AWJ/sMc8dQeD2J8j+Md5rdp4Yk0rXtK1n+2DG8GnWcTG8snLgrLPFMB5p2xlgI5eV35+YdOj/AGN9CjtPCutaq4DXEt0LJX54jiXcQAwBGXkfIx2HpQB6XrPh37AslvGsreH5n81BBkTaVPniWHHOzJyV/h56qSKh8P63aeZJpF/pjS6oLdXlewjDRXUDHCzpgj5WIOQOh49Ca3xF+L2j+BfE9poeoWV7c3Vxa/a90CghU3MoHXOTtavOtc1iLTviD4e+LGiQyXvgP+zf7PujZj95Zgs+d8XYBmUkdiD7ZAPZ7UGBl/si+mt2J4stQVtp9lLfMPwJHtV4+IrW2Vl1ZW0+ZPvLLypH95WHDL79u+Ki0zxLoWuwwNbXdtc21yoeCTIMcw/2T0JHcdR6VrahY2uo2rW17Ak0DdUcZH/1qAGyalYxPbJJeW6tc5MGZAPNxjO3169qS/1Ox08xi/u4LbzOEMzhAx9ATxn2rmLjwRDCrLYOxtz/AMu7vtB/HBVv+BKfrUqeCoVu4XW6ligBLSRxFo2ckHurBQMnsooA3X1zSlOP7RtGb+6kqs35DmrJvbdbUXMsghhP8U37v+eKh0zS7bTVcWwkLPgs0kjOxx7kmm32oaZHHL9subTbEcusjr8pHPQ96AKd0k2t3CwFDHo64aRm+9cnghVHZPUn73Tpk1sPBE8scrxI0sedjlQSmeDg9s1yUOu6j4pt4l8PWtxZafOMtqk+zhOn7pASSx7E4A689K6Ca7sdDtLWC5nMce0xoZGLMQiFiSepwqkk0ASa1frpek3t8y+Z9mgefy84L7VzgfXp+NeF/tB2Vtd+Eb+a+mjXT4fEUN7MjsVWaNIoYHU7ctjLkccgiup1HxFHriWWqXkb29pMwggg3ZLxh1eRyAOrGOONfcmuI/aR8Q6dpfw9t/DUk9lJruqTl7lW5FurNvkZiv3cMUwO5UHBxigC58Ir24S/s79pvMnvZ5byVp2GRbuwQBpBjc21omAPDLGrLzxXt2vqIRZ6hwDaTAsTj/Vt8j8+gB3cddorxv4O20mp3toizQRx2cUDvAuSptApMKgEDKO5MqHnb8y8Yr3HUbSPUNPubOcuIp42iYo21gGGMg9j70Acz8VrpbDwRd30jrGtpPbXBdhkKEuIyT+QNdd16Vweo20ni74e6/4evfn1CKOSxuAv/LRlGVYc8b12n2JPpW94D1Ya74N0fUgRuntkL46BwNrgf8CBoA3qKKKACiiigAooooAKwdY8U2Wk389rcQ3T/Z4Yri5ljQFIIpHdFdiSDjMbZwCQBnGM43q5TVPCj6r4nv7y6vJY9MubK1tXtoSv78xSTuwkyhIXEqj5WBPzA8YoAG8e6It3dwNJJtt1nPmDaRIYQTKqgNuyNrdVAO04JqtqfjqO0gM8GnXcqmOKRYZUaGVledYg2GHA+bPOD2461cPguzEd/BHeXsVleLOHtlEW1TMG3lWKF+rMQCxAJ6YAFWNV8KWOpEtNNdI/2aO2Vo2UFQkgkVhlT8wZQecj2oAVPFNmb9bV7e8QealtJM0Y8uKd0VliY5zuwy8gFckDOeKpR+PdINm11Ml3b25t1uYXmjAE6F1jGwZzne6L82PvA9OatJ4Uthfi5kvb2VDPHdywN5fly3CIqiVgEBDfIpwpC5GdtV38C6VJYWdpJJdtHaWgtIiXXcAJI5Ff7v31eJCO3HINADZPHemJpEuoiOZooJmt7hfNgBhcKHwWMgQ/KykbWbOeO9X9A11dY1HUI4NjWcUdvLBIoILrLHvyc/hVOXwbFKbeR9W1H7VB5qrOEt1bZKEDptEW0D92vIUMOecEitHw94etNCDi0knfdDBAfNYH5Yk2KeAOSOvv6UAVo/FUE1jcXsFjfSWUYLR3GI0ScB9pKlnGBnnL7QQMjI5qCy8daJd2Ju1mdIRbT3RLAEbYH2SgFSQxUkdCQQQQSDTW8F2xsEsV1LUlsoZVltYcxFbZlcOu3MZ3AYwA+4AdOxBJ4G02aztLe5uL2f7PfPf+YzqGld2LOj7VAKMTyoA6CgCOXxls1mKxTTbicyXxsz5fDxf6IlxllbHPz4wDwOc54rW0nxFYarLZx2ZlZ7m2a6AKY8tQwUh/7rbiRj1VvSq8/ha1k1KTUIrq8gu3vxf74yh2v9nW3KgMpG0ogznnJJBFJ4W8PLo19rd64jE+pXjTYjYsqR5JVRnHVmkkI/vSv160AdDVfUrgWen3VyxAEMTyEnoMAn+lWKwPHJaTw7NZxsVlvnSzUj/powU/+O7qAJ/B1v8AZfCukxHdu+zIzBuu4jJ/UmvJfHIt9e+B+r3EwItZbzUJ5GHUBHuMH81FezapeQ6To93ezsI7ezgeZ2PRVRSSfyFeE+LUnufgDpGkSq9pdX9h9tmMa/IVJEkigjud/fsTQByXxn8M2viPUtB1ZNSilhvtJSS1Y4zBGIuAf9l2YlWP3WHvW3Pe2vhP4Y+H/Euk65qVlo+p26LLZ3Nubu0RynKuuDsBYEZUAkjrV7x3oc3hvw94da7tbYz2mnvp8siuWje3B+WPZjLJtA3YwV3Ag8Vofs4alaap4a8Q+BtVtFeHS53EdtcfvFe0mZmVefvAHcM9MFaAJfAHxj8GeKLCCw13UbHTdShby4HDvCpGBgo78qfYn05PSvRIfDlzDctd6BrK28My7iPJV0kb+8QCFOe5AB968M+KX7POnxW9xeeH0aKJeYzGjP5Q9JEHLL/tr8w7hq8ZtdW+IfwiniFnf3lpaudyqrCeymGeq8shz36MPY0AfaknijUdKk8nxDp0EJB4uY5CsLj1DEYH0LA+1ZGv+C9TsNbuPFfw81A2+p3Tia90y6kLWeojaByOsUmAMOvpyME14z4Y/axmSCOLxP4bWWUffuLCfYD/ANs3B5/4F+VdzpP7UPgS8fZeQazp/wDtzWyuv/jjMf0oAl8X6APiNq1rq2h3LeHvG+l25t7vTdQjGZYSd2xsH5l3ZKyLkc/l1PwS8Ma14f8ACep2PiuOEy3WoTTrCNjoI3CgrxwQSGPPODzXHeJ/jN8I/ECRfbdUuxdQ8295b2c0c9u3qj7cj6cg9wawtK/aQ03SNcjsdSv117RHACalBayW9zD/ANdYmAV/qmPpQBu+LvCY+GJutW8P2VzN4VnkMt3aWqCVrFj1kETcSQ+q8FOoOM46vwv4ltri3ikW7uoYGXzFuLNzPBtPTdG4Lx/qv+1XC/tDeN5df+GWl3ngbU5n0K8uQup39kGLW0WMbZFGGUEk5BxnbjvWH4J8N+K/AOhQ6j/Z7+I/BcoWZYYZv9Oto2UN9ohK4IU55QH3wOTQB9H6Y1zceVcQ6rbXlk2TlIh830YNj9KZdL4gW7U2smly2pPIlSRHX6EEg/kK4nw/p9rr2nLrfgXxElxBPj5t2xge6uyj73tIjGtE6t410twt1pEWpQDq8bAMfxXOf+/YoA6LUPDsOoXKy3N5flQ2/wApJyigkYOCMMPwNUNJ+H/hrTLy4vE01Lq9uCDLc3zG5kbHT5pCT3rjde+L+kWGp2mmeItK8TaZdSNvj+z27sH6jbxhjn0212eh6xaeL9GN49prWm2UbFcXyNaNKPXGd233OKALOveI7LQrSZLa3kvJ7eMubW0XJjUd2xwg+v4A1x1xour+L9Vge6bbpEyEXVyGMZ8vIIggXqFbjdIcFsYHFdDceKvD2ieGLzUNBj/ta2tZfIa30VBcyNKTjbhT97nkk/Wuf8P6v4+17VrbVNatbPwh4agcsbOfE93eDBwGPSMdDgfNkYoAs6r4n8N+GfFA0fw/px1bxPfeWr2FgQWijjAAaRidsSqOecEmvDf2kPDWlnxQLuOyU3d3qcaSyzTFfNXyWZlDDpzhQB0Ke9ex3F1o/hxLmDwxp1vo63c2JLiOMCa5kY9v4mOT9f8AdrxT433THxbp+jT6gJLjTYUmlCqJUguJGCor8ZJCA9x8zhumRQBsfC/xZZ6L4o0IahbSW8D2QEJwzCUYZcAnGBHhFwR952xX07qhDWMkQuHt5JwY45IyAwYg4wTkZ+tfFGi6TL4v8LxC4C2sEF1LaQSI5luIGUCWIbf4icyE4I3YJ5IWvoTUvFmzwhpOsW9//pU9jFJc2khPmIYxu84J1ABVgw/uk+lAGt4M8QjUPEsLXWIdUkgNpfREBQ7J80cq84II3jjIrU+H1xplnq/ifw5p7MJtPvmupEIIVRcZkAXPYEsOOBXmXieaPR/Evh3XFEdvdR3cc8sEEZeOa2cgPPF3Ee1ySCcoSeoNes3MFrpnjyzvooIEfV4GtZZQgDM8eXTJ78bx+AoA6miiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuf1H/TfF+mWgGY7KJ72Q9txzHGP1kP/Aa6Cue8JAXc2q6x1F7cFYW9YY/kXHsSHYezUAc38fdQa1+Gt7YQSiO81maHSbc+rzOFP/ju8/hWL8WtRTTtNutGaZLXRotKcSM3BTywGAQjnJG0Y7gH0NUPi5rtvL8V/CumXAD2OhQya7djBKiXBSDdjkYOWOATjnGK4X4geIra6tXg1xvtD3KFL23mkxKiuD5UZA/jjTfIrjhs4PWgDr/jPf2uu2XhW7tpGn024jW5WeNwmFGHG3PKs5CrkjaRkZFeJX+t6t4E8UWnjHSJXkuBOLWWDYRFNEVyUcfwMSCduMZIKnjFej3tlqWueHNE+w211d6rp9nHYSxW1qSroh2BAT8rJ/GxYjIUYOaivfg5e680DeMtStvDeiRyEi1ikElxOAMKRnIQkljty+Cx9qAPYPAfxI0L4i6Zv0nUhYajGV3wGRS6lgSBg/eHB7dqoeItDg1F7u08Qae2mrOWVrqOJZ7C654eWP8Agb/a+Ujs9Zdn8KfC9xoFnpGjeFIktYJFkGrajmO5Yht25SBvOfQ7V9sV3Fv4e1jRUmi0XVEvdOdiV07VQXEaHqiTDLBevDh/TpQB84+Mv2d4Q8N1pM09pBK255bdDe2u0/xIFxKg9iHH+3Xjet/DbxPpDB/7NOo2+7Am09vtCn/eC/Mn0YKa+wdUtrjw5ZTzaFDqHhO9GWaNj9r02Qk84ydiH3Pl/wBa5mH4meEfETHT/ibo1vEhaNIdX8grBKxGRh1JaMgg8hiB6igD5ITULywYw3SMzLG0XlTpho89MEjI/TuOlQRNbzzossZ/eK2TFHuZWJJGF3DP4nueuBX3k3w78K6fY3WtWmrSjSpYA7G6eO+tQg5DqJVb8wazNZ+Fng8wwS6lJ4fjiueY5hpkMfmcZBDKRngigD4607X77wndxXXhrVTDdqiCV4BhJ1Zc7XQkqwXoQRznnnk+x/DL9o280aCPTNR0EXUOT5cdk5AXuQqNnaO+AcDsBXpln8JfhZbMrXN1bXJU7tqbcHtyACTXpXhn4c+DdDEdxpGg2CyHDrPJF5j8jqC2SOD2xQB4VpOlar8QfGJ1v4XWOteA7ec79Vv522Q3DY+XZbjh2znJyBySeTzrQeBdZvb0w+OPirr9tId8S2VxG1lHK3RSrLLskXvheT04r6A1rSrLVdNez1BX+zfe/dytEVx3DKQRj615BeeFR4h1D+x9O8X+KotEuYXf99crcCVU43JvjZhHkgbmb5jwM9aAN7wB8Nda8LanbzS+LYrjT4Rj7JbaRFCZRj/lpMzPI3ry2fep7v4M+GtTvHuPEN1ruu7pTKItR1OWSNcnO0KCBgdhWZ8MPhxpPhHR5pb6XV1ggnzDJe38kYdF6MYVbYvOcA8njIHSu68Xa2mj6W+pX99BpmiRR+ZcXcmTLyeERMdT+JycAUAX9C0PSPDWm/ZNFsLTTbJMsUgjEa+7H1Pua4PWPF2m6gLqfw3NDelXaJ9TumLW1scEMsYyC7D/AGePVq8+8Ua145+Kep2dj4e8J38PghCfPGpztZ/2gMceY33/AC84O1c7u/t2+h/B+O5u0vPG97HqKoAIdIskMGn24A4UJnMgGP4jj2oA4y1tvFeqmPVPAtg2oT2w/c6pfukcMzA4PlqeNnU/KMf7R614J4i8L+K/B/iNJ/G9vPC1/cyCW5fEiTM6kb96k7vvMcdR+NfoLDFHBEkUKLHEihVRBgKB0AA6Cua1nw/cT2c9sTBrGnTEmTT9UG9W5zhZMEj2DA/hQB8eeFGOi6lNH9huLhrO4hUFrn7M8ahRH5i4OC5Dk5zmMqM8ZNesfD67g13QLLWrSK5WTS9RvbX7a7HzLcOqSkyR9JEzI6sMcKSRWjq/wr8IfZ9RtLd7zwtd30jSFb9BJb7jyfLkzgA9CA4yMggjis/w98P/ABV4bgeVQysmqvdw3WlN51uYzDhX8nd5hcscE/NxkEEAUAT+MZV8U/BC08R2UKR6lpNxJaNJHPuWOAyGKVSR99CpBAx0wa9E8FXNx44+E+kzlxaa3bxoA6EN5VzFwDwSCrDnryr14j4T1DxBDoHxB0hobSDLyXA0MQusty8oGZICcHbld3A+XgYqj8FPHVj4J+Ld1odo01v4S1t08pbzCG3nKDrzgYbdGfXC9MUAfT3gHxOvijR5ZpI0g1G0ne0vrZW3eROn3k9e4rpa8n8Qv/wr/wCK9pr+4R+HfFJSw1DPCw3ig+TL7BgChPtk16xQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQ3l3b2UDT3txDbwL96SVwij6k8VwvizxVq114jl8NeDGsY7u0iW41XVLz54dOjbOwbQRulYAsASAAMng1S0ePRYXW+W01zxjfKN39pywiVM9/K3FY1Hp5Yx7mgCz4x8eodLNn4YsdR1G/1FvsVnPFAUg81gefNfCnaoZsjI+XrTLbW761WPRrafTtNNpGsP2W1jl1K5iAGAH2BVQkYPOetdRofinR9euXtLW4MWpQrvksrmMw3MQ6ZMbgHHONwyPeszwYq+F4oPDOoKEl3ObS8J4v8ksWY/8APbqWHflhkZAAOK/4QHR9V1q+1XUtC8R61qN9Is0z3siWkZKABAFDKQFAGAc12Gg+F1s7l5bTw3oek7tx8/8A19xuxwSdo/8AQq7eigDCbQ7u4UC+1u+dRj5LYLbqf++Rux+NWtP0HTLCbzraziFx/wA9n+eT/vpsn9a06KACiiigArk/E/w58IeJ0ca14fsJ3bOZVj8uTnvvXBz+NdZRQB49p/w/1r4bXCzeCL+61PwqGd7vw3dbXYqwOTBIRnI67DgNzkkmtY6xFoVnba7pM8Vz4JnlVbu2aI79NJyDIvdUDY3oR8nJGORXpdcJ4q0mfQL678SaFZPewXIxrOkpyLuIDBljQ8GZR2/jAwecUAYnicXHhTxHp1zZJqF3Y3s48kQCSZUYkDY37wD5snb/APWrtdQ8VWkOmpd2ivdCXIjEYPLBtrKSAdpB65rntIg0rVPD02g/aBquhvaxXFgyuRPHCThcMccxkcMDuXAB5HPiHiW3+JGmeMLzwppjxa7OdOe80zUJdiySQhvv5I2tKNxU56na3uQDvItW1XxP4r1KyvNdurfRdKiF9qyIq7Y4z8yW2QBncoYnIPyjHevaxPjTPPt7eQgQ70gVQrn5chQDwD2wa8R/Z4vruP4SyaxqMb6rq3iDV5W2S4HmudseCcHCKsTMeOApwO1dX438diHw5eXMMzWNi0gVbmFw11Jb52NJBHjlnk2xR+7bzgCgDM17xnNpeqWhNm2t6090YEtYmyqz4yba3HALIvMkzcIAc8kKOz0Lwzc3F5BrXi6ZLzWFG6K2jYm1sc9olP3m7GRhuPbaOKyfhX4KOkQjXdbtY4deuohGlsr70023zlbaM9z3d+ruSSTXodABRRRQAUUUUAMmijnieKeNJInGGRwCCPQg1yd18OvDzu0unQ3ejz5JEmlXclrtPrsRgh/FSK6+igDlf+Ecvvss0N9qMGup8vkJq1pGfLwfmJZFGTj2615d8Q/g/p2rW080PguAaokgmiudMvQom+cEo6SYA3DIJwcZzXvdBIAJJAA5JNAHzVe+A7XxR4a/4QlvGGu6da216PJs9csBI8coU4ijmBUOuH4AJ7Yr1jwrbeMfCnhmHT9VWHxPLaqUiuYZRBK6KPkVlfgtxjO4+9TeJtQtNctGSaVLfw5bTRTXF+5I8945A6xw/wB75lGWH0XJ5F3+1vEt9ELrSdFtIrU8pHqM7QzSD1KqrBM9snPqBQBoeFPEVt4k003NvFPbXET+Vc2lwmya2lHVHH8iOCOQSK2q851DVJftc+uaPps1vr9gI11bTJcK9za85ZSOHKfMyMOu1l/iwPQbS5hvLWG5tZFlt5kWSN16MpGQR9QaAJaKKKACiiigAooooAKKKKACiiigArO8RX76Zo1zcwp5lwAEhTGd8rEKi/ixFaNYusILnXtFtmPyI0l2V9SihR+RkB/CgDBsfBVuJ7axnMVxpduDc3qMdzX985BMk474A3AHjLDjCiu3VQqhVACgYAHQCmpDHHJI8caK8hBdgMFiBgE+vAAp9AGV4g8P6dr0EaahATJEd0FxGxjmgb+9HIuGU/Q/XNc7qA1DTrV7HxRA+t6GcbdQgjxcQYOQ0qL6cESR8jGSo6129FAHL6Vq01rZxytMdY0dxmHUbbEjqv8A01VeuP7yj6gda6O1uYbuBJraVJYmGVdDkGsS88OLFcT3vh+YaZqEp3PtXMEzeskfAJ/2hhves1NVXT5JbfVLaLQdSu2GLxVElrO47huACeeGwfrQB2VFZk+sRWl20WoRtbREgRXDcxSZH94fdPXg4rTBBAIOQe9ABRRRQAUUUUAFFFFAHnHim2n8Fvd6npM62+kXcwmnjkGYracnlj/dhl6Pj7rYf+9XL3OrwaP8QfAt1BGsWkXl3c6cUmbEmnzTRKfs+O6M6oy84644K49ruIYrm3kguI0lhlUo8bqGVlIwQQeoIr5a+PNjrHgTR7jSNEt5dQ8N/udVs5ZnzJo80U6rhG6vHhgoU8qG64HIB6PrV1ZeDJ/Evhx5/slrqso1Gzbp5UcxK3Yj902yPgcjzK4fxb4uaz8XeHdOvY1lk02NdQWxZkMdvfXHy2kJQ4YiGMlwF/iwSQOR6H8RBNr/AIO8PeOfC72f9o2kQnt2vI90JguUVZN464Xcr/WPkUlj8L9L8OaN9vnjOs+I3ka4vdYmit2mmdvvMGnDLGgHAC9vXk0AeqW+4W8QeQSttGZAAN5x1wPWpK4/wn4htFgWyuLwO6c+Y87TbQf+eku1UBJOAq8dAK7CgAooooAKKKKACiquo6haabCJb64jhQnA3Hlj6AdSfYVzOv8AiOaCGItJ/ZUExxFvi868uD/dhgGefdgcd1HWgDf1fWbTSxGs7PJcy8RW0K75ZT/sqP59B3IrjdY1W51W9Gnm1e9uwcnSbeT91FxwbyYcAd9gzn0ap9H8P6jqHmS3CS6NZT/6xRL5moXQ/wCms3Plj/YQnHqOldlpenWmlWaWmnW8dvbp0RBgfU+p9zQBjaR4bK3cWo65Ml/qUYAiUJtgtfaFO3+8cscduldHRRQBgeJNMmkv9N1jT3jjvbByr+YcLLbuR5qMfYAMPdR61W8FzRwTalpMLh7W2dbmzcfda2mBdQp7gMJFHsBXRX0yW1lcTyAFIo2dgfQDJriPCSvZz+D/ADE2tc6IYWXoVKCJh+W5hQB3tFFFABRRRQAUUUUAFFFFABRRRQAVj3mV8V6Yx6Na3C5990R/ofyrYrF8UB4IrPUY8/6DOJZAO8RBR/yDZ/CgDaopFYMoZSCpGQR0NLQAUUUUAFR3EEVzA8NxEksLjayOoZWHoQetSUUAczLoF5pkcn/CPXCG2I5029y8BHojfeT6cj2qha6hFaXQtY3fQ749LK9+a2lP/TN+n/fJB/2a7WoL6ztr+1ktr6CK4t5Bho5VDKfwNAFH+1/soUavA1mT/wAtc74T/wAD7f8AAgK1EdZEV0YMjDIIOQRXO/2Beaav/FPag0cQ4Fle5mgx6Kc70/Ake1Y8l/HpTOb+2vPDkhJPnwj7RZMfU4GFz6sEPvQB3dFYdhql41qk5jttStWBK3WnSBg3/ACf5Masx69prTCF7tIJz0inBif8mwaANOigEEAg5FFABXl/x70Z9W8MPFGjSG5trmyChsAu6eZFn/tpEn516hWN4wtXu/D12IVDTRBbiMEdWjYOB+O3H40AeS/sra6PE3wqudF1MBnsZJLdk2BA0EgLLgADjlx+Feq+C7iV9FWzu333unubOY9yU+63/Al2t+NeBfCC9tvCvxlvtCjnjVLqaW3CYJLwuouLVicYyFZ16nGccV70w/szxmH6QavFtPPSeIcfmmf++BQBzPirSLTTNUW5Fvc3TSFpQI9sWzJ5G6OIyfjmt/wn4jGouLK4i8u6Rc7VU4A9OfmGBjlguT0FdDfWsN5bNDcRrIh52sMjP0ryi/8AET6Dcv51wthbxkhY1AjVMnGArBBnnujn0oA9eorlNF8XxappyyadYahdMoC72hMUbnHUPIFBHuB+FVbjXLm8uDALwB+9ppKfaJfo0p+Rf0+tAHVX+o2mnoGu51j3cKvVmPoFHJ/CqEl3qN4jm2i+wW4UnzZ03zMPVYx0/wCBflWTYaPqcjtJDHBowf70xP2q8f6u2VX/AMerd0fQ7PSnklhEst1KAJbm4kMksgHqx7ewwPagDmtMttT1GV5rG1m05Tlf7S1RRLdyDv5cXSMfX/viuh0Tw9YaRJJPAkk19L/rby5cyzSexc9B/sjAHYVr0UAFFFFABRRRQA2RFkjZJFDIwKspGQQexrA1NVXxb4eiiUARxXJwv8KhUH5ciuhrAsT9u8X6hcgkxWEK2aehdsO/5DyxQBv0UUUAFFFFABRRRQAUUUUAFFFFABTZEWSNkkUMjAqykZBB7U6igDC0CR9OnfRbs5MQL2ch/wCWkGeF/wB5OFPtg963az9a00ajbKI5DDdwt5tvOOsbjofcHoR3BNN0PUxqMEiyqIb63byrmDPMb4z+KkYIPcGgDSooooAKKKKACiiigAooooAwZ/CmlNLLNZRPpt1KcvPp7mBmPqwX5W/4EDUbWWt28Zilmstatv7l1EIZP++lBRv++RXRUUAcfIbO2bE+larpTY5ltMtGPf8Adkj81p9vqdvIwFp4sjUD+C6SPd+oU11tRT20FwMTwxyg8YdQ386AMSO8viuIdW0e4/2ipBP5OaVrrVkAElxohB65Z1/qatSeHdFlOX0jTyeufs6Z/lQnhzRUJK6TY5PrAp/pQB86eNI30TWLLUlvGkltzkwWExaEz2sgeMsO58qVRz9K+gPEKNq/hqK+0sGS4iEd/Z46syjcB/wIEr/wKvOPjD4ctI5Fkhiis7IGGeVo1RABuMMh5UqABKjHg/dFdZ8F9SN54Iis5Hd59Kmk093Yk7wh/dsCQCQYyhzgZzQBJPqs3iSGC40zTNde0ZARi4S0ilB5yW3eZ7ccVSu9E1+1tI4NFisdGt5G+eOwt1upmPXLyS7VBz/EQxrofDEUmm6pq2kuFFssv2uzA7RyEll9Plfd+BFdDJvMbeWVEmDtLDIB96APKdL8PWD6p5+r3lzr91GQxWeZ71we4CoFijHsAa9P05IktI1htRaJjiHaq7fwXiuenkhMgiuNXnndSQbbTY9oJ9Dtyw/FhWto8RhLCGwNrA3zFpJN0jn1I5/U0AalFFFABRRRQAUUUUAFFFFAGfr2ojStMluQnmy8JDEDzLIxwqj6kim+HtObTNKiglcSXLEy3Eo/5aSscu35nj2xWdbMNe1/7UpD6XprMkJ6ia45DN9EGVHuW9K6OgAooooAKKKKACiiigAooooAKKKKACiiigArB1+zuLe5TWdJj8y9hXZPAAM3UPUp/vDJZT65HRjW9RQBXsLyDULKG7tJBJBMoZGHcfTsfUHpViuZuA3hvVzcpj+w7+XNyDx9lnYgCQf7DnhvRsN3Y101ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHI/EjS11PSoYS2z7QzWLOByomQopH0k8pv+A1xnwJ1CJr7U7eMy4vIIbxjIEUidQY512qSQVIjzuYtz2GK9M8VWsl74d1CKDcbgRGSEA4zInzJ/48orxuxnj0L4hQaml4wtJb5DGkkgVRa3qqyoqliQBKxOEUAlMselAHr3iQiyey1YcC0k2THOP3MhCuT7A7W/4Ca26iu7eO7tZradd0UyNG49VIwazfCs8sujRw3T77uzZrSc9yyHG7/gQ2t9GFACmyu183zNRS2tsnalvCqFR2yzZ/kKqRvpMNysiz3F/dIflKu85B+g+UfpW5cW8VwoWeNJEB3BXGRn1qpJqNnauLeFXdx0it4i2PyGB+NAF6Ni8asVZCwB2t1HsadTIXMkSOUaMsMlGxkexxT6ACiiigAooooAK5zX7ufUb7+wdKmMczKHvrhDzbQnsD2kfBC+gBbsM2/EusNpcEEVpD9p1O8fybS3z958ZLN6Io5Y+nuQKl8PaQukWTRtK1xdzOZrq5cYaeU9WPoOgA7AAdqALljaQWNnDa2kSxW8KhI0XooFT0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEdzBFc28sFxGskMqlHRhkMpGCCPTFY2gPJp1w2iXkrSNEpezlfrLADjBPdkyFPqNp7mt2srxDYTXlrHNYlU1G0fzrZm6FsYKH/AGWBKn657UAatFVNKv4tSsIrqHID5DI33kYHDKfcEEH6VboAKKKKACiiigAooooAKKKKACiiigArwvxzoqyX+n7xnAudIJfAIKt5kGwkEK2xjg7WIC/LzXuleY/FWzH9jeIZNqyNALfVo42XO4x/JIO/GxQOQevQ0Adz4W1JtX8OadfyoUmnhVpFKFCr4ww2nkcg8Hn1qNT9i8Tsp4h1GLcvtLHwfzQj/vg1zfwkvC1hqmnSxNBJa3IlELQtFtSVQ4wpRON2/GFx6ZrqfEUE0lik9qjSXNrKs8aL1bB+ZfxUsPxoA1KzH0uSe7kkur64ktyfktkxGij0OOW/E1p0UANijSGNY4lCIowFUYAFOoooAKKKKACqmr6jbaRptxf30nl20C73IGT7ADuScADuTVuuWgI8T62J/mOjaZMREf4bq4Xq/uiHgdi2T/CKALPhrTrlp5tZ1hAup3agLDnItIeqxA+vdj3b2AroKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMFx/Y+viUHFhqTBWHaO47H2Djg+4HrW9VXVbJNR064tJCVWVSAw6qezD3Bwfwqt4dv31DTFacAXcLGC4X0kXhvwPUexFAGnRRRQAUUUUAFFFFABRRRQAUUUUAFYGv2UM+q2bXBcQ3UM1hKFHDK6ggE54+6cfWt+o7iLzo9gkkj5B3IcHg5x+PSgDO8P2a29jAJEAuYlMLyKjJ5m3jcQSS3AHJz+tatRxQxRGQxRohkbe5UY3N0yfU8CpKACiiigAooooAKKKr6lew6dp9ze3b7Le3jaWRvRVGTQBh+KLi4v7qLw/pkxhnuU8y7uEOGtrfoSP9tj8q+nzHtW7YWdvp9lBaWcSw20CCOONeiqOAKxfBVlLHpsmpX641LVH+1T56oCPkj+irgfXPrXQ0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVK10+O21K9u4iwN3sMi543KMZA9SMA/QVdooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKhvLWC9tnt7uGOeB+GjkUMrc55B61NRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24242=[""].join("\n");
var outline_f23_43_24242=null;
var title_f23_43_24243="Abdominal scintigram with leak";
var content_f23_43_24243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdominal scintigram showing a peritoneal leak in a peritoneal dialysis patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 465px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) 15 min activity within the peritoneal cavity. At 2 hr (B and C) leakage of dialysate occurs into the mid lower anterior abdominal wall. Small leakage into the scrotum (D) at 2 hr is also demonstrable with high intensity scintiphoto.",
"    <div class=\"footnotes\">",
"     P: pubis; S: scrotum.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walker JV, Fish MB. Scintigraphic detection of abdominal wall and diaphragmatic peritoneal leaks in patients on continuous ambulatory peritoneal dialysis. J Nucl Med 1988; 29:1596. Copyright &copy; 1988 Society of Nuclear Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24243=[""].join("\n");
var outline_f23_43_24243=null;
var title_f23_43_24244="Nitisinone: Drug information";
var content_f23_43_24244=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitisinone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/51/5940?source=see_link\">",
"    see \"Nitisinone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/10/5284?source=see_link\">",
"    see \"Nitisinone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Orfadin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F201713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      4-Hydroxyphenylpyruvate Dioxygenase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F201701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Must be used in conjunction with a diet restricted in tyrosine and phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HT-1:",
"     </b>",
"     Oral: Initial: 1 mg/kg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">",
"     <b>",
"      Dosing adjustment for inadequate response: Note:",
"     </b>",
"     Inadequate response is defined as continued abnormal biological parameters (erythrocyte PBG-synthase activity, urine 5-ALA, and urine succinylacetone) despite treatment. If the aforementioned parameters are not available, may use urine succinylacetone, liver function tests, alpha-fetoprotein, serum tyrosine, and serum phenylalanine to evaluate response (exceptions may include during initiation of therapy and exacerbations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Abnormal biological parameters at 1 month:",
"     </i>",
"     Increase dose to 1.5 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Abnormal biological parameters at 3 months:",
"     </i>",
"     Further increase to maximum dose of 2 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F201708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/10/5284?source=see_link\">",
"      see \"Nitisinone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Must be used in conjunction with a diet restricted in tyrosine and phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HT-1:",
"     </b>",
"     Oral: Infants and Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F201702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orfadin&reg;: 2 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Distributed by Rare Disease Therapeutics, Inc; for information regarding acquisition of product, call Accredo Health Group, Inc at 1-888-454-8860",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F201685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer in 2 divided doses in the morning and evening at least 1 hour prior to, or 2 hours after a meal. Dose does not need to be split evenly; divide total dose as to limit the number of total capsules administered at each administration. Capsules may be opened and contents suspended in a small quantity of water, formula, or apple sauce; use immediately.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F201684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hereditary tyrosinemia type 1 (HT-1) as an adjunct to dietary restriction of tyrosine and phenylalanine",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F201711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (1%), dry skin (1%), exfoliative dermatitis (1%), maculopapular rash (1%), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (3%), leukopenia (3%), epistaxis (1%), granulocytopenia (1%), porphyria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic neoplasm (8%), hepatic failure (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (2%), corneal opacity (2%), keratitis (2%), photophobia (2%), blepharitis (1%), cataracts (1%),  eye pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, amenorrhea, brain tumor, bronchitis, corneal ulceration, cyanosis, dehydration, diarrhea, enanthema, encephalopathy, gastritis, gastroenteritis, gastrointestinal hemorrhage, headache, hepatic dysfunction, hepatomegaly, hyperkinesias, hypoglycemia, infection, liver enzymes increased, melena, nervousness, otitis, pathologic fracture, respiratory insufficiency, seizure, septicemia, somnolence, thirst, tooth discoloration, tyrosine levels increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F201688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F201673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic effects: Failure to adequately restrict dietary tyrosine and phenylalanine may lead to hyperkeratotic plaques on the soles and palms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Leukopenia and/or thrombocytopenia have been reported; may be due to underlying liver disease rather than drug-related (McKiernan, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurological effects: Failure to adequately restrict dietary tyrosine and phenylalanine may lead to developmental delay and mental retardation; clinical evaluation is recommended for any patient exhibiting abrupt changes in neurological status while on therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Failure to adequately restrict dietary tyrosine and phenylalanine may lead to ocular toxicities (eg, conjunctivitis, corneal ulcers, corneal opacities, eye pain, keratitis, photophobia). Slit-lamp examination of the eyes is recommended prior to initiation of therapy and in patients who develop symptoms of toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dietary restrictions: Must be used with dietary restriction of tyrosine and phenylalanine; inadequate restriction can result in toxic effects to the eyes, skin, and nervous system. Evaluate plasma tyrosine concentrations in patients who develop signs and symptoms of toxicity. Nutritional consultation is required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F201697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Effect of taking with food is unknown. Tyrosine toxicity can occur without proper dietary restriction of tyrosine and phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F201704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F201691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because the effect of food is unknown, nitisinone should be taken at least 1 hour prior to, or 2 hours after a meal. Dietary restriction of tyrosine and phenylalanine is required.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Orfadin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (60): $4765.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (60): $11913.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (60): $23826.59",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F201680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dietary tyrosine and phenylalanine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liver: Ultrasound, computerized tomography, magnetic resonance imaging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic exam: Slit-lamp examination prior to initiation of therapy and in patients who develop symptoms of ocular toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Plasma tyrosine: Concentrations should be kept &lt;500 &mu;mol/L to avoid toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Plasma succinylacetone: May take up to 3 months to normalize after start of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Platelets, white blood cell counts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum alpha-fetoprotein: To monitor effectiveness of treatment and potential liver neoplasia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum phosphate in patients with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Urine succinylacetone: Should not be detectable during treatment; dose should be increased if detectable after the first month of treatment.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Orfadin (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F201672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In patients with HT-1, tyrosine metabolism is interrupted due to a lack of the enzyme (fumarylacetoacetate hydrolase) needed in the last step of tyrosine degradation. Toxic metabolites of tyrosine accumulate and cause liver and kidney toxicity. Nitisinone competitively inhibits 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme present early in the tyrosine degradation pathway, thereby preventing the build-up of the toxic metabolites.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F201687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Limited pharmacokinetic studies exist for children or HT-1 patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Bioavailability: &gt;90% (animal studies)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 54 hours (healthy volunteers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 3 hours (healthy volunteers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (healthy volunteers; Hall, 2001)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hall MG, Wilks MF, Provan WM, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and Mesotrione, Inhibitors of 4-Hydroxyphenyl Pyruvate Dioxygenase (HPPD) Following a Single Dose to Healthy Male Volunteers,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2001, 52(2):169-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/43/24244/abstract-text/11488774/pubmed\" id=\"11488774\" target=\"_blank\">",
"        11488774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holme E and Lindstedt S, &ldquo;Nontransplant Treatment of Tyrosinemia,&rdquo;",
"      <i>",
"       Clin Liver Dis",
"      </i>",
"      , 2000, 4(4):805-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/43/24244/abstract-text/11232358/pubmed\" id=\"11232358\" target=\"_blank\">",
"        11232358",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindstedt S, Holme E, Lock EA, et al, &ldquo;Treatment of Hereditary Tyrosinaemia Type 1 by Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8823):813-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/43/24244/abstract-text/1383656/pubmed\" id=\"1383656\" target=\"_blank\">",
"        1383656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McKiernan PJ, &ldquo;Nitisinone in the Treatment of Hereditary Tyrosinaemia Type 1,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2006, 66(6):743-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/43/24244/abstract-text/16706549/pubmed\" id=\"16706549\" target=\"_blank\">",
"        16706549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10149 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24244=[""].join("\n");
var outline_f23_43_24244=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201700\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201713\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201701\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201708\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201702\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201683\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201670\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234123\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201685\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201684\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201711\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201688\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201673\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299764\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221931\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201697\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201678\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201690\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201704\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201691\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323495\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201680\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038706\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201672\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201687\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10149\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10149|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/51/5940?source=related_link\">",
"      Nitisinone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/10/5284?source=related_link\">",
"      Nitisinone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_43_24245="Bloody peritoneal dialysate (hemoperitoneum)";
var content_f23_43_24245=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bloody peritoneal dialysate (hemoperitoneum)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24245/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24245/contributors\">",
"     Anthony Bleyer, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24245/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24245/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24245/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24245/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24245/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/43/24245/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloody peritoneal dialysate (hemoperitoneum) in the peritoneal dialysis patient is an uncommon occurrence. The etiology, diagnosis, and treatment of this problem will be reviewed here. Other abdominal disorders in dialysis patients, including abnormalities requiring immediate surgical therapy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20986?source=see_link\">",
"     \"Gastrointestinal disease in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hemoperitoneum varies from 6 percent overall to as high as 57 percent in premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Bloody peritoneal dialysate may be related to the peritoneal dialysis catheter, the peritoneal dialysis procedure, the underlying renal disease (such as polycystic renal disease or acquired cystic changes) or may be due to factors unrelated to renal disease. Performance of peritoneal dialysis exchanges allows early detection of intra-abdominal bleeding, including benign cases in patients not on PD in which this finding would be otherwise clinically silent.",
"   </p>",
"   <p>",
"    Causes of hemoperitoneum were reviewed in a single center series of 424 patients, 26 patients (6 percent) developed one or more episodes of hemoperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/1\">",
"     1",
"    </a>",
"    ]. Based upon severity and cause of bleeding, patients could be divided into different groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest group (n = 21) of cases, bleeding was mild, asymptomatic, and resulted in pinkish or red discoloration of the fluid. These patients were treated conservatively and did not receive extensive evaluation. Menstrual bleeding was believed responsible in seven cases, while a bleeding diathesis (use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or thrombocytopenia) was responsible in four patients.",
"     </li>",
"     <li>",
"      Peritoneal bleeding after transplant nephrectomy, increased physical activity, catheter repositioning, and femoral hematoma were responsible for single cases.",
"     </li>",
"     <li>",
"      Minor bleeding with significant pathology was found in single patients with pancreatitis, sclerosing peritonitis, and post-colonoscopy, respectively.",
"     </li>",
"     <li>",
"      Severe bleeding requiring intervention was observed in six patients, three with likely ovarian cyst rupture, one postsplenectomy, one postcatheter placement, and one with sclerosing peritonitis.",
"     </li>",
"     <li>",
"      The cause was uncertain in six patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Menstrual bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign hemoperitoneum occurs in over one-half of menstruating women on peritoneal dialysis; this is likely caused by ovulation, retrograde menstruation, or endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In one study of 27 reproductive age women undergoing continuous ambulatory peritoneal dialysis (CAPD) for more than three months, four of seven who menstruated developed hemoperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/2\">",
"     2",
"    </a>",
"    ]. Of 37 episodes of hemoperitoneum, 22 and 15 occurred at midcycle and with menstruation, respectively.",
"   </p>",
"   <p>",
"    Such intraabdominal bleeding would rarely be observed if peritoneal dialysis were not being performed. It is important to note that a very small amount of blood (less than 1 mL) is enough to make two liters of peritoneal dialysate appear blood-tinged.",
"   </p>",
"   <p>",
"    When such episodes occur, the woman should be reassured that the hemoperitoneum is benign and that it will likely resolve spontaneously. Rapid flushes and instillation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (typically 500",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    of instilled volume) in the dialysate to prevent catheter clotting are usually done. Infusing cool dialysate (eg, room temperature) may also be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/4\">",
"     4",
"    </a>",
"    ]. Most commonly, the hemoperitoneum will clear after one to three rapid flushes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Post-catheter insertion or manipulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After insertion of the peritoneal catheter, bleeding into the peritoneal cavity occurs in less than 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Such bleeding is usually mild and resolves with the performance of several exchanges. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=see_link\">",
"     \"Placement and maintenance of the peritoneal dialysis catheter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Catheter-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, the peritoneal dialysis catheter may cause enough blunt trauma resulting in a local laceration. There has been one case report of a peritoneal catheter eroding into a mesenteric artery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/5\">",
"     5",
"    </a>",
"    ]. There have also been several reports of splenic lacerations resulting in massive hemoperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This is unusual, and likely will be much less common now that \"curled tip\" rather than \"straight tip\" PD catheters are becoming standard. More commonly but still rare, the PD catheter may cause a mild contusion of the surface of the peritoneal cavity resulting in some bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Retroperitoneal pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoperitoneum may be the result of pathology in the retroperitoneum, often involving the kidney. Cyst rupture in patients with autosomal dominant polycystic kidney disease, acquired cystic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/8\">",
"     8",
"    </a>",
"    ], and renal tumors are potential causes of bloody dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. These patients may also have hematuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=see_link\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=see_link\">",
"     \"Acquired cystic disease of the kidney in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Additional causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerosing peritonitis is an important and ominous cause of bloody dialysate. It should be considered in patients who have been on peritoneal dialysis for a long period of time. Peritoneal calcification has also been associated with bloody peritoneal dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoperitoneum may also develop as the result of intraabdominal pathology which could occur in non-dialysis patients. Potential causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Splenic rupture and infarct [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Carcinomatosis of the liver [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Liver rupture and liver cyst rupture [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Retroperitoneal hematoma [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Iliopsoas hematoma [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bleeding from the outer uterine wall in a pregnant patient [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional causes include hemorrhagic luteal cyst, ovarian cyst rupture, pregnancy, aneurysm rupture, vascular catastrophe, colonoscopy, and bleeding diathesis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although anecdotally reported, bloody peritoneal dialysate is not a common presenting sign of peritonitis. In a review of 103 episodes of peritonitis in CAPD patients, for example, bloody peritoneal dialysate was not mentioned as a presenting sign in any case [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any clinical problem, a careful history should be obtained. Important considerations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severity and amount of bleeding",
"     </li>",
"     <li>",
"      Features of the bleeding, particularly whether it was self-limited, continuous, or recurrent",
"     </li>",
"     <li>",
"      Associated symptoms, including those of bleeding disorders (eg, purpura)",
"     </li>",
"     <li>",
"      Reproductive status",
"     </li>",
"     <li>",
"      History of recent procedures, such as colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/13,19\">",
"       13,19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      History of recent trauma to the patient or dialysis catheter",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , antiplatelet agents, or anticoagulants",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The extent of bleeding and associated symptoms are of primary importance in determining further evaluation. If bleeding is very mild, self-limited, and not associated with other symptoms, the patient may not require further evaluation. This is especially likely if the patient is menstruating.",
"   </p>",
"   <p>",
"    For the woman who has bleeding associated with ovulation or menstruation, it is important to note that ovulation frequently stops as the patient begins dialysis; thus, continued menstrual bleeding may be the result of an ovarian cyst or tumor. Imaging of the ovaries and gynecologic consultation is appropriate in this setting.",
"   </p>",
"   <p>",
"    If the bleeding is heavy, recurrent,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated with pain and fever, urgent evaluation is required to exclude underlying intraabdominal pathology, such as cyst rupture or a vascular catastrophe. Findings on physical examination such as a rebound or guarding do not occur with benign intraperitoneal bleeding and should be treated as a surgical emergency. In this setting, a peritoneal fluid white blood cell count, differential, culture, and amylase must be obtained, in addition to a complete peripheral blood count and serum coagulation studies. A dialysate spun hematocrit of greater than 2 percent suggests significant intraperitoneal pathology. All of the possible disorders in this setting are cause for great concern, and merit surgical consultation and consideration of early laparoscopy or laparotomy.",
"   </p>",
"   <p>",
"    For the first occurrence of mild self-limited bleeding, obtaining peritoneal fluid erythrocyte count, white blood cell count, amylase, culture, and peripheral white blood cell count may be indicated. A spun hematocrit may be performed on the peritoneal fluid if there is concern that bleeding is severe. A peritoneal fluid amylase level greater than 50",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    is suggestive of an intraabdominal process such as a perforated ulcer or gall bladder. Further evaluation is subsequently performed based upon the results of these studies.",
"   </p>",
"   <p>",
"    An abdominal imaging study, such as an abdominal CT scan, ultrasound, or magnetic resonance imaging, may also be indicated. Intraabdominal air is usually present in peritoneal dialysis patients so an abdominal flat plate is less likely to be helpful. Contrast should be avoided in patients with remaining residual function. Angiography is a last resort that may be required for more definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the underlying cause is essential, and curative management may require emergent evaluation and care. If the cause of bleeding is idiopathic or benign, the following supportive measures may be indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Instillation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       units/L)",
"      </span>",
"      in the dialysate may be useful to prevent clotting in the peritoneal catheter.",
"     </li>",
"     <li>",
"      Frequent exchanges may be useful.",
"     </li>",
"     <li>",
"      Some have recommended the use of room temperature dialysis exchanges to cause peritoneal vasoconstriction and decrease bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For women who are menstruating, oral contraceptives may prevent ovulation and control bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24245/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or other anticoagulants should be balanced against the therapeutic indications in the individual patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24440672\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of bloody peritoneal dialysate (hemoperitoneum) in the peritoneal dialysis patient varies from 6 percent overall to as high as 57 percent in premenopausal women. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ovulation, retrograde menstruation, and endometriosis are common benign causes of hemoperitoneum among menstruating women. Such bleeding generally resolves spontaneously. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Menstrual bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other causes of hemoperitoneum include catheter-related problems such as lacerations or contusions, sclerosing peritonitis or retroperitoneal pathology, such as cyst rupture or renal tumors. Additional causes include splenic rupture and infarct, carcinomatosis of the liver, liver cyst rupture and others. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of hemoperitoneum includes the assessment of severity and characteristics, and the determination of associated symptoms, reproductive status, history of recent procedures or trauma to either the patient or dialysis catheter, and the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , antiplatelet agents, or anticoagulants. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild self-limited bleeding in a menstruating patient that is not associated with other symptoms may not require further evaluation. However, continued menstrual bleeding among women on dialysis may be the result of an ovarian cyst or tumor. Imaging of the ovaries and gynecologic consultation is appropriate in this setting. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the first occurrence of mild self-limited bleeding in a non-menstruating patient, obtaining peritoneal fluid erythrocyte count, white blood cell count, amylase, culture, and peripheral white blood cell count is indicated. Further evaluation is performed based upon the results of these studies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heavy or recurrent bleeding or bleeding that is associated with pain and fever requires urgent evaluation. Physical findings such as a rebound or guarding should be treated as a surgical emergency. A peritoneal fluid white blood cell count, differential, culture, and amylase should be obtained, in addition to a complete peripheral blood count and serum coagulation studies. A dialysate spun hematocrit of greater than 2 percent suggests significant intraperitoneal pathology. Surgical consultation should be obtained with consideration of early laparoscopy or laparotomy. Imaging studies, such as an abdominal CT scan, ultrasound, or magnetic resonance imaging, may be indicated. Angiography is a last resort that may be required for more definitive diagnosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of the underlying cause is essential for patients with severe bleeding. If the cause of bleeding is idiopathic or benign, supportive measures include the instillation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       units/L)",
"      </span>",
"      in the dialysate to prevent clotting in the peritoneal catheter, frequent exchanges, and the use of room temperature dialysis exchanges. Oral contraceptives may prevent ovulation and control bleeding among menstruating women. Stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or other anticoagulants should be balanced against the therapeutic indications in the individual patient. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/1\">",
"      Greenberg A, Bernardini J, Piraino BM, et al. Hemoperitoneum complicating chronic peritoneal dialysis: single-center experience and literature review. Am J Kidney Dis 1992; 19:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/2\">",
"      Harnett JD, Gill D, Corbett L, et al. Recurrent hemoperitoneum in women receiving continuous ambulatory peritoneal dialysis. Ann Intern Med 1987; 107:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/3\">",
"      Tse KC, Yip PS, Lam MF, et al. Recurrent hemoperitoneum complicating continuous ambulatory peritoneal dialysis. Perit Dial Int 2002; 22:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/4\">",
"      Goodkin DA, Benning MG. An outpatient maneuver to treat bloody effluent during continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1990; 10:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/5\">",
"      Miller R, Denman R, Saltissi D, et al. Erosion of a mesenteric vessel by a Tenckhoff catheter. Perit Dial Int 1996; 16:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/6\">",
"      Van der Niepen P, Sennesael JJ, Verbeelen DL. Massive hemoperitoneum due to spleen injury by a dislocated Tenckhoff catheter. Perit Dial Int 1994; 14:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/7\">",
"      de los Santos, CA, d'Avila, DO, von Eye, O, Mottin, CM. Rupture of the spleen: a complication of continuous ambulatory peritoneal dialysis. Perit Dial Int 1986; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/8\">",
"      Borr&agrave;s M, Valdivielso JM, Egido R, et al. Haemoperitoneum caused by bilateral renal cyst rupture in an ACKD peritoneal dialysis patient. Nephrol Dial Transplant 2006; 21:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/9\">",
"      Rinaldi S, Sera F, Verrina E, et al. The Italian Registry of Pediatric Chronic Peritoneal Dialysis: a ten-year experience with chronic peritoneal dialysis catheters. Perit Dial Int 1998; 18:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/10\">",
"      Garc&iacute;a Falc&oacute;n T, Rodr&iacute;guez-Carmona A, P&eacute;rez Font&aacute;n M, et al. Complications of permanent catheter implantation for peritoneal dialysis: incidence and risk factors. Adv Perit Dial 1994; 10:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/11\">",
"      Warady, BA, Bohl, V, Alon, U, Hellerstein, S. Symptomatic peritoneal calcification in a child: Treatment with tidal peritoneal dialysis. Perit Dial Int 1994; 14:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/12\">",
"      Syed A, Holley JL, Piraino B. Splenic infarct presenting as sterile peritonitis with peripheral embolic phenomena. Adv Perit Dial 1993; 9:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/13\">",
"      Lew SQ. Hemoperitoneum: bloody peritoneal dialysate in ESRD patients receiving peritoneal dialysis. Perit Dial Int 2007; 27:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/14\">",
"      Fine A, Novak C. Hemoperitoneum due to carcinomatosis in the liver of a CAPD patient. Perit Dial Int 1996; 16:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/15\">",
"      Fern&aacute;ndez Gir&oacute;n F, Hermosilla S&aacute;nchez F, Parall&eacute; Alcalde M, Gonz&aacute;lez Mart&iacute;nez J. Hemoperitoneum in peritoneal dialysis secondary to retroperitoneal hematoma. Perit Dial Int 1996; 16:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/16\">",
"      Campisi S, Cavatorta F, De Lucia E. Iliopsoas spontaneous hematoma: an unusual cause of hemoperitoneum in CAPD patients. Perit Dial Int 1992; 12:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/17\">",
"      Lew SQ. Persistent hemoperitoneum in a pregnant patient receiving peritoneal dialysis. Perit Dial Int 2006; 26:108.",
"     </a>",
"    </li>",
"    <li>",
"     Vas, SI. Peritonitis. In: Peritoneal Dialysis, 3 ed, Nolph, KD (Ed), Kluwer Academic Publishers, Boston 1989. p.261.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24245/abstract/19\">",
"      Walshe JJ, Lee JB, Gerbasi JR. Continuous ambulatory peritoneal dialysis complicated by massive hemoperitoneum after colonoscopy. Gastrointest Endosc 1987; 33:468.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1923 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-57BF54AE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24245=[""].join("\n");
var outline_f23_43_24245=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24440672\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Menstrual bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Post-catheter insertion or manipulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Catheter-related",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Retroperitoneal pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Additional causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24440672\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=related_link\">",
"      Acquired cystic disease of the kidney in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20986?source=related_link\">",
"      Gastrointestinal disease in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=related_link\">",
"      Placement and maintenance of the peritoneal dialysis catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=related_link\">",
"      Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_43_24246="Neurologic complications of bacterial meningitis in the neonate";
var content_f23_43_24246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic complications of bacterial meningitis in the neonate",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24246/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24246/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24246/contributors\">",
"     Carol J Baker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24246/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24246/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24246/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24246/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24246/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24246/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/43/24246/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial meningitis is more common in the first month than at any other time of life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite advances in infant intensive care, neonatal meningitis remains a devastating disease. The mortality rate declined from almost 50 percent in the 1970s to contemporary rates of less than 10 to 15 percent in the late 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. However, the morbidity is relatively unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/6\">",
"     6",
"    </a>",
"    ]. Among survivors of group B streptococcal meningitis, 22 percent were neurologically impaired at hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/7\">",
"     7",
"    </a>",
"    ]. Survivors remain at high risk for neurologic sequelae and lifelong impairment as a result of infectious insult to their developing brains [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurologic complications of bacterial meningitis in the neonate will be discussed here. The clinical features, diagnosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute complications of neonatal bacterial meningitis include cerebral edema (vasogenic and cytotoxic), increased intracranial pressure, ventriculitis, cerebritis, hydrocephalus, brain abscess, cerebral infarction, and subdural effusion or empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Development of these complications may necessitate additional evaluation, neurosurgical consultation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lengthened duration of antimicrobial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ventriculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventriculitis (inflammation of the ventricular fluid and lining of the ventricles, usually in association with obstruction to cerebrospinal fluid flow) is a common complication of neonatal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In one series of gram-negative meningitis in 72 neonates, ventriculitis occurred in 20 percent (diagnosed either by ventricular tap or cranial computed tomography) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no reliable clinical signs of ventriculitis, although evidence of increased intracranial pressure (ICP) usually is present [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/13\">",
"     13",
"    </a>",
"    ]. It must be suspected on the basis of failure to respond clinically and bacteriologically to appropriate antimicrobial therapy; if ventriculitis results in obstruction to cerebrospinal fluid (CSF) flow, the access of systemic antibiotics to the ventricular CSF can be limited [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Monitoring response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuroimaging should be performed to make the diagnosis. Cranial sonography can demonstrate findings suggestive of ventriculitis or obstructed flow of CSF (intraventricular strands attached to ventricular surface, echogenic ependyma, dilated ventricles) and can be performed at the bedside [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. Contrast-enhanced computer tomography (CT) or magnetic resonance imaging (MRI) can demonstrate enhancement of the lining of the ventricles.",
"   </p>",
"   <p>",
"    Ventricular fluid aspiration is indicated for infants who have ventriculitis with an obstruction to the flow of CSF. In this setting, cultures of CSF often remain positive for the infecting organism for several days or longer.",
"   </p>",
"   <p>",
"    The management of infants with ventriculitis is best undertaken in consultation with specialists in pediatric infectious diseases and pediatric neurosurgery. Treatment can involve direct instillation of an antimicrobial such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    directly into the ventricle. The duration of antimicrobial therapy may extend several weeks longer than the time required to sterilize the ventricular CSF and can be as long as six to eight weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocephalus occurs in approximately 24 percent of infants with neonatal meningitis overall [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/15\">",
"     15",
"    </a>",
"    ], 30 to 44 percent of cases of gram-negative neonatal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/12,16\">",
"     12,16",
"    </a>",
"    ], and 56 percent of fatal cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/17\">",
"     17",
"    </a>",
"    ]. Hydrocephalus is more common in meningitis caused by group B streptococcus (GBS) type III than by other types of GBS, and in K1",
"    <em>",
"     Escherichia coli",
"    </em>",
"    meningitis than in non-K1",
"    <em>",
"     E. coli",
"    </em>",
"    meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical findings of hydrocephalus include signs of increased intracranial pressure (bradycardia, hypertension, respiratory depression) and accelerated head growth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10\">",
"     10",
"    </a>",
"    ]. However, these are late findings; significant dilatation of the ventricles can occur before head growth becomes abnormal.",
"   </p>",
"   <p>",
"    Diagnosis is made with neuroimaging. In the neonate, cranial sonography is the preferred technique for the initial examination because it is portable and avoids ionizing radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anesthesia. The management of hydrocephalus is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=see_link\">",
"     \"Hydrocephalus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Brain abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain abscess occurs in 13 percent of patients with neonatal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/15\">",
"     15",
"    </a>",
"    ], and in 11 to 19 percent of patients with gram-negative neonatal bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. The risk of brain abscess is increased in neonates with meningitis caused by",
"    <em>",
"     Citrobacter koseri",
"    </em>",
"    (previously",
"    <em>",
"     diversus",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/19-21\">",
"     19-21",
"    </a>",
"    ],",
"    <em>",
"     Serratia marcescens",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/22\">",
"     22",
"    </a>",
"    ],",
"    <em>",
"     Proteus mirabilis",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/8,23\">",
"     8,23",
"    </a>",
"    ], and",
"    <em>",
"     Enterobacter sakazakii",
"    </em>",
"    (also known as",
"    <em>",
"     Cronobacter",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings consistent with brain abscess(es) typically develop in the second week of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10\">",
"     10",
"    </a>",
"    ]. The findings can be subtle and include vomiting, bulging fontanelle, increased head circumference, separation of the cranial sutures, hemiparesis, focal seizures, and increased peripheral white blood cell (WBC) count [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/8,10,26\">",
"     8,10,26",
"    </a>",
"    ]. Development of a brain abscess should be suspected in neonates with bacterial meningitis and new-onset seizures or prominent focal cerebral signs, or poor clinical response to antibiotic therapy. Marked clinical deterioration can occur if the abscess ruptures into the lateral ventricle or subarachnoid space [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10,27\">",
"     10,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings on repeat lumbar puncture (LP) can include CSF pleocytosis of up to a few hundred cells, with a predominance of mononuclear cells, and elevated protein [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/27\">",
"     27",
"    </a>",
"    ]. If the abscess has ruptured into the lateral ventricle or subarachnoid space, the CSF WBC count and protein can be increased, and the CSF glucose can be decreased compared with those at the time of initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If brain abscess is suspected, neuroimaging should be performed. Contrast-enhanced CT or MRI are preferred, although cranial sonography can demonstrate an echogenic rim with a hypoechogenic center, but sonographic differentiation between hemorrhagic necrosis and abscess is not always possible [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/14\">",
"     14",
"    </a>",
"    ]. Characteristic cranial CT or MRI findings of brain abscess include a variably circumscribed region of decreased attenuation and contrast enhancement of the rim [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10\">",
"     10",
"    </a>",
"    ]. The area of decreased attenuation is often of greater extent than the abscess itself because of the presence of cerebritis with surrounding edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A neurosurgeon should be consulted regarding the need for surgical intervention (needle aspiration or excision). Serial brain imaging at weekly or biweekly intervals should be performed to monitor the evolution of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10\">",
"     10",
"    </a>",
"    ]. The duration of antibiotic therapy may need to be extended to six to eight weeks depending on the clinical and radiographic response [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/28\">",
"     28",
"    </a>",
"    ]. The minimum duration of treatment for brain abscess complicating GBS meningitis is 21 days, and for brain abscess complicating gram-negative meningitis is 21 days or at least 14 days after sterilization of CSF is achieved.",
"   </p>",
"   <p>",
"    The development of a brain abscess is associated with poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10\">",
"     10",
"    </a>",
"    ]. In one series of 30 cases of neonatal brain abscess (20 were associated with meningitis, 27 were caused by",
"    <em>",
"     Proteus",
"    </em>",
"    species), there were four deaths (three from the initial illness and one from a shunt complication) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/8\">",
"     8",
"    </a>",
"    ]. Among the 27 who survived the acute illness, 16 had seizures. Among the 17 survivors who were followed until two years of age, 13 (76 percent) had an intelligence quotient (IQ) or developmental quotient (DQ) less than 80.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy studies indicate that infarction occurs in 30 to 50 percent of cases of fatal neonatal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/4,17,29\">",
"     4,17,29",
"    </a>",
"    ]. Thrombosis more often occurs in small than in major vessels and involves veins more often than arteries. In one series, more than one-half of cases of infarction occurred in the first week after the diagnosis of meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/29\">",
"     29",
"    </a>",
"    ]. Clinical manifestations of cerebral infarction include focal seizures and hemiparesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=see_link\">",
"     \"Stroke in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Subdural effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural effusion occurs in approximately 11 percent of neonates with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/15\">",
"     15",
"    </a>",
"    ], and 7 to 13 percent of those with gram-negative meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. However, clinically significant subdural effusion is uncommon in neonates with bacterial meningitis, and subdural empyema is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical findings of subdural effusion are often subtle or absent. They can include bulging fontanelle, accelerated head growth, or signs of increased ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10,15\">",
"     10,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most subdural effusions resolve spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10,28,30,31\">",
"     10,28,30,31",
"    </a>",
"    ]. Indications for aspiration can include suspicion that the fluid is infected (eg, subdural empyema), imminent development of craniocerebral disproportion, focal neurologic findings,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evidence of increased ICP if the findings appear to be related to the effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10,30\">",
"     10,30",
"    </a>",
"    ]. Subdural empyema is best managed by surgical drainage if the collection is large [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHRONIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic complications of neonatal meningitis include hydrocephalus, multicystic encephalomalacia and porencephaly (the end of the continuum of multifocal parenchymal injury), and cerebral cortical and white matter atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/10\">",
"     10",
"    </a>",
"    ]. The clinical manifestations of these complications include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/12,15,30\">",
"     12,15,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Developmental delay in approximately 25 percent",
"     </li>",
"     <li>",
"      Late-onset seizures in approximately 20 percent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link\">",
"       \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cerebral palsy in approximately 20 percent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link\">",
"       \"Epidemiology and etiology of cerebral palsy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"       \"Clinical features of cerebral palsy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hearing loss (which occurs acutely) in approximately 10 percent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link\">",
"       \"Etiology of hearing impairment in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"       \"Evaluation of hearing impairment in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cortical blindness in &lt;10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three to 12 years (mean seven years) after GBS meningitis in term infants, 25 percent of children have mild-to-moderate neurologic impairments and 19 percent have severe neurologic impairments [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional adverse outcomes, such as progressive myelopathy and arachnoiditis and infantile spasms in an infant who also had extensive sinus thrombosis, have occurred following neonatal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24246/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The rate of chronic complications varies to some extent with the causative organism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute complications of neonatal bacterial meningitis include cerebral edema, increased intracranial pressure, ventriculitis, hydrocephalus, brain abscess, cerebral infarction, and subdural effusion or empyema. Neonates being treated for bacterial meningitis should be monitored for signs of acute complications throughout their course. Clinical manifestations may include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Failure to respond clinically and bacteriologically to appropriate antimicrobial therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Monitoring response to therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Signs of increased intracranial pressure (bradycardia, hypertension, respiratory depression, bulging fontanelle, accelerated head growth, separation of the cranial sutures) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Hydrocephalus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Brain abscess'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Subdural effusion'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hemiparesis (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Brain abscess'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Infarction'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Focal seizures or new-onset seizures (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Brain abscess'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Infarction'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Development of these complications may necessitate additional evaluation, neurosurgical consultation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased duration of antimicrobial therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic complications of neonatal meningitis include hydrocephalus, multicystic encephalomalacia and porencephaly (the end of the continuum of multifocal parenchymal injury), and cerebral cortical and white matter atrophy. The clinical manifestations of these complications include developmental delay, late-onset seizures, cerebral palsy, hearing loss, cortical blindness, and learning disabilities. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chronic complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/1\">",
"      Wenger JD, Hightower AW, Facklam RR, et al. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group. J Infect Dis 1990; 162:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/2\">",
"      Harvey D, Holt DE, Bedford H. Bacterial meningitis in the newborn: a prospective study of mortality and morbidity. Semin Perinatol 1999; 23:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/3\">",
"      de Louvois J, Halket S, Harvey D. Neonatal meningitis in England and Wales: sequelae at 5 years of age. Eur J Pediatr 2005; 164:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/4\">",
"      Bortolussi R, Krishnan C, Armstrong D, Tovichayathamrong P. Prognosis for survival in neonatal meningitis: clinical and pathologic review of 52 cases. Can Med Assoc J 1978; 118:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/5\">",
"      Chang CJ, Chang WN, Huang LT, et al. Neonatal bacterial meningitis in southern Taiwan. Pediatr Neurol 2003; 29:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/6\">",
"      Polin RA, Harris MC. Neonatal bacterial meningitis. Semin Neonatol 2001; 6:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/7\">",
"      Levent F, Baker CJ, Rench MA, Edwards MS. Early outcomes of group B streptococcal meningitis in the 21st century. Pediatr Infect Dis J 2010; 29:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/8\">",
"      Renier D, Flandin C, Hirsch E, Hirsch JF. Brain abscesses in neonates. A study of 30 cases. J Neurosurg 1988; 69:877.",
"     </a>",
"    </li>",
"    <li>",
"     Estripeaut D, Saez-Llorens X. Perinatal bacterial diseases. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.979.",
"    </li>",
"    <li>",
"     Volpe JJ. Bacterial and fungal intracranial infections. In: Neurology of the newborn, 4th ed, WB Saunders Company, Philadelphia 2001. p.774.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/11\">",
"      Salmon JH. Ventriculitis complicating meningitis. Am J Dis Child 1972; 124:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/12\">",
"      Unhanand M, Mustafa MM, McCracken GH Jr, Nelson JD. Gram-negative enteric bacillary meningitis: a twenty-one-year experience. J Pediatr 1993; 122:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/13\">",
"      Miyairi I, Causey KT, DeVincenzo JP, Buckingham SC. Group B streptococcal ventriculitis: a report of three cases and literature review. Pediatr Neurol 2006; 34:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/14\">",
"      Yikilmaz A, Taylor GA. Sonographic findings in bacterial meningitis in neonates and young infants. Pediatr Radiol 2008; 38:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/15\">",
"      Pong A, Bradley JS. Bacterial meningitis and the newborn infant. Infect Dis Clin North Am 1999; 13:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/16\">",
"      McCracken GH Jr, Threlkeld N, Mize S, et al. Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation. JAMA 1984; 252:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/17\">",
"      Berman PH, Banker BQ. Neonatal meningitis. A clinical and pathological study of 29 cases. Pediatrics 1966; 38:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/18\">",
"      de Louvois J. Acute bacterial meningitis in the newborn. J Antimicrob Chemother 1994; 34 Suppl A:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/19\">",
"      Kline MW, Kaplan SL. Citrobacter diversus and neonatal brain abscess. Pediatr Neurol 1987; 3:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/20\">",
"      Graham DR, Band JD. Citrobacter diversus brain abscess and meningitis in neonates. JAMA 1981; 245:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/21\">",
"      Doran TI. The role of Citrobacter in clinical disease of children: review. Clin Infect Dis 1999; 28:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/22\">",
"      Campbell JR, Diacovo T, Baker CJ. Serratia marcescens meningitis in neonates. Pediatr Infect Dis J 1992; 11:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/23\">",
"      Phan H, Lehman D. Cerebral abscess complicating Proteus mirabilis meningitis in a newborn infant. J Child Neurol 2012; 27:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/24\">",
"      Willis J, Robinson JE. Enterobacter sakazakii meningitis in neonates. Pediatr Infect Dis J 1988; 7:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/25\">",
"      Iversen C, Lehner A, Mullane N, et al. Identification of \"Cronobacter\" spp. (Enterobacter sakazakii). J Clin Microbiol 2007; 45:3814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/26\">",
"      Hoffman HJ, Hendrick EB, Hiscox JL. Cerebral abscesses in early infancy. J Neurosurg 1970; 33:172.",
"     </a>",
"    </li>",
"    <li>",
"     Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.222.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/28\">",
"      Rabe EF, Flynn RE, Dodge PR. Subdural collections of fluid in infants and children. A study of 62 patients with special reference to factors influencing prognosis and the efficacy of various forms of therapy. Neurology 1968; 18:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/29\">",
"      Friede RL. Cerebral infarcts complicating neonatal leptomeningitis. Acute and residual lesions. Acta Neuropathol 1973; 23:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/30\">",
"      Feigin RD, McCracken GH Jr, Klein JO. Diagnosis and management of meningitis. Pediatr Infect Dis J 1992; 11:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/31\">",
"      Syrogiannopoulos GA, Nelson JD, McCracken GH Jr. Subdural collections of fluid in acute bacterial meningitis: a review of 136 cases. Pediatr Infect Dis 1986; 5:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/32\">",
"      Libster R, Edwards KM, Levent F, et al. Long-term outcomes of group B streptococcal meningitis. Pediatrics 2012; 130:e8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/33\">",
"      de Goede CG, Jardine PE, Eunson P, et al. Severe progressive late onset myelopathy and arachnoiditis following neonatal meningitis. Eur J Paediatr Neurol 2006; 10:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24246/abstract/34\">",
"      Soman TB, Moharir M, DeVeber G, Weiss S. Infantile spasms as an adverse outcome of neonatal cortical sinovenous thrombosis. J Child Neurol 2006; 21:126.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6017 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24246=[""].join("\n");
var outline_f23_43_24246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ventriculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Brain abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Subdural effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHRONIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=related_link\">",
"      Clinical features and diagnosis of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=related_link\">",
"      Stroke in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=related_link\">",
"      Treatment and outcome of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_43_24247="Bronchiolitis in adults";
var content_f23_43_24247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bronchiolitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24247/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24247/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24247/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24247/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24247/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24247/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/43/24247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchiolitis and bronchiolitis obliterans are general terms used to describe a nonspecific inflammatory injury that primarily affects the",
"    <strong>",
"     small airways",
"    </strong>",
"    (eg, less than 2 mm in diameter), often sparing a considerable portion of the interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The terms are often confusing because they describe both a clinical syndrome and a constellation of histopathologic abnormalities that may occur in a variety of disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/4\">",
"     4",
"    </a>",
"    ]. Unfortunately, much of the literature about bronchiolitis consists of isolated case reports or small case series. In addition, tissue confirmation of the diagnosis has not been described in many of these reports [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, many uncertainties remain regarding the epidemiology, pathophysiology, long-term sequelae, and therapy of bronchiolitis. The most important clinical syndromes associated with bronchiolitis are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef70650 \" href=\"UTD.htm?5/12/5326\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/3,6\">",
"     3,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of bronchiolitis in adults is provided here. The acute infectious bronchiolitis that occurs predominantly in young children is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=see_link\">",
"     \"Bronchiolitis in infants and children: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=see_link\">",
"     \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A discussion of the idiopathic form of organizing pneumonia also known as bronchiolitis obliterans organizing pneumonia (BOOP) is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"     \"Cryptogenic organizing pneumonia\"",
"    </a>",
"    .) \"BOOP\" refers to disorders characterized histologically by intraluminal polyps in the respiratory bronchioles, alveolar ducts, and alveolar spaces, accompanied by organizing pneumonia in the more distal parenchyma.",
"   </p>",
"   <p>",
"    Another potentially confusing entity is bronchiolitis obliterans syndrome (BOS). BOS is a clinical term that refers to the progressive airflow limitation caused by small airway obstruction that may occur following lung transplantation. BOS is defined by lung function changes, not by histology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most instances, the pathogenesis of bronchiolitis remains poorly defined. Injury to the bronchiolar epithelium appears to initiate the process (",
"    <a class=\"graphic graphic_figure graphicRef70237 \" href=\"UTD.htm?42/58/43948\">",
"     figure 1",
"    </a>",
"    ). The alveoli immediately adjacent to the small airways are also frequently involved. The repair process may result in complete recovery or may be characterized by excessive proliferation of granulation tissue that causes narrowing or obliteration of the airway lumen. In some cases, fibrosis is primarily submucosal and peribronchiolar in distribution, resulting in extrinsic narrowing or obliteration of the bronchiolar lumen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two general classification schemes are useful in defining cases of bronchiolitis: a clinical classification [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/7\">",
"     7",
"    </a>",
"    ] and a histopathologic classification [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following clinical classification divides bronchiolitis into several groups based primarily upon etiology (",
"    <a class=\"graphic graphic_table graphicRef70650 \" href=\"UTD.htm?5/12/5326\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhalational injury, infections, and drug-induced processes are recognized by their association with an acute illness or known exposure before the onset of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/9-13\">",
"       9-13",
"      </a>",
"      ]. Examples include inhalation of nitrogen oxides, ammonia, welding fumes, or food flavoring fumes (eg, diacetyl); infection with respiratory syncytial virus, adenovirus, or Mycoplasma pneumoniae; and ingestion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , gold, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Idiopathic cases are often characterized by the insidious onset of cough or dyspnea. An obstructive ventilatory defect, without significant responsiveness to bronchodilators, may be present. These cases are frequently confused with more common causes of these symptoms, such as asthma or chronic obstructive pulmonary disease (COPD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathologic classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several histopathological patterns have been described: permanent extrinsic narrowing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obliteration of small airways, referred to as \"constrictive\" bronchiolitis; fibrous tissue proliferation within the airways, referred to as \"proliferative\" bronchiolitis; follicular bronchiolitis; airway-centered interstitial fibrosis; and diffuse panbronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. Constrictive and proliferative bronchiolitis are nonspecific pathologic descriptions and may co-exist (",
"    <a class=\"graphic graphic_table graphicRef50736 graphicRef60031 \" href=\"UTD.htm?6/2/6189\">",
"     table 2A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/15\">",
"     15",
"    </a>",
"    ]. In most instances, it appears that proliferative bronchiolitis, the more frequent variety of bronchiolitis, is an \"early\" lesion that may completely or partially resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Constrictive bronchiolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constrictive bronchiolitis is an uncommon histologic finding characterized by alterations in the walls of membranous and respiratory bronchioles, often without extensive changes in alveolar ducts and alveolar walls. These changes lead to concentric narrowing or complete obliteration of the airway lumen (",
"    <a class=\"graphic graphic_picture graphicRef75444 \" href=\"UTD.htm?16/7/16504\">",
"     picture 1",
"    </a>",
"    ). The associated lesions comprise a spectrum of abnormalities that can include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Subtle cellular infiltrates around the small airways",
"     </li>",
"     <li>",
"      Bronchiolectasia with mucus stasis, distortion, and fibrosis",
"     </li>",
"     <li>",
"      Total obliterative bronchiolar scarring (",
"      <a class=\"graphic graphic_picture graphicRef62630 \" href=\"UTD.htm?34/5/34904\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations of constrictive bronchiolitis usually include progressive airflow obstruction, sometimes in the presence of a relatively normal chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The clinical severity depends upon the type, extent, and severity of the initial lung injury. Constrictive bronchiolitis is the lesion most commonly seen following inhalation injury (",
"    <a class=\"graphic graphic_table graphicRef58035 \" href=\"UTD.htm?9/57/10139\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/8,17\">",
"     8,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Proliferative bronchiolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proliferative bronchiolitis is characterized by a more cellular appearance, fibroblast proliferation, and an organizing intraluminal exudate that occludes bronchioles from within. It is more common than constrictive bronchiolitis and is seen in association with many pulmonary disorders (",
"    <a class=\"graphic graphic_table graphicRef63546 \" href=\"UTD.htm?18/42/19116\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/15\">",
"     15",
"    </a>",
"    ]. The characteristic intraluminal fibrotic buds, called Masson bodies, are seen in respiratory bronchioles; when they extend beyond alveolar ducts to alveoli, the term organizing pneumonia is used.",
"   </p>",
"   <p>",
"    Proliferative bronchiolitis is particularly extensive or prominent in patients with cryptogenic organizing pneumonitis (COP), also called idiopathic bronchiolitis obliterans with organizing pneumonia (idiopathic BOOP). In COP, Masson bodies extend to the alveoli and may extend from one alveolus to another through the pores of Kohn (",
"    <a class=\"graphic graphic_picture graphicRef60476 \" href=\"UTD.htm?14/53/15194\">",
"     picture 3",
"    </a>",
"    ). Inflammatory changes in the surrounding alveolar walls and prominent foamy macrophages in alveolar spaces (ie, organizing pneumonia) are commonly present in COP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"     \"Cryptogenic organizing pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Follicular bronchiolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular bronchiolitis is characterized by lymphoid hyperplasia of bronchus-associated lymphoid tissue (BALT) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Hyperplastic lymphoid follicles with reactive germinal centers distributed along the bronchioles are the most characteristic features. Most cases of follicular bronchiolitis are associated with collagen vascular diseases, particularly rheumatoid arthritis and Sj&ouml;gren's syndrome. Other associations, such as immunodeficiency or hypersensitivity reaction, are less frequent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Airway-centered interstitial fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway-centered interstitial fibrosis (ACIF), also called idiopathic bronchiolocentric interstitial pneumonia and chronic bronchiolitis with fibrosis, is a form of bronchiolitis in which the key histopathologic finding is a centrilobular and bronchiolocentric inflammatory infiltrate with peribronchiolar fibrosis and an absence of granulomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Goblet cell metaplasia, squamous metaplasia, and necrosis have also been described. Many of the cases were thought to be characteristic of hypersensitivity pneumonitis (HP) on clinical grounds, although no specific antigens were identified.",
"   </p>",
"   <p>",
"    The typical patient is a middle-aged woman (40 to 50 years old) with a chronic nonproductive cough. The clinical course is worse than that of most patients with HP, nonspecific interstitial pneumonia (NSIP), or respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), the other diagnoses in the differential. Both restrictive and obstructive patterns may be found on lung function testing.",
"   </p>",
"   <p>",
"    Many of the reported patients had a history of smoking, raising concerns that cigarette smoking may be a contributor to airway injury. Chronic silent microaspiration and toxic or hypersensitivity reactions may contribute to the development of this pattern of injury in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Unlike hypersensitivity pneumonitis, the percentage of lymphocytes on bronchoalveolar lavage is less than 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Diffuse panbronchiolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse panbronchiolitis (DPB) is a distinct clinicopathologic syndrome that involves the upper and lower respiratory tracts. It occurs mainly among the Japanese and has rarely been reported outside the Far East. The histologic lesion of DPB is centered on the respiratory bronchiole, and consists of a transmural infiltrate composed of lymphocytes, plasma cells, and distinctive lipid-laden \"foamy\" macrophages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43769?source=see_link\">",
"     \"Diffuse panbronchiolitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchiolitis should be considered in patients who present with the insidious onset of cough and dyspnea, especially when the symptoms and signs do not follow a typical pattern for asthma or chronic obstructive pulmonary disease. As an example, bronchiolitis should be in the differential when airflow limitation is irreversible or associated with a gas transfer abnormality in a nonsmoker.",
"   </p>",
"   <p>",
"    A multidisciplinary approach that considers the etiologic and histopathologic classifications and radiographic pattern is often helpful. The clinical setting may also alert the clinician to suspect bronchiolitis; for example, recent toxic fume exposure, symptoms of viral infection, history of organ transplantation, or concomitant connective tissue disease.",
"   </p>",
"   <p>",
"    When bronchiolitis is suspected, the most helpful tests are chest imaging, usually a high resolution CT (HRCT) scan, and pulmonary function testing with diffusing capacity and ambulatory oximetry.",
"   </p>",
"   <p>",
"    The differential diagnosis of bronchiolitis includes chronic obstructive pulmonary disease, hypersensitivity pneumonitis, sarcoidosis, and severe asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chest imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many cases of chronic bronchiolitis, the plain chest radiographic findings are normal or show only increased bronchial wall thickening. Hyperinflation (without marked flattening of the diaphragms or hyperlucent areas) may be the only abnormality noted. In proliferative bronchiolitis, the chest radiographic findings are characterized by air-space opacifications.",
"   </p>",
"   <p>",
"    High resolution computed tomography (HRCT) is more likely to identify findings consistent with bronchiolitis than plain chest radiographs, particularly when inspiratory and expiratory HRCT images are obtained (",
"    <a class=\"graphic graphic_table graphicRef52577 \" href=\"UTD.htm?0/24/396\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/18,25,26\">",
"     18,25,26",
"    </a>",
"    ]. These findings may be sufficient to make the diagnosis in cases where there is a clear precipitating factor, although a biopsy is often still necessary. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Lung biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The most consistent abnormalities on HRCT are expiratory air trapping (mosaic or diffuse) and bronchial wall thickening (eg, centrilobular nodules and \"v\" or \"y\" shaped branching linear opacities). In addition, a pattern of diffuse ground glass opacity and a mosaic pattern of attenuation are seen in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/27\">",
"     27",
"    </a>",
"    ]. Except for a mosaic pattern of attenuation, which is highly suggestive of bronchiolitis obliterans, it is often difficult to distinguish severe asthma from bronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/18,28\">",
"     18,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cylindric bronchial dilation or bronchiectasis can be seen with constrictive bronchiolitis, particularly in cases related to transplantation, collagen vascular disease, inhalation of toxic fumes, and previous infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/26\">",
"     26",
"    </a>",
"    ]. Subpleural distribution of patchy consolidation or ground glass density is a characteristic finding of proliferative bronchiolitis on HRCT. Well or poorly-defined nodules on CT scans may correlate with areas of organizing pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with follicular bronchiolitis, the HRCT shows centrilobular and peribronchial nodules. The tree-in-bud pattern may be present. Areas of ground glass opacity and rarely, bronchial dilation and interlobular septal thickening may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/18,29\">",
"     18,29",
"    </a>",
"    ]. Thin-walled cysts may also be seen (especially in patients with concomitant lymphocytic interstitial pneumonia); they are thought to be due to check-valve obstruction of small bronchioles by lymphatic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HRCT scans of airway-centered interstitial fibrosis show a combination of peribronchovascular ground glass opacities with traction bronchiectasis and thickening of bronchial walls. The latter is characteristic of more advanced peribronchiolar fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of chest imaging in diffuse panbronchiolitis is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43769?source=see_link&amp;anchor=H10#H10\">",
"     \"Diffuse panbronchiolitis\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing is helpful for defining the severity of disease and supporting the diagnosis. In constrictive bronchiolitis, tests of lung function may be normal or show obstructive changes with air trapping. In proliferative bronchiolitis, a restrictive pattern is the most common abnormality. Diffusing capacity is usually reduced in both types, particularly as the disease progresses. Resting hypoxemia is frequently present in both patterns of bronchiolitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of cases, open or thoracoscopic lung biopsy is required to make a definitive diagnosis, although tissue confirmation may not be necessary in patients with a clear predisposition and typical HRCT. Transbronchial lung biopsy is often",
"    <strong>",
"     inadequate",
"    </strong>",
"    for diagnosis, because these processes involve the respiratory and membranous bronchioles. One exception to this is in the case of bronchiolitis obliterans following lung transplantation. Little is known about the value of bronchoalveolar lavage (BAL) in these cases.",
"   </p>",
"   <p>",
"    The histopathologic lesions are often subtle, and specific attention must be placed on examining the small airways. This may include step sectioning of the tissue with special stains (elastic stains) to identify remnants of the small airway walls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the various forms of bronchiolitis depends upon the underlying cause or associated disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Constrictive and proliferative bronchiolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following general principles have been used to guide therapy for constrictive and proliferative bronchiolitis, although data from randomized trials are lacking.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The natural history and clinical course of bronchiolitis is variable. Constrictive bronchiolitis tends to be progressive and less responsive to therapy. Conversely, proliferative bronchiolitis tends to be more responsive to therapy, often with complete clinical recovery, including physiological and radiographic improvement, in the majority of patients.",
"     </li>",
"     <li>",
"      Inhaled bronchodilators and cough suppressants are often employed to control the cough that is frequently present.",
"     </li>",
"     <li>",
"      Macrolide antibiotics are being increasingly used in the long-term management of cryptogenic bronchiolitis because of their success in improving symptoms, lung function, and mortality in patients with diffuse panbronchiolitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/30-33\">",
"       30-33",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       Erythromycin",
"      </a>",
"      impairs neutrophil chemotaxis, neutrophil superoxide production, neutrophil-derived elastolytic activity, and decreases the number of neutrophils in BAL fluid following challenge with gram-negative bacteria. In addition, erythromycin has been shown to reduce the circulating pool of T lymphocytes bearing HLA-DR, a marker of cellular activation. The optimal therapy is still unknown, as the one randomized trial was small and had methodologic problems [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/33\">",
"       33",
"      </a>",
"      ]. Low doses of oral erythromycin (200 to 600",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (250 or 500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      have been used for most patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43769?source=see_link\">",
"       \"Diffuse panbronchiolitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoids are commonly employed and are quite effective in cases of proliferative bronchiolitis, particularly when it is associated with organizing pneumonia (eg, cryptogenic organizing pneumonia) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/34\">",
"       34",
"      </a>",
"      ]. We usually start with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      lean body weight per day to a maximum of 60 mg per day, given as a single oral dose in the morning. Prednisone is gradually tapered over three to six months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"       \"Cryptogenic organizing pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In bronchiolitis due to toxic inhalation injury, glucocorticoids are occasionally effective in the management of both the acute-phase illness (pulmonary edema) and the late-phase illness (bronchiolitis obliterans). Relapses have been reported with the premature cessation of glucocorticoid therapy in some of these patients.",
"     </li>",
"     <li>",
"      Constrictive bronchiolitis in the setting of rheumatoid arthritis is sometimes related to medication (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      , gold), so any potential culprit medications should be discontinued. High dose systemic glucocorticoids have been used with variable success. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of lung disease associated with rheumatoid arthritis\", section on 'Obliterative bronchiolitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The tumor necrosis factor-alpha (TNF-alpha) inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , have been suggested as possible treatment for constrictive bronchiolitis associated with rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/35\">",
"       35",
"      </a>",
"      ]. It is not known whether they would be beneficial in other forms of constrictive bronchiolitis.",
"     </li>",
"     <li>",
"      In patients with bronchiolitis obliterans following organ transplantation, intensification of immunosuppression is sometimes successful. Gastroesophageal reflux disease (GERD) is prevalent in lung transplantation recipients and non-acid reflux has been associated with the development of bronchiolitis obliterans syndrome. Aggressive therapy for GERD, possibly including surgery, has been proposed to prevent progression of BOS, although additional studies are needed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"       \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link&amp;anchor=H19#H19\">",
"       \"Chronic lung transplant rejection: Bronchiolitis obliterans\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link&amp;anchor=H464750157#H464750157\">",
"       \"Pulmonary complications after allogeneic hematopoietic cell transplantation\", section on 'Airflow obstruction and bronchiolitis obliterans'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Follicular bronchiolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular bronchiolitis is usually treated as part of the underlying disease, whether it is a connective tissue or associated with immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/1,18\">",
"     1,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Airway-centered interstitial fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for airway-centered interstitial fibrosis is not known. In some patients, the disease appears to stabilize or improve during treatment with systemic or inhaled glucocorticoid; however, disease has progressed despite glucocorticoid treatment in about half of the patients reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24247/abstract/15,22\">",
"     15,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diffuse panbronchiolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main treatment for diffuse panbronchiolitis is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or another macrolide antibiotic such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43769?source=see_link&amp;anchor=H13#H13\">",
"     \"Diffuse panbronchiolitis\", section on 'Treatment and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchiolitis and bronchiolitis obliterans are general terms used to describe a nonspecific inflammatory injury that primarily affects the",
"      <strong>",
"       small airways",
"      </strong>",
"      and generally spares the interstitium. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchiolitis may be caused by inhalation injury, infection, or drugs; associated with organ transplantation or connective tissue disease; or may be idiopathic (",
"      <a class=\"graphic graphic_table graphicRef70650 \" href=\"UTD.htm?5/12/5326\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main pathologic categories of bronchiolitis are: constrictive, proliferative, follicular, airway-centered interstitial fibrosis, and diffuse panbronchiolitis. The constrictive and proliferative patterns may occur together. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathologic classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic findings consistent with bronchiolitis (eg, mosaic attenuation, centrilobular nodules and \"v\" or \"y\" shaped branching linear opacities) are more likely to be identified on high resolution CT scans (HRCT) than on plain chest radiographs, particularly when inspiratory and expiratory images are obtained; however, HRCT may also be normal. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Chest imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the majority of cases, open or thoracoscopic lung biopsy is required to make a definitive diagnosis, although tissue confirmation may not be necessary in patients with a clear predisposition and typical HRCT. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lung biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes chronic obstructive pulmonary disease, hypersensitivity pneumonitis, sarcoidosis, and severe asthma. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of drugs have been associated with bronchiolitis (",
"      <a class=\"graphic graphic_table graphicRef70650 \" href=\"UTD.htm?5/12/5326\">",
"       table 1",
"      </a>",
"      ); potential culprit medications should be stopped in any patient who develops bronchiolitis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We typically prescribe cough suppressants (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16101?source=see_link\">",
"       guaifenesin",
"      </a>",
"      ) and inhaled bronchodilators for patients with cough related to chronic bronchiolitis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with constrictive bronchiolitis, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (200 to 600",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or another macrolide antibiotic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with proliferative bronchiolitis, we suggest a trial of oral glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of lean body weight, up to 60 mg per day) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/1\">",
"      Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med 2003; 168:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/2\">",
"      King TE Jr. Overview of bronchiolitis. Clin Chest Med 1993; 14:607.",
"     </a>",
"    </li>",
"    <li>",
"     King TE Jr. Bronchiolitis. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), B.C. Decker, Hamilton, ON, Canada 2003. p.787.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/4\">",
"      Colby, TV, Myers, JL. The clinical and histologic spectrum of bronchiolitis obliterans including bronchiolitis obliterans organizing pneumonia (BOOP). Semin Respir Med 1992; 13:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/5\">",
"      Green M, Turton CW. Bronchiolitis and its manifestations. Eur J Respir Dis Suppl 1982; 121:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/6\">",
"      Cordier JF. Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis. Thorax 2007; 62:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/7\">",
"      Epler GR, Colby TV. The spectrum of bronchiolitis obliterans. Chest 1983; 83:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/8\">",
"      Myers JL, Colby TV. Pathologic manifestations of bronchiolitis, constrictive bronchiolitis, cryptogenic organizing pneumonia, and diffuse panbronchiolitis. Clin Chest Med 1993; 14:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/9\">",
"      Hendrick DJ. \"Popcorn worker's lung\" in Britain in a man making potato crisp flavouring. Thorax 2008; 63:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/10\">",
"      van Rooy FG, Rooyackers JM, Prokop M, et al. Bronchiolitis obliterans syndrome in chemical workers producing diacetyl for food flavorings. Am J Respir Crit Care Med 2007; 176:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/11\">",
"      Hsiue TR, Guo YL, Chen KW, et al. Dose-response relationship and irreversible obstructive ventilatory defect in patients with consumption of Sauropus androgynus. Chest 1998; 113:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/12\">",
"      Lockey JE, Hilbert TJ, Levin LP, et al. Airway obstruction related to diacetyl exposure at microwave popcorn production facilities. Eur Respir J 2009; 34:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/13\">",
"      Harber P, Levine J, Bansal S. How frequently should workplace spirometry screening be performed?: optimization via analytic models. Chest 2009; 136:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/14\">",
"      Garg K, Lynch DA, Newell JD, King TE Jr. Proliferative and constrictive bronchiolitis: classification and radiologic features. AJR Am J Roentgenol 1994; 162:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/15\">",
"      Visscher DW, Myers JL. Bronchiolitis: the pathologist's perspective. Proc Am Thorac Soc 2006; 3:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/16\">",
"      Ghanei M, Tazelaar HD, Chilosi M, et al. An international collaborative pathologic study of surgical lung biopsies from mustard gas-exposed patients. Respir Med 2008; 102:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/17\">",
"      King MS, Eisenberg R, Newman JH, et al. Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan. N Engl J Med 2011; 365:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/18\">",
"      Pipavath SJ, Lynch DA, Cool C, et al. Radiologic and pathologic features of bronchiolitis. AJR Am J Roentgenol 2005; 185:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/19\">",
"      Romero S, Barroso E, Gil J, et al. Follicular bronchiolitis: clinical and pathologic findings in six patients. Lung 2003; 181:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/20\">",
"      Yousem SA, Dacic S. Idiopathic bronchiolocentric interstitial pneumonia. Mod Pathol 2002; 15:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/21\">",
"      Yi XH, Chu HQ, Cheng XM, et al. Idiopathic airway-centered interstitial fibrosis: report of two cases. Chin Med J (Engl) 2007; 120:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/22\">",
"      Churg A, Myers J, Suarez T, et al. Airway-centered interstitial fibrosis: a distinct form of aggressive diffuse lung disease. Am J Surg Pathol 2004; 28:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/23\">",
"      de Carvalho ME, Kairalla RA, Capelozzi VL, et al. Centrilobular fibrosis: a novel histological pattern of idiopathic interstitial pneumonia. Pathol Res Pract 2002; 198:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/24\">",
"      Fukuoka J, Franks TJ, Colby TV, et al. Peribronchiolar metaplasia: a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease: clinicopathologic features of 15 cases. Am J Surg Pathol 2005; 29:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/25\">",
"      Hwang JH, Kim TS, Lee KS, et al. Bronchiolitis in adults: pathology and imaging. J Comput Assist Tomogr 1997; 21:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/26\">",
"      Lynch DA. Imaging of small airways disease and chronic obstructive pulmonary disease. Clin Chest Med 2008; 29:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/27\">",
"      Devakonda A, Raoof S, Sung A, et al. Bronchiolar disorders: a clinical-radiological diagnostic algorithm. Chest 2010; 137:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/28\">",
"      Jensen SP, Lynch DA, Brown KK, et al. High-resolution CT features of severe asthma and bronchiolitis obliterans. Clin Radiol 2002; 57:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/29\">",
"      Howling SJ, Hansell DM, Wells AU, et al. Follicular bronchiolitis: thin-section CT and histologic findings. Radiology 1999; 212:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/30\">",
"      Nagai H, Shishido H, Yoneda R, et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/31\">",
"      Azuma A, Kudoh S. Securing the safety and efficacy of macrolide therapy for chronic small airway diseases. Intern Med 2005; 44:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/32\">",
"      Khalid M, Al Saghir A, Saleemi S, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005; 25:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/33\">",
"      Yang M, Dong BR, Lu J, et al. Macrolides for diffuse panbronchiolitis. Cochrane Database Syst Rev 2010; :CD007716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/34\">",
"      King TE Jr, Mortenson RL. Cryptogenic organizing pneumonitis. The North American experience. Chest 1992; 102:8S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24247/abstract/35\">",
"      Cortot AB, Cottin V, Miossec P, et al. Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept. Respir Med 2005; 99:511.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4323 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24247=[""].join("\n");
var outline_f23_43_24247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathologic classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Constrictive bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Proliferative bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Follicular bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Airway-centered interstitial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Diffuse panbronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chest imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Constrictive and proliferative bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Follicular bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Airway-centered interstitial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diffuse panbronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4323|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/58/43948\" title=\"figure 1\">",
"      Pathogenesis of bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4323|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/7/16504\" title=\"picture 1\">",
"      Constrictive bronchiolitis Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/5/34904\" title=\"picture 2\">",
"      Constrictive bronchiolitis High",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/53/15194\" title=\"picture 3\">",
"      COP lung biopsy high power",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4323|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/12/5326\" title=\"table 1\">",
"      Causes of bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/6/7276\" title=\"table 2A\">",
"      Comparison of bronchiolitis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/31/30203\" title=\"table 2B\">",
"      Comparison of bronchiolitis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/57/10139\" title=\"table 3\">",
"      Constrictive bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/42/19116\" title=\"table 4\">",
"      Proliferative bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/24/396\" title=\"table 5\">",
"      CT patterns bronchiolitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=related_link\">",
"      Bronchiolitis in infants and children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=related_link\">",
"      Bronchiolitis in infants and children: Treatment; outcome; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43769?source=related_link\">",
"      Diffuse panbronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_43_24248="Bites of recluse spiders";
var content_f23_43_24248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bites of recluse spiders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24248/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24248/contributors\">",
"     Richard S Vetter, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24248/contributors\">",
"     David L Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24248/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24248/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24248/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24248/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/43/24248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The entomology of recluse spiders (Genus Loxosceles) and the clinical manifestations, diagnosis, differential diagnosis, and management of their bites will be reviewed here. An overview of spider bites and the management of bites of other spiders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=see_link\">",
"     \"Approach to the patient with a suspected spider bite: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENTOMOLOGY OF RECLUSE SPIDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spiders of the genus",
"    <em>",
"     Loxosceles",
"    </em>",
"    are known colloquially as recluse spiders, violin spiders, fiddleback spiders, and in South America, by the nonspecific name \"brown spiders.\"",
"   </p>",
"   <p>",
"    <em>",
"     Loxosceles",
"    </em>",
"    spiders have gained notoriety in the medical literature and lay press because their bites sometimes become necrotic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, this is a relatively uncommon sequela, and is largely limited to areas of the United States where these spiders are endemic (",
"    <a class=\"graphic graphic_figure graphicRef56537 \" href=\"UTD.htm?38/20/39236\">",
"     figure 1",
"    </a>",
"    ). Outside of these regions, the vast majority of necrotic skin lesions are caused by other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=see_link\">",
"     \"Approach to the patient with a suspected spider bite: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Appearance and identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recluse spiders are rather nondescript brown spiders (",
"    <a class=\"graphic graphic_picture graphicRef70229 \" href=\"UTD.htm?9/11/9397\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79463 \" href=\"UTD.htm?4/52/4933\">",
"     picture 2",
"    </a>",
"    ). The most accurate method of identifying a recluse spider involves counting the eyes. Most spiders have eight eyes in two rows of four. In contrast, recluse spiders have six eyes, with a pair in front, a pair on both sides, and a gap between the pairs (",
"    <a class=\"graphic graphic_picture graphicRef60968 \" href=\"UTD.htm?24/23/24947\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Identifying a recluse spider on the basis of body markings is less reliable. The brown recluse is described as having a violin pattern on its anterior cephalothorax, although this has led to widespread misidentification of common, harmless spiders as brown recluse when the dark markings on spiders' bodies are mistakenly interpreted as violins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Additionally, the violin marking is absent in many juvenile and recently-molted brown recluses and absent altogether in some other recluse species. Other features of recluse spiders include monochromatic legs, a monochromatic abdomen, and fine hairs (but not conspicuous spines) on the legs (",
"    <a class=\"graphic graphic_picture graphicRef79463 \" href=\"UTD.htm?4/52/4933\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common spider mistaken for",
"    <em>",
"     Loxosceles",
"    </em>",
"    is",
"    <em>",
"     Kukulcania",
"    </em>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef64635 \" href=\"UTD.htm?40/35/41525\">",
"     picture 4",
"    </a>",
"    ), which has a darkened pattern on the cephalothorax near the eyes of the tan males that can be mistaken for a violin pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/9\">",
"     9",
"    </a>",
"    ]. Female",
"    <em>",
"     Kukulcania",
"    </em>",
"    are black or dark brown, velvety in texture, and resemble small tarantulas, although people still mistake them for brown recluse spiders.",
"    <em>",
"     Kukulcania",
"    </em>",
"    spiders are found in the southern third of the United States from the San Francisco Bay through southern California, east through Texas to Florida and north to North Carolina and Virginia. They are frequently found in homes, although verified bites from these spiders are virtually unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Geographic location",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are 100",
"    <em>",
"     Loxosceles",
"    </em>",
"    species in the world, although only a few have extensive distributions and also exist where humans live. The majority is found in North and South America (",
"    <a class=\"graphic graphic_table graphicRef59049 \" href=\"UTD.htm?43/20/44365\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/9\">",
"     9",
"    </a>",
"    ]. Recluse bites are rare elsewhere, although they have been reported in South Africa and Australia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, recluse spiders are found in limited areas of the South, West, and Midwest (",
"      <a class=\"graphic graphic_figure graphicRef56537 \" href=\"UTD.htm?38/20/39236\">",
"       figure 1",
"      </a>",
"      ) and rarely outside these endemic areas [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/10\">",
"       10",
"      </a>",
"      ]. The brown recluse,",
"      <em>",
"       L. reclusa",
"      </em>",
"      , is the most widespread and the best known of North American recluse spiders. It is a",
"      <strong>",
"       synanthropic",
"      </strong>",
"      spider (ie, its population numbers increase in association with humans) and these spiders are commonly encountered within homes in endemic areas [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In South America,",
"      <em>",
"       Loxosceles",
"      </em>",
"      spiders of medical importance are found in Brazil and Chile. The most common species involved in envenomations are",
"      <em>",
"       L. laeta, L. intermedia",
"      </em>",
"      , and",
"      <em>",
"       L. gaucho",
"      </em>",
"      .",
"      <em>",
"       Loxosceles laeta",
"      </em>",
"      is often considered the most dangerous of the recluse spiders, in part because it is the species that attains the largest body size.",
"     </li>",
"     <li>",
"      The Mediterranean recluse,",
"      <em>",
"       L. rufescens",
"      </em>",
"      , has been transported around the world and continues to establish isolated populations inside buildings on many continents. It has been found in many American cities, where these spiders tend to develop dense populations within isolated buildings. However, despite these infestations, verified bites from Mediterranean recluse are exceedingly rare.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Habitat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recluses are found mostly inside homes, in basements, in attics, behind bookshelves and dressers, and in cupboards. As their name implies, these spiders prefer dark, quiet areas that are rarely disturbed (",
"    <a class=\"graphic graphic_table graphicRef59049 \" href=\"UTD.htm?43/20/44365\">",
"     table 1",
"    </a>",
"    ). Out of doors, they are found under objects, such as rocks or the bark of dead trees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS OF BITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loxoscelism is the term for the medical manifestations of bites by recluse spiders. In this review, the term is used to refer to both local and systemic symptoms resulting from bites, although toxicologists sometimes use the term to refer exclusively to the systemic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Venom properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Loxosceles",
"    </em>",
"    venom contains a large number of enzymes and biologically active substances, of which sphingomyelinase D is the most important. This enzyme is unique in nature to",
"    <em>",
"     Loxosceles",
"    </em>",
"    and its sister genus,",
"    <em>",
"     Sicarius",
"    </em>",
"    , but is absent in all other spiders including other closely related haplogyne spiders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sphingomyelinase is believed responsible for skin necrosis and the systemic manifestations of Loxosceles envenomation. It activates complement, induces neutrophil chemotaxis, induces apoptosis of keratinocytes and other cells, and initiates the generation of potent collagen and elastin-degrading metalloproteinases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recluse spiders (like most spiders) typically bite humans only as a desperate last line of defense as they are being crushed between flesh and some object. This happens most frequently indoors, as a result of rolling over on the spider in bed or putting on clothing or footwear that has been left in closets or on the floor, in which the spider has sought refuge.",
"   </p>",
"   <p>",
"    Recluse spider bites typically occur on the upper arm, thorax, or inner thigh. Bites on the hands or face (ie, uncovered areas) are rare.",
"   </p>",
"   <p>",
"    Recluse bites can be sustained out of doors, although these spiders are rarely found in living vegetation. Patients reporting a painful bite while reaching into living foliage are more likely to have sustained an insect sting or puncture by thorns or other sharp plant matter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Symptoms following bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms may be divided into acute local symptoms, systemic symptoms, and, in a subset of bites, necrosis of the bite site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Acute local symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial bite of a",
"    <em>",
"     Loxosceles",
"    </em>",
"    spider is usually painless, although they can occasionally be painful or cause a burning sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/15\">",
"     15",
"    </a>",
"    ]. The site can sometimes be identified by two small cutaneous puncture marks with surrounding erythema. The bite is usually a red plaque (",
"    <a class=\"graphic graphic_picture graphicRef71174 \" href=\"UTD.htm?3/34/3617\">",
"     picture 5",
"    </a>",
"    ) or papule, which often develops central pallor. The pain typically increases over the next two to eight hours, and may become severe. In most cases, this lesion is self-limited and resolves without further complications in approximately one week [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/16\">",
"     16",
"    </a>",
"    ]. In some, however, the lesion will develop a dark, depressed center over the ensuing 24 to 48 hours, culminating in a dry eschar that subsequently ulcerates. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Necrosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some patients develop urticaria or a morbilliform rash in the hours after the bite; this has been suggested by some as evidence of a prior bite, although the phenomenon has not been studied formally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Systemic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic symptoms are an infrequent complication of recluse bites, and do not correlate to local findings. Small children may be more susceptible to systemic symptoms. The following nonspecific signs and symptoms may appear over several days following a recluse bite [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malaise",
"     </li>",
"     <li>",
"      Nausea and vomiting",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Myalgias",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rare complications include acute hemolytic anemia, disseminated intravascular coagulopathy, rhabdomyolysis, myonecrosis, renal failure, coma, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/17\">",
"     17",
"    </a>",
"    ]. The risk of these complications from",
"    <em>",
"     Loxosceles",
"    </em>",
"    bites is extremely low in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link&amp;anchor=H24#H24\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\", section on 'Insect, spider, and snake bites'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Case reports of",
"    <em>",
"     Loxosceles",
"    </em>",
"    bites during pregnancy have documented no adverse effects on infant outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/16\">",
"     16",
"    </a>",
"    ]. In contrast, these complications are more common with loxoscelism from the South American species",
"    <em>",
"     L. laeta",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Antivenoms for South American recluses'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of lesions become necrotic, usually over the course of several days. The original papule or plaque develops a dusky red or blue color in the center of the lesion, and a dry, depressed center may herald necrosis. There may be anesthesia in the center. An eschar forms and subsequently breaks down to form an ulcer. The lesion may enlarge in a gravitational manner [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A fully developed necrotic lesion is usually 1 to 2 cm in diameter, although skin loss can be more extensive and ulcers as large as 40 cm or more have rarely been described. These most typically occur over fatty tissue on the buttocks and thighs.",
"   </p>",
"   <p>",
"    Lesions usually stop extending within 10 days of the bite, and most lesions heal by secondary intent over several weeks, without scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/18\">",
"     18",
"    </a>",
"    ]. Some necrotic lesions take months to heal fully. Permanent scarring or requirement for surgical repair is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Prevention and treatment of necrosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis of a spider bite is most often based on the history and clinical presentation. An assay for",
"    <em>",
"     Loxosceles",
"    </em>",
"    venom has been developed but is not commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/20\">",
"     20",
"    </a>",
"    ]. Of note, the diagnosis of a spider bite can be considered definitive only if both of the following criteria are fulfilled:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A spider was observed inflicting the bite.",
"     </li>",
"     <li>",
"      The spider was recovered, collected, and properly identified by an expert entomologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If both of the above conditions are not met, then other conditions such as vasculitis, infection, vascular problems, or other relevant disorders must be excluded.",
"   </p>",
"   <p>",
"    The general approach to a patient suspected of having a spider bite, as well as the differential diagnosis of an uncomplicated (lacking signs of necrosis) spider bite, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=see_link\">",
"     \"Approach to the patient with a suspected spider bite: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous conditions have been mistaken for a necrotic recluse spider bite (",
"    <a class=\"graphic graphic_table graphicRef64314 \" href=\"UTD.htm?12/9/12445\">",
"     table 2",
"    </a>",
"    ). The most common disorders in the differential diagnosis are presented in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Solitary ulcerated lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that can cause single ulcerated lesions include infections, trauma, vascular diseases, pyoderma gangrenosum, and vasculitides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common infections that can become necrotic include staphylococcus and streptococcal infections, deep fungal infections, and atypical mycobacterial infections (",
"    <a class=\"graphic graphic_table graphicRef64314 \" href=\"UTD.htm?12/9/12445\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections can begin with singular papules or pustules that may evolve to necrotic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. CA-MRSA is far more prevalent than spider bites. CA-MRSA strains both in the United States and in Europe have an enhanced virulence that has resulted in the more striking clinical manifestations, compared with non-MRSA. Infections occur both sporadically and as institutional epidemics in nursing homes, prisons, military barracks, and athletic facilities. Risk factors and epidemiology of CA-MRSA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient who had recently traveled to the tropics and presented with a skin ulcer would require evaluation for the various infections that can cause ulcerating lesions (",
"    <a class=\"graphic graphic_table graphicRef56355 \" href=\"UTD.htm?38/62/39916\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20152?source=see_link\">",
"     \"Skin lesions in the returning traveler\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foot and ankle ulcers can be seen in patients with chronic venous insufficiency, arterial insufficiency, or diabetes mellitus, and a history of the underlying disease should alert clinicians to this possibility. These ulcers are distinguishable by various characteristics (",
"    <a class=\"graphic graphic_table graphicRef63577 \" href=\"UTD.htm?5/32/5645\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=see_link\">",
"     \"Diagnostic evaluation of chronic venous insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Pyoderma gangrenosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyoderma gangrenosum is an idiopathic disorder in which dark, blue-red papules progress to necrotic ulcerating lesions. Patients may report a history of antecedent trauma at the site or have signs of systemic illness. Borders are typically irregular and the lesion may have a purulent base (",
"    <a class=\"graphic graphic_picture graphicRef53733 \" href=\"UTD.htm?38/17/39187\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55967 \" href=\"UTD.htm?30/56/31618\">",
"     picture 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2328?source=see_link\">",
"     \"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vasculitides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis and necrotizing vasculitis may present with singular lesions (",
"    <a class=\"graphic graphic_picture graphicRef78697 \" href=\"UTD.htm?9/36/9794\">",
"     picture 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=see_link\">",
"     \"Diseases with eosinophilic involvement of specific organs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systemic symptoms of recluse spider envenomation (eg, malaise, nausea and vomiting, fever, and myalgias) are sufficiently nonspecific that an accompanying lesion, preferably with an identifiable spider, is essential for making the diagnosis of a spider bite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of a recluse spider bite involves local wound care, pain management, and tetanus prophylaxis if indicated.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    may be administered in some cases, both to prevent progression to necrosis, and to reduce pain. An array of other interventions have been reported in the medical literature, although most are based upon animal studies or isolated human case reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Local wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment measures following any spider bite include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clean the bite with mild soap and water.",
"     </li>",
"     <li>",
"      Apply cold packs, taking care not to freeze the tissue.",
"     </li>",
"     <li>",
"      Maintain the affected body part in an elevated or neutral position (if possible).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     General measures following bites",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administer pain medication as needed. Some patients will respond to nonsteroidal antiinflammatory medications, while others may require opioids.",
"     </li>",
"     <li>",
"      Administer tetanus prophylaxis if indicated (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most bites can be managed with minimal intervention and heal without scarring. Resolving bites should be monitored for the development of secondary bacterial infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Indications for antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are prescribed only if there are signs of infection such as increased erythema, fluctuation, and suppuration. If infection is suspected, it should be treated with antibiotics for cellulitis, as outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef64128 \" href=\"UTD.htm?23/12/23756\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prevention and treatment of necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    may be administered for the purpose of preventing the development of necrosis, provided the patient does not have glucose-6-phosphate dehydrogenase (G6PD) deficiency. However, evidence showing improved outcomes in humans receiving dapsone for recluse spider bites is lacking and some experts do not advocate its use. Dapsone may also be helpful for reducing pain in lesions with established necrosis, in one author's (DLS) experience. It is proposed to act by inhibiting neutrophil chemotaxis and lysosomal free radical generation. Early animal studies of dapsone demonstrated marked reduction of ulceration in rabbits and guinea pigs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], although subsequent studies have not shown clear benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], and no controlled trials in humans have been performed.",
"   </p>",
"   <p>",
"    Potential recipients of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    should be screened for G6PD deficiency because hemolytic anemia is a more common complication of dapsone in patients with reduced activity of this enzyme and they should not receive this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/27\">",
"     27",
"    </a>",
"    ]. The results of screening tests are usually available within 24 hours, and we await confirmation that the patient is not G6PD deficient before administering dapsone. Even patients with normal G6PD activity will commonly experience a drop in hemoglobin by 1 to 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    during therapy. Other uncommon but serious side effects of dapsone include aplastic anemia, methemoglobinemia, and dapsone hypersensitivity syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    if the lesion has developed a dusky center indicating that it may be progressing to necrosis. Dapsone may be dosed initially (in adults) at 50 mg twice daily, and increased to 100 mg twice daily if the lesion appears to progress further towards necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. Pediatric dosing is based upon weight. We usually administer a 10 day course. Once the lesion is demarcated and clinically stable, debridement and wound care may assist healing. A small minority of necrotic lesions later require surgical revision of scars, including skin grafting.",
"   </p>",
"   <p>",
"    Several other therapies have been proposed or performed but are not recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Insufficiently studied treatments",
"      </strong>",
"      &ndash; Therapies which have not been adequately studied in humans include antihistamines, glucocorticoids, empiric administration of topical or systemic antibiotics, vasodilators,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , hyperbaric oxygen,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"       dextran",
"      </a>",
"      , and local electric shock [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/28-30\">",
"       28-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Application of topical tetracycline has been shown to reduce the progression of dermonecrotic lesions in rabbits exposed to",
"      <em>",
"       Loxosceles intermedia",
"      </em>",
"      venom but awaits further study in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Role of surgical interventions",
"      </strong>",
"      &ndash; Early surgical excision",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      curettage of a necrotic lesion is potentially harmful",
"      <strong>",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/28,31-33\">",
"       28,31-33",
"      </a>",
"      ]. One retrospective study of 31 patients with bites affecting the upper extremity or hand concluded that painful and recurrent wound breakdown occurred more often with early surgical excision [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Antivenoms for South American recluses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antivenoms for the treatment of recluse spider bites are available in Brazil, Mexico, and Peru, although not in the United States. As mentioned previously, the bites of South America",
"    <em>",
"     Loxosceles",
"    </em>",
"    species (eg,",
"    <em>",
"     L. gaucho",
"    </em>",
"    ) are more severe than those of recluse spiders found in the United States.",
"   </p>",
"   <p>",
"    Observational studies in humans and animal trials suggest that South American recluse antivenoms may reduce the risk of dermatonecrosis, as well as systemic envenomation and its severe complications (eg, hemolysis, renal failure, and disseminated intravascular coagulation). However, definite benefit in humans is not well established [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24248/abstract/15,34-37\">",
"     15,34-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DISCHARGE INSTRUCTIONS AND AFTER CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be counseled about how to care for the bite site and advised to watch the site for signs of secondary bacterial infection (eg, fever, spreading redness, pus formation or drainage), as well as progressive skin changes that suggest early necrosis (ie, enlargement of the lesion or",
"    <span class=\"nowrap\">",
"     black/blue",
"    </span>",
"    color changes).",
"   </p>",
"   <p>",
"    Patients who are concerned about avoiding future recluse bites should be counseled to shake out clothes, shoes, gloves, and other items that have been unused or lying on the floor before putting them on.",
"   </p>",
"   <p>",
"    Beds should be modified so that only the legs of the bed touch the floor: beds should be moved away from the wall, bedding should be tucked in and bed ruffles removed, and items should not be stored beneath the bed.",
"   </p>",
"   <p>",
"    Insecticides may be effective for controlling recluse populations within the home; however, these must be properly administered by a pest control professional. Placement of sticky traps next to baseboards but out of reach of curious children and pets is another useful method to eliminate brown recluse spiders from a building.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/16/10498?source=see_link\">",
"       \"Patient information: Spider bites (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recluse spiders (Genus",
"    <em>",
"     Loxosceles",
"    </em>",
"    ) are one of a handful of spiders throughout the world which are capable of inflicting medically significant bites in humans. They are found mostly in certain parts of North and South America. In the United States, recluse spiders are limited to areas of the South, West, and Midwest (",
"    <a class=\"graphic graphic_figure graphicRef56537 \" href=\"UTD.htm?38/20/39236\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Entomology of recluse spiders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Entomology and clinical features of bites",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recluse spiders are nondescript brown spiders (",
"      <a class=\"graphic graphic_picture graphicRef70229 \" href=\"UTD.htm?9/11/9397\">",
"       picture 1",
"      </a>",
"      ) that can be more reliably identified by their distinctive eye pattern (three pairs) (",
"      <a class=\"graphic graphic_picture graphicRef60968 \" href=\"UTD.htm?24/23/24947\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Entomology of recluse spiders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recluse spider bites are usually sustained indoors, as a result of rolling over on the spider in bed or putting on clothing or footwear in which the spider has sought refuge. These spiders are not aggressive and generally bite humans only when being crushed between flesh and some object. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Habitat'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients presenting with possible spider bites should always be questioned carefully regarding the circumstances surrounding the bite. Other disorders are responsible for most lesions attributed to spider bites (",
"      <a class=\"graphic graphic_table graphicRef64314 \" href=\"UTD.htm?12/9/12445\">",
"       table 2",
"      </a>",
"      ), unless the patient witnessed the spider inflicting the bite and can retrieve the spider for identification by an entomologist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=see_link\">",
"       \"Approach to the patient with a suspected spider bite: An overview\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Loxoscelism is the term for the medical manifestations of bites by recluse spiders. The initial bite of a",
"      <em>",
"       Loxosceles",
"      </em>",
"      spider is usually painless, although some are painful or have a burning quality. The bite is usually a red plaque (",
"      <a class=\"graphic graphic_picture graphicRef71174 \" href=\"UTD.htm?3/34/3617\">",
"       picture 5",
"      </a>",
"      ), which can sometimes be identified by two small cutaneous puncture marks with surrounding erythema. In most cases, this lesion is self-limited and resolves without further complications. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Acute local symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic symptoms are more common in small children than adults. These may appear over several days following a bite and include malaise, nausea and vomiting, fever, and myalgias. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Systemic symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A minority of lesions become necrotic, usually over the course of several days. These generally heal by secondary intent over several weeks, without scarring. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Necrosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment summary",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate management includes local wound care, pain medication if needed, and possible administration of tetanus prophylaxis (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Local wound care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'General measures following bites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotics for cellulitis are indicated only if there are signs or symptoms of infection, such as increased erythema, fluctuation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      suppuration (",
"      <a class=\"graphic graphic_table graphicRef64128 \" href=\"UTD.htm?23/12/23756\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Indications for antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with bites that have a dusky center or other signs of developing necrosis, we suggest administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). After screening for glucose-6-phosphate dehydrogenase deficiency, we give adults 50 mg to 100 mg twice daily, for 10 days. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Prevention and treatment of necrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not performing early surgical excision",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      curettage of a necrotic lesion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, once the lesion is demarcated and clinically stable, debridement and wound care may assist healing. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Prevention and treatment of necrosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/1\">",
"      Macchiavello, A. Cutaneous arachidism or gangrenous spot of Chile. Puerto Rico J Pub Health Trop Med 1947; 22:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/2\">",
"      ATKINS JA, WINGO CW, SODEMAN WA. Probable cause of necrotic spider bite in the Midwest. Science 1957; 126:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/3\">",
"      Vetter RS, Cushing PE, Crawford RL, Royce LA. Diagnoses of brown recluse spider bites (loxoscelism) greatly outnumber actual verifications of the spider in four western American states. Toxicon 2003; 42:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/4\">",
"      Vetter RS, Edwards GB, James LF. Reports of envenomation by brown recluse spiders (Araneae: Sicariidae) outnumber verifications of Loxosceles spiders in Florida. J Med Entomol 2004; 41:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/5\">",
"      Bennett RG, Vetter RS. An approach to spider bites. Erroneous attribution of dermonecrotic lesions to brown recluse or hobo spider bites in Canada. Can Fam Physician 2004; 50:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/6\">",
"      Frithsen IL, Vetter RS, Stocks IC. Reports of envenomation by brown recluse spiders exceed verified specimens of Loxosceles spiders in South Carolina. J Am Board Fam Med 2007; 20:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/7\">",
"      Vetter R. Identifying and misidentifying the brown recluse spider. Dermatol Online J 1999; 5:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/8\">",
"      Vetter RS. Arachnids submitted as suspected brown recluse spiders (Araneae: Sicariidae): Loxosceles spiders are virtually restricted to their known distributions but are perceived to exist throughout the United States. J Med Entomol 2005; 42:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/9\">",
"      Swanson DL, Vetter RS. Loxoscelism. Clin Dermatol 2006; 24:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/10\">",
"      Swanson DL, Vetter RS. Bites of brown recluse spiders and suspected necrotic arachnidism. N Engl J Med 2005; 352:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/11\">",
"      Vetter RS, Barger DK. An infestation of 2,055 brown recluse spiders (Araneae: Sicariidae) and no envenomations in a Kansas home: implications for bite diagnoses in nonendemic areas. J Med Entomol 2002; 39:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/12\">",
"      Sandidge J. Predation by cosmopolitan spiders upon the medically significant pest species Loxosceles reclusa (Araneae: Sicariidae): limited possibilities for biological control. J Econ Entomol 2004; 97:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/13\">",
"      Binford GJ, Wells MA. The phylogenetic distribution of sphingomyelinase D activity in venoms of Haplogyne spiders. Comp Biochem Physiol B Biochem Mol Biol 2003; 135:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/14\">",
"      Tambourgi DV, Paix&atilde;o-Cavalcante D, Gon&ccedil;alves de Andrade RM, et al. Loxosceles sphingomyelinase induces complement-dependent dermonecrosis, neutrophil infiltration, and endogenous gelatinase expression. J Invest Dermatol 2005; 124:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/15\">",
"      Isbister GK, Fan HW. Spider bite. Lancet 2011; 378:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/16\">",
"      Anderson PC. Loxoscelism threatening pregnancy: five cases. Am J Obstet Gynecol 1991; 165:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/17\">",
"      Fran&ccedil;a FO, Barbaro KC, Abdulkader RC. Rhabdomyolysis in presumed viscero-cutaneous loxoscelism: report of two cases. Trans R Soc Trop Med Hyg 2002; 96:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/18\">",
"      Futrell JM. Loxoscelism. Am J Med Sci 1992; 304:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/19\">",
"      Kemp ED. Bites and stings of the arthropod kind. Treating reactions that can range from annoying to menacing. Postgrad Med 1998; 103:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/20\">",
"      Stoecker WV, Green JA, Gomez HF. Diagnosis of loxoscelism in a child confirmed with an enzyme-linked immunosorbent assay and noninvasive tissue sampling. J Am Acad Dermatol 2006; 55:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/21\">",
"      Dominguez TJ. It's not a spider bite, it's community-acquired methicillin-resistant Staphylococcus aureus. J Am Board Fam Pract 2004; 17:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/22\">",
"      El Fakih, RO, Moore, TA, Mortada, RA. The danger of diagnostic error: community-acquired MRSA or a spider bite? Kansas J Med 2008; 1:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/23\">",
"      King LE Jr, Rees RS. Dapsone treatment of a brown recluse bite. JAMA 1983; 250:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/24\">",
"      Barrett SM, Romine-Jenkins M, Fisher DE. Dapsone or electric shock therapy of brown recluse spider envenomation? Ann Emerg Med 1994; 24:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/25\">",
"      Phillips S, Kohn M, Baker D, et al. Therapy of brown spider envenomation: a controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine. Ann Emerg Med 1995; 25:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/26\">",
"      Elston DM, Miller SD, Young RJ 3rd, et al. Comparison of colchicine, dapsone, triamcinolone, and diphenhydramine therapy for the treatment of brown recluse spider envenomation: a double-blind, controlled study in a rabbit model. Arch Dermatol 2005; 141:595.",
"     </a>",
"    </li>",
"    <li>",
"     Wolverton, SE. Comprehensive Dermatologic Drug Therapy, Saunders, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/28\">",
"      Berger RS. The unremarkable brown recluse spider bite. JAMA 1973; 225:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/29\">",
"      Paix&atilde;o-Cavalcante D, van den Berg CW, Gon&ccedil;alves-de-Andrade RM, et al. Tetracycline protects against dermonecrosis induced by Loxosceles spider venom. J Invest Dermatol 2007; 127:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/30\">",
"      Paix&atilde;o-Cavalcante D, van den Berg CW, de Freitas Fernandes-Pedrosa M, et al. Role of matrix metalloproteinases in HaCaT keratinocytes apoptosis induced by loxosceles venom sphingomyelinase D. J Invest Dermatol 2006; 126:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/31\">",
"      Auer AI, Hershey FB. Proceedings: Surgery for necrotic bites of the brown spider. Arch Surg 1974; 108:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/32\">",
"      DeLozier JB, Reaves L, King LE Jr, Rees RS. Brown recluse spider bites of the upper extremity. South Med J 1988; 81:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/33\">",
"      Rees RS, Altenbern DP, Lynch JB, King LE Jr. Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision. Ann Surg 1985; 202:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/34\">",
"      Isbister GK, Graudins A, White J, Warrell D. Antivenom treatment in arachnidism. J Toxicol Clin Toxicol 2003; 41:291.",
"     </a>",
"    </li>",
"    <li>",
"     Bernstein, JN. Antidotes in depth. In: Goldfrank's Toxicologic Emergencies, 8th, Flomenbaum, NE, Goldfrank, LR, et al (Eds), McGraw Hill, New York 2006. p.1623.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/36\">",
"      Pauli I, Puka J, Gubert IC, Minozzo JC. The efficacy of antivenom in loxoscelism treatment. Toxicon 2006; 48:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24248/abstract/37\">",
"      Hogan CJ, Barbaro KC, Winkel K. Loxoscelism: old obstacles, new directions. Ann Emerg Med 2004; 44:608.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6485 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24248=[""].join("\n");
var outline_f23_43_24248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENTOMOLOGY OF RECLUSE SPIDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Appearance and identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Geographic location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Habitat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS OF BITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Venom properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Symptoms following bites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Acute local symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Systemic symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Solitary ulcerated lesion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Vascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Pyoderma gangrenosum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vasculitides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Local wound care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      General measures following bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Indications for antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prevention and treatment of necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Antivenoms for South American recluses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DISCHARGE INSTRUCTIONS AND AFTER CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Entomology and clinical features of bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6485\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6485|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/20/39236\" title=\"figure 1\">",
"      US geographic distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6485|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/11/9397\" title=\"picture 1\">",
"      Recluse spider A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/52/4933\" title=\"picture 2\">",
"      Recluse spider  B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/23/24947\" title=\"picture 3\">",
"      Recluse spider eye pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/35/41525\" title=\"picture 4\">",
"      Spider kukulcania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/34/3617\" title=\"picture 5\">",
"      Brown recluse spider bite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/17/39187\" title=\"picture 6\">",
"      Pyoderma gangrenosum early",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/56/31618\" title=\"picture 7\">",
"      Pyoderma gangrenosum 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/36/9794\" title=\"picture 8\">",
"      Leukocytoclastic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6485|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/20/44365\" title=\"table 1\">",
"      Spider entomology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/9/12445\" title=\"table 2\">",
"      Common misdiagnosis recluse spider bite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/62/39916\" title=\"table 3\">",
"      Skin ulcers in travelers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/32/5645\" title=\"table 4\">",
"      Differentiation of foot ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 5\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/12/23756\" title=\"table 6\">",
"      Empiric antibiotics cellulitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=related_link\">",
"      Approach to the patient with a suspected spider bite: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=related_link\">",
"      Diagnostic evaluation of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=related_link\">",
"      Diseases with eosinophilic involvement of specific organs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/16/10498?source=related_link\">",
"      Patient information: Spider bites (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2328?source=related_link\">",
"      Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20152?source=related_link\">",
"      Skin lesions in the returning traveler",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_43_24249="Treatment of Staphylococcus aureus bacteremia in adults";
var content_f23_43_24249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Staphylococcus aureus bacteremia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24249/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24249/contributors\">",
"     Vance G Fowler, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24249/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24249/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24249/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24249/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/43/24249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus aureus is a leading cause of both community-acquired and hospital-acquired bacteremia. Patients with S. aureus bacteremia (SAB) can develop diverse complications (eg, infective endocarditis [IE] or vertebral osteomyelitis), which may be difficult to recognize and which can lead to disability or death.",
"   </p>",
"   <p>",
"    In the preantibiotic era, mortality due to SAB exceeded 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/1\">",
"     1",
"    </a>",
"    ]. In the postantibiotic era, mortality rates of 20 to 40 percent have been reported in most case series of patients with SAB; these rates have not changed over the past several decades despite seemingly important diagnostic and therapeutic advances [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Mortality appears to be higher with methicillin-resistant (MRSA) compared with methicillin-sensitive S. aureus (MSSA) bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment failure (defined as death during a 30-day period following treatment, persistent bacteremia greater than 10 days after the initiation of appropriate therapy, or recurrence of bacteremia within 60 days of discontinuation of therapy) occurs relatively often in patients with SAB, particularly in patients with infections due to MRSA or in those who receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the treatment of SAB in adults, both the choice of antibiotics and the duration of therapy, will be reviewed here. The epidemiology, risk factors, and complications of SAB and treatment of methicillin-resistant or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant S. aureus infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=see_link\">",
"     \"Epidemiology of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26649?source=see_link\">",
"     \"Complications of Staphylococcus aureus bacteremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of IE among patients with SAB is 25 to 32 percent, and many cases are not suspected clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Therefore, in general, transesophageal echocardiogram (TEE) should be pursued in the setting of SAB to rule out IE. Possible exceptions are patients who have no underlying cardiac predisposing conditions or clinical signs of endocarditis whose fever and bacteremia resolve within 72 hours following removal of a likely focus (such as intravascular catheter removal). Transthoracic echocardiography (TTE) is not sufficient for ruling out IE; TEE is most sensitive when performed five to seven days after the onset of bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Echocardiographic examination is not necessary for infants and children with CRBSI who do not have other indicators of endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of nosocomial SAB, the following criteria have been shown to have excellent negative predictive value for the presence of IE: (1) prolonged bacteremia &gt;4 days, (2) presence of a permanent intracardiac device, (3) hemodialysis dependency, and (4) spinal infection or nonvertebral osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/11\">",
"     11",
"    </a>",
"    ]. In the absence of these criteria, the risk of IE is relatively low and routine TEE may not be necessary. However, we agree with established guidelines that transthoracic echocardiography should be performed in every patient with S. aureus bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of antibiotic for treatment of SAB depends on whether culture and susceptibility results are available at the initiation of treatment and, if available, whether the S. aureus isolate is methicillin-susceptible or methicillin-resistant.",
"   </p>",
"   <p>",
"    Bedside infectious disease consultation is an important component of management for patients with S. aureus bacteremia and should occur whenever feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. In one retrospective study comparing bedside consultation with telephone consultation for management of 342 patients with S. aureus bacteremia, bedside consultation was associated with a significantly lower 90-day mortality (1 versus 8 percent; odds ratio [OR] 0.09; 95% confidence interval [CI] 0.13-0.51) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/18\">",
"     18",
"    </a>",
"    ]. Another study noted that even among patients treated with an appropriate duration of therapy, significantly fewer relapses were observed among those who received bedside consultation (6 versus 18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Empiric treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled studies have evaluated empiric antibiotic regimens for SAB. Treatment regimens are based on the likelihood that MRSA is the cause of infection. We suggest empiric treatment of staphylococcal (or gram-positive cocci) bacteremia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per 24 hours in two equally divided doses, not to exceed 2 g per 24 hours unless concentrations in serum are inappropriately low). Vancomycin treatment is recommended whether the bacteremia is community- or hospital-acquired because of the frequency of MRSA strains in both the community and hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/19\">",
"     19",
"    </a>",
"    ]. Once susceptibility results are available, if the isolate is MSSA, antibiotic treatment should be modified to a beta-lactam as discussed in the following section [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Methicillin-susceptible S. aureus (MSSA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin is the drug of choice for SAB if the S. aureus isolate is sensitive to penicillin, however, less than 5 percent of isolates are sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, the optimal therapy for MSSA bacteremia, in most cases, is the intravenous administration of a beta-lactam agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    (or flucloxacillin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/21\">",
"     21",
"    </a>",
"    ] in some countries outside the United States), or a first-generation cephalosporin, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    . These drugs are both bactericidal and relatively safe.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    should not be given as primary therapy for methicillin-sensitive strains since data in both humans and animal models suggest that vancomycin is less effective in the treatment of SAB than beta-lactam agents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/22-31\">",
"     22-31",
"    </a>",
"    ]. The superiority of beta-lactams compared with vancomycin in treatment of SAB is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter, prospective observational study of 505 patients with SAB,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      was superior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      in preventing persistent bacteremia or relapse of bacteremia for MSSA; the failure rate was 4 versus 20 percent with vancomycin [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective observational study of 54 cases of bacteremic MSSA pneumonia, mortality was significantly higher with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      compared with flucloxacillin (47 versus 0 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 294 consecutive patients with SAB at a single institution,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      therapy was associated with a higher risk of relapse confirmed by pulsed-field gel electrophoresis (odds ratio, 4.1; 95% CI, 1.5-11.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on observational studies and clinical experience, we recommend the following antibiotic treatment of MSSA bacteremia in adults, in the following order of preference:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       Penicillin G",
"      </a>",
"      (4 million units every four hours), only if susceptibility of the isolate is confirmed by an in vitro test for beta-lactamase production",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       Nafcillin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      (2 g every four hours) or flucloxacillin (2 g every six hours)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       Cefazolin",
"      </a>",
"      (2 g every eight hours).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend the use of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"      nafcillin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"      oxacillin",
"     </a>",
"     /flucloxacillin",
"    </span>",
"    in patients who are hospitalized, but often choose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    for outpatient therapy as it has a longer half-life and is easier to administer because of the need for less frequent dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Penicillin allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     Cefazolin",
"    </a>",
"    is recommended for patients with penicillin allergy that does not involve an anaphylactic reaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases of anaphylactic penicillin allergy, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per 24 hours in two equally divided doses; with goal trough levels 15 to 20 mcg",
"    <span class=\"nowrap\">",
"     /mL).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative agents for the treatment of SAB should be reserved for those patients intolerant to beta-lactams and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and should be guided by the results of susceptibility testing. Patients whose infection requires treatment with an alternative agent should preferably be treated by clinicians who are experts in the treatment of infectious diseases and who are familiar with the available (and limited) literature on the efficacy, dosing, and side effects of such therapy. The use of all alternative agents is limited because of the development of resistance or an increased rate of adverse effects during therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"       Daptomycin",
"      </a>",
"      &mdash; Daptomycin (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily) has been approved by the Food and Drug Administration (FDA) for the treatment of SAB and right-sided endocarditis. Patients receiving daptomycin should be monitored for skeletal muscle complication and undergo serum creatine phosphokinase (CPK) levels weekly while on therapy. In addition, development of resistance to daptomycin on therapy has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A treatment trial involving 246 patients with SAB with or without endocarditis randomly assigned patients to either daptomycin (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV per day) or standard therapy (low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      plus an antistaphylococcal penicillin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/35\">",
"       35",
"      </a>",
"      ]. Daptomycin was not inferior to standard therapy (successful outcomes in 44 versus 42 percent with standard therapy) for SAB or right-sided endocarditis. Daptomycin resistance (MIC &ge;2",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      developed in six patients.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      &mdash; Although linezolid may be a potential alternative drug for the treatment of SAB [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/36\">",
"       36",
"      </a>",
"      ], several important factors limit the widespread use of linezolid as an antistaphylococcal agent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/37\">",
"       37",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Side effects from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      (eg, thrombocytopenia, anemia) are common and can be severe [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Resistance has been reported in S. aureus and enterococci to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/39,40\">",
"       39,40",
"      </a>",
"      ], including horizontal transfer of resistance element cfr [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/41\">",
"       41",
"      </a>",
"      ] and treatment-emergent resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Treatment failures attributed to low serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      levels among patients receiving oral linezolid have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"       Quinupristin-dalfopristin",
"      </a>",
"      &mdash; Quinupristin-dalfopristin is also a potential alternative drug for the treatment of SAB, but several important factors also limit its use as an antistaphylococcal agent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/37\">",
"       37",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"       Quinupristin-dalfopristin",
"      </a>",
"      requires central venous administration due to the risk of severe infusion-associated phlebitis",
"     </li>",
"     <li>",
"      Side effects from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"       quinupristin-dalfopristin",
"      </a>",
"      (eg, hyperbilirubinemia, myalgias) are common and can be severe [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Resistance has been reported in S. aureus and enterococci to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"       quinupristin-dalfopristin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    are primarily indicated for the treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococcal (VRE) infections. Neither has been approved by the FDA for the treatment of SAB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=see_link\">",
"     \"Treatment of enterococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, despite the above caveats, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    are occasionally useful for the treatment of bacteremia due to S. aureus in patients with true allergy or severe intolerance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Linezolid can also occasionally be useful as oral therapy to complete a full course of treatment after initial therapy with vancomycin. Comparative clinical trials are required to further delineate the precise clinical roles of these two antibiotics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       Trimethoprim",
"      </a>",
"      component 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/49\">",
"       49",
"      </a>",
"      ]",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      &mdash; 600 mg every eight hours; the D test should be performed on S. aureus isolates and clindamycin should not be used when the isolates are D-zone positive, indicating the inducible MLS(B) form of resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/50-52\">",
"       50-52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of antibacterial susceptibility testing\", section on 'D test'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      &mdash; 100 mg every 12 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Teicoplanin &mdash; Teicoplanin (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily) has the same spectrum of activity as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      . In clinical studies, it has had comparable efficacy as vancomycin, but is associated with fewer side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/54\">",
"       54",
"      </a>",
"      ]. It is not available for use in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Synergistic aminoglycosides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-dose aminoglycosides should NOT be combined routinely with antistaphylococcal penicillins or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for treatment of SAB. Although in vitro and in experimental models of endocarditis have demonstrated that combination therapy facilitates more rapid killing of MSSA than monotherapy, the evidence for clinically significant benefit is minimal. This was illustrated by a randomized trial of 48 patients with MSSA native valve endocarditis; patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    for the first two weeks of therapy had more rapid clearing of bacteremia than those who received nafcillin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/55\">",
"     55",
"    </a>",
"    ]. However, cure rates were comparable and combination nafcillin and gentamicin therapy was associated with a higher incidence of renal dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link&amp;anchor=H16#H16\">",
"     \"Antimicrobial therapy of native valve endocarditis\", section on 'Staphylococcal endocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequently, a randomized trial including 236 patients with SAB and endocarditis demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    monotherapy is not inferior to low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    plus an antistaphylococcal penicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ; those in the standard therapy arm experienced significantly more renal impairment than those in the daptomycin arm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/35\">",
"     35",
"    </a>",
"    ]. An investigation of safety data from the trial noted significantly greater reduction in creatinine clearance among those who received initial low dose gentamicin than those who did not (22 versus 8 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, low-dose aminoglycosides should NOT be combined routinely with antistaphylococcal penicillins or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for treatment of SAB. The limited benefit must be weighed against evidence for potential harm, particularly in the elderly and in those with diabetes and mild baseline renal dysfunction. The American Heart Association guidelines state that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    in the treatment of native valve endocarditis should be considered optional [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Methicillin-resistant S. aureus (MRSA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with infection due to MRSA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\", section on 'Bacteremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mortality appears to be higher with MRSA compared with MSSA bacteremia, with the possible exception of patients with pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a review of 438 patients with SAB, 193 of whom were infected with MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/3\">",
"     3",
"    </a>",
"    ]. The patients with MRSA infection had a significantly higher mortality rate at 90 days, except for those with pneumonia, an effect that persisted after adjustment for confounders (34 versus 20 percent, adjusted hazard ratio 1.8, 95% CI 1.2-3.0).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, parenteral therapy is the preferred route of treatment for all forms of SAB. However, oral therapy occasionally can be used to complete a full course of therapy in patients who lack intravenous access or refuse intravenous therapy, or to provide a longer course of therapy in selected patients.",
"   </p>",
"   <p>",
"    For the reasons cited above, beta-lactam agents are preferred to non-beta-lactam drugs for MSSA bacteremia. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Methicillin-susceptible S. aureus (MSSA)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    (500 to 1000 mg every six to eight hours) in adults.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     Cephalexin",
"    </a>",
"    is an alternative for patients without type 1 allergy to penicillin.",
"   </p>",
"   <p>",
"    The following caveats apply to the oral therapy of serious staphylococcal infections:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral therapy is in general less effective than parenteral therapy",
"     </li>",
"     <li>",
"      Compliance should be carefully emphasized and closely monitored",
"     </li>",
"     <li>",
"      Oral therapy should be avoided in patients with significant gastrointestinal disease or in those who develop gastrointestinal side effects",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy for SAB depends on the etiology of infection (eg, occult endocarditis or other deep-seated infection, catheter-related infection, prosthetic device, etc).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of treatment for SAB varies depending on clinical circumstances, and the optimal duration is not certain. Controversy stems from the difficulty in establishing the source of infection and determining whether complications of SAB are likely to occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26649?source=see_link\">",
"     \"Complications of Staphylococcus aureus bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 1950s report noted a rate of IE of approximately 67 percent among patients with SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/58\">",
"     58",
"    </a>",
"    ]. As a result, prolonged antibiotic therapy (four weeks or greater) was advised for most patients, and this recommendation became a widely used standard for care.",
"   </p>",
"   <p>",
"    Subsequently the necessity for prolonged treatment has been questioned, especially in patients with catheter-associated S. aureus bacteremia (CASAB) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. A 1992 review concluded that the optimal duration of intravenous antibiotic therapy for uncomplicated CASAB should never be &lt;10 days, but need not be &gt;14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/61\">",
"     61",
"    </a>",
"    ]. However, a subsequent meta-analysis of short course (two weeks or less) therapy for CASAB found that the available data were seriously flawed by selection bias and statistical imprecision, and the authors concluded that the optimal duration of antibiotic therapy for CASAB was unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1998, a study of 244 patients with SAB stratified by the relative risk for complications was performed; treatment was based on clinical criteria, including the absence or presence of a removable focus of infection, prosthetic material,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a deep focus of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/17\">",
"     17",
"    </a>",
"    ]. The duration of antibiotic therapy was determined by a patient-specific approach incorporating clinical, microbiologic, and echocardiographic criteria (echocardiography was advised to identify all patients with occult endocarditis). The clinical course was closely monitored for evidence of complicated infection and the time to defervescence (maximum temperature &lt;38.0&ordm;C). Follow-up blood cultures taken two to four days after the institution of therapy were also used to decide upon the length of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26649?source=see_link&amp;anchor=H11#H11\">",
"     \"Complications of Staphylococcus aureus bacteremia\", section on 'Endocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion consists of general suggestions to guide clinical decisions; these parameters may be combined with a patient-specific approach for determining the duration of antibiotic therapy. For example, patients with low risk for complications or relapse may be reasonably treated for longer periods of time if the consequences of a relapse or recurrence would be catastrophic. On the other hand, patients with a high risk of relapse may be treated for shorter periods if other clinical considerations (such as malignant disease or coexisting social or medical issues) are significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Removable focus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have shown that only a minority of patients with CASAB can be cured with antimicrobial therapy if the catheter present at the time of bacteremia is not removed. In two series, for example, bacteriologic cure was achieved without removal of the device in only 17 to 18 percent of patients with Hickman CASAB or dialysis patients with tunneled, cuffed dialysis CASAB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retaining an intravascular foreign body in the setting of SAB has been associated with recurrent bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In a series of 23 patients who had a device at the time of the initial SAB that was not removed, 78 percent relapsed within 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/23\">",
"     23",
"    </a>",
"    ]. These early recurrences were usually due to the same isolate and may represent a true relapse of the original infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, prompt catheter removal may not prevent the development of IE. In one series of 21 cases of SAB that occurred 2 to 11 days after catheter insertion (mean 5.2 days), IE developed in eight despite prompt removal of the catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of prosthetic material or devices in a patient with SAB increases the risk of relapsing infection. This was illustrated in a series of 294 consecutive patients with SAB at a single medical center: The 23 patients with relapse after therapy were much more likely to have an indwelling foreign body than the 271 patients without relapse (83 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/23\">",
"     23",
"    </a>",
"    ]. The median time to relapse after the first detected bacteremic episode in patients with unremoved foreign bodies was 69 days (range 35 to 89 days).",
"   </p>",
"   <p>",
"    Patients with cardiac devices (eg, permanent pacemaker or defibrillator) who develop SAB are at significant risk for device infection. Among 33 prospectively identified patients with both a permanent cardiac device and SAB, for example, the rate of confirmed device infection was 45.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Deep focus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SAB arising from a deep focus of infection (such as vertebral osteomyelitis or a deep tissue abscess) are highly likely to experience a relapse of staphylococcal infection if a short course of therapy is administered; the presence of a deep focus of infection is highly predictive of relapse even with prolonged antibiotic treatment.",
"   </p>",
"   <p>",
"    In 1998 series cited above, 7 of 48 patients (15 percent) with a deep staphylococcal infection at the time of SAB had late relapse despite &ge;4 weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/17\">",
"     17",
"    </a>",
"    ]. In another report, 6 of 23 patients (26 percent) with relapse of SAB (documented by pulsed-field gel electrophoresis) had a deep metastatic infection at the onset of their first episode of SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no controlled trials examining the duration of antimicrobial therapy in SAB. Treatment recommendations are based on the clinical case series noted above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Removable focus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without hematogenous complications or risk factors may be treated with 14 days of therapy in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24249/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Valvular abnormalities predisposing to endocarditis are absent.",
"     </li>",
"     <li>",
"      Afebrile with no localizing complaints attributable to metastatic staphylococcal infection within 72 hours after initiating intravenous antistaphylococcal therapy and removal of the presumed focus of infection.",
"     </li>",
"     <li>",
"      Follow-up blood cultures drawn two to four days after initiating intravenous antistaphylococcal therapy and removing the presumed focus of infection are negative.",
"     </li>",
"     <li>",
"      No indwelling devices, such as prosthetic joints, heart valves, or vascular grafts are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Deep focus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suspected or proven deep tissue infection includes the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacteremia associated with IE",
"     </li>",
"     <li>",
"      Bacteremia accompanied by a known deep tissue site of infection",
"     </li>",
"     <li>",
"      Bacteremia in patients with a negative TEE that persists 48 to 96 hours after initiating intravenous antistaphylococcal therapy.",
"     </li>",
"     <li>",
"      Endocarditis &mdash; Endocarditis is defined using the Duke criteria (",
"      <a class=\"graphic graphic_table graphicRef73023 graphicRef53004 \" href=\"UTD.htm?42/47/43773\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"       \"Diagnostic approach to infective endocarditis\"",
"      </a>",
"      .) Patients with endocarditis due to S. aureus should receive four to six weeks of parenteral antistaphylococcal therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"       \"Antimicrobial therapy of native valve endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extracardiac infection &mdash; The possible presence of an extracardiac deep metastatic infection is usually suspected from symptoms or signs of suppuration in bone, deep organ spaces, or tissues (eg, back or joint pain, thrombosis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pus at the site of a vascular catheter). Other clues to the presence of such a deep focus include persistent fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      positive blood cultures after starting appropriate antistaphylococcal therapy. The diagnosis usually requires a careful history and physical examination and radiographic or other diagnostic measures such as ultrasonography or radionuclide scanning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"       \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with deep tissue infection, such as osteomyelitis, mediastinitis, or deep abscesses, should receive four to eight weeks of intravenous antibiotic therapy with or without surgical drainage or debridement whenever feasible or practical. Duration is dependent on the clinical response to treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"       \"Overview of osteomyelitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Persistent SAB &mdash; Most patients with SAB who have positive blood cultures more than 72 hours after starting therapy should be considered to have complicated bacteremia. In such patients who have a negative TEE, a search should be initiated for a deep focus of infection. We suggest intravenous antistaphylococcal therapy should be given for four to six weeks depending on the clinical response to treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Valvular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;SAB in patients with cardiac valvular abnormalities predisposing to endocarditis (eg, valvular regurgitation or stenosis) without evidence of vegetation on TEE (performed 5 to 7 days after onset of therapy) may be treated with 14 days of intravenous antistaphylococcal therapy. These patients may have persistent signs of infection up to 72 hours after initiating therapy but should have negative surveillance cultures within three days or more after starting therapy and lack signs of deep staphylococcal infection (such as mediastinitis, osteomyelitis, or septic thrombophlebitis) by clinical examination or further diagnostic studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=see_link\">",
"       \"Patient information: Sepsis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staphylococcus aureus is a leading cause of both community-acquired and hospital-acquired bacteremia and has a mortality rate of 20 to 40 percent. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of antibiotic for treatment depends on whether culture and susceptibility results are available at the initiation of treatment and if available whether the S. aureus isolate is methicillin-susceptible (MSSA) or methicillin-resistant (MRSA). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend bedside infectious disease consultation for management of patients with S. aureus bacteremia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest empiric treatment of staphylococcal (eg, or gram-positive cocci) bacteremia with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per 24 hours in two equally divided doses). (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Empiric treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treating MSSA bacteremia with a beta-lactam antibiotic in preference to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"       daptomycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) in the following order of preference:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Penicillin (4 million units every four hours), if susceptible",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       Nafcillin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      (2 g every four hours) or flucloxacillin (2 g every six hours)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       Cefazolin",
"      </a>",
"      (2 g every eight hours)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per 24 hours in two equally divided doses) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"       daptomycin",
"      </a>",
"      (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Methicillin-susceptible S. aureus (MSSA)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest",
"      <strong>",
"       NOT",
"      </strong>",
"      using alternative agents other than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"       daptomycin",
"      </a>",
"      , except in patients who are intolerant of beta-lactams and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Alternative agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       NOT",
"      </strong>",
"      routinely combining low-dose aminoglycosides with antistaphylococcal penicillins or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      for treatment of SAB (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Synergistic aminoglycosides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of therapy should be based upon whether the infection represents bacteremia due to a removable focus of infection, bacteremia in a patient with valvular abnormalities but no evidence of endocarditis, or complicated bacteremia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/1\">",
"      Skinner, D, Keefer, CS. Significance of bacteremia caused by Staphylococcus aureus: A study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals. Arch Intern Med 1941; 68:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/2\">",
"      Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis 1987; 9:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/3\">",
"      Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007; 28:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/4\">",
"      Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/5\">",
"      Abraham J, Mansour C, Veledar E, et al. Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J 2004; 147:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/6\">",
"      Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997; 30:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/7\">",
"      Sullenberger AL, Avedissian LS, Kent SM. Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia. J Heart Valve Dis 2005; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/8\">",
"      Rosen AB, Fowler VG Jr, Corey GR, et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. Ann Intern Med 1999; 130:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/9\">",
"      Sochowski RA, Chan KL. Implication of negative results on a monoplane transesophageal echocardiographic study in patients with suspected infective endocarditis. J Am Coll Cardiol 1993; 21:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/10\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/11\">",
"      Kaasch AJ, Fowler VG Jr, Rieg S, et al. Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia. Clin Infect Dis 2011; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/12\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/13\">",
"      Jenkins TC, Price CS, Sabel AL, et al. Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/14\">",
"      Honda H, Krauss MJ, Jones JC, et al. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010; 123:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/15\">",
"      Lahey T, Shah R, Gittzus J, et al. Infectious diseases consultation lowers mortality from Staphylococcus aureus bacteremia. Medicine (Baltimore) 2009; 88:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/16\">",
"      Rieg S, Peyerl-Hoffmann G, de With K, et al. Mortality of S. aureus bacteremia and infectious diseases specialist consultation--a study of 521 patients in Germany. J Infect 2009; 59:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/17\">",
"      Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/18\">",
"      Forsblom E, Ruotsalainen E, Ollgren J, J&auml;rvinen A. Telephone consultation cannot replace bedside infectious disease consultation in the management of Staphylococcus aureus Bacteremia. Clin Infect Dis 2013; 56:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/19\">",
"      Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/20\">",
"      Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/21\">",
"      Sutherland R, Croydon EA, Rolinson GN. Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin. Br Med J 1970; 4:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/22\">",
"      Hartstein AI, Mulligan ME, Morthland VH, Kwok RY. Recurrent Staphylococcus aureus bacteremia. J Clin Microbiol 1992; 30:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/23\">",
"      Fowler VG Jr, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/24\">",
"      Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991; 115:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/25\">",
"      Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/26\">",
"      Mortara LA, Bayer AS. Staphylococcus aureus bacteremia and endocarditis. New diagnostic and therapeutic concepts. Infect Dis Clin North Am 1993; 7:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/27\">",
"      Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/28\">",
"      Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/29\">",
"      Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006; 42 Suppl 1:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/30\">",
"      Gonz&aacute;lez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/31\">",
"      Gentry CA, Rodvold KA, Novak RM, et al. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997; 17:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/32\">",
"      Vikram HR, Havill NL, Koeth LM, Boyce JM. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 2005; 43:5384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/33\">",
"      Hayden MK, Rezai K, Hayes RA, et al. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43:5285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/34\">",
"      Sharma M, Riederer K, Chase P, Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2008; 27:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/35\">",
"      Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/36\">",
"      Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/37\">",
"      Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/38\">",
"      Waldrep TW, Skiest DJ. Linezolid-Induced anemia and thrombocytopenia. Pharmacotherapy 2002; 22:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/39\">",
"      Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/40\">",
"      Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/41\">",
"      S&aacute;nchez Garc&iacute;a M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/42\">",
"      Gao W, Chua K, Davies JK, et al. Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog 2010; 6:e1000944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/43\">",
"      Sperber SJ, Levine JF, Gross PA. Persistent MRSA bacteremia in a patient with low linezolid levels. Clin Infect Dis 2003; 36:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/44\">",
"      Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001; 32:e83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/45\">",
"      Werner G, Cuny C, Schmitz FJ, Witte W. Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol 2001; 39:3586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/46\">",
"      Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/47\">",
"      Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/48\">",
"      Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 48:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/49\">",
"      Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/50\">",
"      Mart&iacute;nez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/51\">",
"      Sande MA, Johnson ML. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis 1975; 131:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/52\">",
"      Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarditis. Clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin. Am J Med 1976; 60:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/53\">",
"      Clumeck N, Marcelis L, Amiri-Lamraski MH, Gordts B. Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J Antimicrob Chemother 1984; 13 Suppl C:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/54\">",
"      Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/55\">",
"      Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med 1982; 97:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/56\">",
"      Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/57\">",
"      Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/58\">",
"      WILSON R, HAMBURGER M. Fifteen years' experience with staphylococcus septicemia in a large city hospital; analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954. Am J Med 1957; 22:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/59\">",
"      Ehni WF, Reller LB. Short-course therapy for catheter-associated Staphylococcus aureus bacteremia. Arch Intern Med 1989; 149:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/60\">",
"      Iannini PB, Crossley K. Therapy of Staphylococcus aureus bacteremia associated with a removable focus of infection. Ann Intern Med 1976; 84:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/61\">",
"      Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992; 14:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/62\">",
"      Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med 1993; 119:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/63\">",
"      Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 1990; 89:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/64\">",
"      Marr KA, Sexton DJ, Conlon PJ, et al. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997; 127:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/65\">",
"      Watanakunakorn C, Baird IM. Staphylococcus aureus bacteremia and endocarditis associated with a removable infected intravenous device. Am J Med 1977; 63:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24249/abstract/66\">",
"      Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 2001; 104:1029.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2134 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24249=[""].join("\n");
var outline_f23_43_24249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Empiric treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Methicillin-susceptible S. aureus (MSSA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Penicillin allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Synergistic aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Methicillin-resistant S. aureus (MRSA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Removable focus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Deep focus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Removable focus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Deep focus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Valvular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2134\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2134|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/26/9644\" title=\"table 1A\">",
"      Duke criteria for IE I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/31/6653\" title=\"table 1B\">",
"      Duke criteria for IE II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26649?source=related_link\">",
"      Complications of Staphylococcus aureus bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=related_link\">",
"      Epidemiology of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=related_link\">",
"      Overview of antibacterial susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=related_link\">",
"      Tunneled, cuffed hemodialysis catheter-related bacteremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_43_24250="Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis";
var content_f23_43_24250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24250/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24250/contributors\">",
"     Russell D Cohen, MD, FACG, AGAF",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24250/contributors\">",
"     Adam C Stein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24250/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24250/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/43/24250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/43/24250/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/43/24250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with ulcerative colitis (UC) requires glucocorticoids to control symptoms while others continue to have symptoms despite glucocorticoid treatment. Glucocorticoids are intended for short-term use only, and patients should be transitioned to safer, effective medical therapies or referred to surgery if their disease cannot be well controlled when glucocorticoids are discontinued.",
"   </p>",
"   <p>",
"    This topic review will discuss the approach to managing adults with steroid-refractory and steroid-dependent ulcerative colitis. A general overview of the management of mild to moderate and severe or fulminant ulcerative colitis and the management of left-sided colitis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"     \"Management of mild to moderate ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following definitions of ulcerative colitis have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Steroid-responsive disease &ndash; Clinical response to high dose glucocorticoids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      40 to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or equivalent) within 30 days for oral therapy or 7 to 10 days for IV therapy.",
"     </li>",
"     <li>",
"      Steroid-dependent disease &ndash; Ulcerative colitis is defined as steroid-dependent if glucocorticoids cannot be tapered to less than 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      within three months of starting steroids, without recurrent disease, or if relapse occurs within three months of stopping glucocorticoids.",
"     </li>",
"     <li>",
"      Steroid-refractory disease &ndash; Lack of a meaningful clinical response to glucocorticoids up to doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      40 to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (or equivalent) within 30 days for oral therapy or 7 to 10 days for IV therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89942021\">",
"    <span class=\"h1\">",
"     EVALUATION OF A PATIENT WITH STEROID-DEPENDENT OR STEROID-REFRACTORY ULCERATIVE COLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to assess disease severity, rule out an underlying infection, and alternate diagnoses (eg, Crohn&rsquo;s disease) in patients with steroid-refractory or steroid-dependent ulcerative colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89940863\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood counts, measurement of C-reactive protein (CRP), and erythrocyte",
"    <strong>",
"    </strong>",
"    sedimentation (ESR) rate can help determine the severity of the underlying inflammation. In addition, CRP levels may have a role in distinguishing between active ulcerative colitis and Crohn&rsquo;s disease from those with symptoms caused by functional disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Normal CRP, ESR, white blood cell count, hematocrit, and platelet count are more consistent with irritable bowel syndrome (IBS) rather than active IBD.",
"   </p>",
"   <p>",
"    Positive serology for antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) are not diagnostic for ulcerative colitis or Crohn&rsquo;s, respectively, given the limited sensitivity and specificity of the tests. However, when they are performed in combination, the results may help differentiate between ulcerative colitis, Crohn&rsquo;s disease, and indeterminate colitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8279?source=see_link&amp;anchor=H6829241#H6829241\">",
"     \"Irritable bowel syndrome in patients with inflammatory bowel disease\", section on 'Laboratory testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689190#H12689190\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Serologic markers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89940949\">",
"    <span class=\"h2\">",
"     Stool studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stool evaluation is necessary in patients with steroid-dependent or steroid-refractory ulcerative colitis in order to exclude a superimposed infection.",
"   </p>",
"   <p>",
"    Stool studies should include stool Clostridium difficile toxin, routine stool cultures, and specific testing for E. coli 0157:H7. Microscopy for ova and parasites (three samples) and a Giardia stool antigen test and Cryptosporidium testing by immunofluorescence or other antigen-detection assays should also be performed, particularly if the patient is in an endemic area or has risk factors such as travel. In addition, specific testing for sexually transmitted diseases including Neisseria gonorrhea, herpes simplex virus, and Treponema pallidum should be considered, particularly in patients with severe rectal symptoms. Elevated levels of fecal calprotectin and fecal lactoferrin suggest the presence of underlying inflammation rather than a functional disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8279?source=see_link&amp;anchor=H6829248#H6829248\">",
"     \"Irritable bowel syndrome in patients with inflammatory bowel disease\", section on 'Stool studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H15443523#H15443523\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic evaluation may be required to confirm the presence, severity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extent of inflammation and can exclude the presence of an infection such as CMV. In patients with CMV colitis, conventional hematoxylin and eosin stains reveal enlarged (cytomegalic) cells that are often two- to fourfold larger than surrounding cells, usually with large eosinophilic intranuclear inclusions, sometimes surrounded by a clear halo, and smaller cytoplasmic inclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/12\">",
"     12",
"    </a>",
"    ]. Immunoperoxidase-staining can aid in the detection and should be done to confirm suspected CMV. A full colonoscopy with adequate evaluation of the terminal ileum (with biopsies of the ileum and throughout the colon in separate jars) may be helpful in excluding Crohn's disease, which would have direct implications upon surgical options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13722?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Full colonoscopy should be avoided in hospitalized patients with severe colitis because of the potential to precipitate toxic megacolon. In such patients, a sigmoidoscopy limited to the rectum and distal sigmoid should be performed with biopsies to assist in confirming the diagnosis and excluding CMV.",
"   </p>",
"   <p>",
"    The symptoms in patients with ulcerative colitis may be caused by other pathologies in the absence of active colitis. Upper endoscopy with biopsies of the stomach and duodenum (even if endoscopically normal) may be helpful in confirming a diagnosis of Crohn&rsquo;s disease or excluding other malabsorptive processes, such as celiac disease. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3946366\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is no active colitis or ileitis on colonoscopy, yet the patient still has symptoms, small bowel imaging with computed tomography (CT) enterography, magnetic resonance (MR) enterography, or a dedicated small bowel series should be performed to rule out Crohn's disease of the small bowel. CT and MR enterography have high sensitivities for detecting active small bowel inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/13\">",
"     13",
"    </a>",
"    ]. CT enterography has the advantage of better temporal resolution, mesenteric imaging, and shorter length of examination. It is preferred when there is a suspicion of an intra-abdominal abscess. MR enterography is gradually replacing CT enterography. MR enterography has the advantage of avoiding radiation exposure and better characterization of stenotic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/14\">",
"     14",
"    </a>",
"    ]. MR enterography is preferred when there is a suspicion of intestinal fistulae. A dedicated small bowel series by an experienced gastrointestinal radiologist may be helpful when analyzing patients with previous small bowel stricturoplasty, or to clarify whether an obstruction is from a stricture versus an adhesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689169#H12689169\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A CT scan or magnetic resonance imaging (MRI) of the abdomen and pelvis should also be considered in patients in whom there is a concern for an abscess, diverticulitis, fistula formation, perforation, megacolon, or potentially unrelated abdominal process (eg, a kidney stone). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526355188\">",
"    <span class=\"h1\">",
"     STEROID-DEPENDENT ULCERATIVE COLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative colitis is defined as steroid-dependent if glucocorticoids cannot be tapered to less than 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    within three months of starting steroids without recurrent disease, or if relapse occurs within three months of stopping glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/1\">",
"     1",
"    </a>",
"    ]. An approach to the treatment of steroid-dependent ulcerative colitis is presented in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef65085 \" href=\"UTD.htm?14/60/15311\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527391245\">",
"    <span class=\"h2\">",
"     Avoidance of contributing factors and assessment of compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactose intolerance is frequently noted in patients with ulcerative colitis. Calcium supplementation should be maintained in patients with limited lactose intake to minimize the risk of bone loss. Patients with active colitis should avoid foods that can mimic symptoms of active colitis, such as high fiber, nuts, seeds, corn, popcorn, and fatty foods. Patients with active distal colitis may develop severe constipation. In these patients, high fiber foods are beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=see_link&amp;anchor=H3593887#H3593887\">",
"     \"Nutrition and dietary interventions in adults with inflammatory bowel disease\", section on 'Dietary interventions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link&amp;anchor=H12#H12\">",
"     \"Lactose intolerance\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stress may have a role in the exacerbation of symptoms of inflammatory bowel disease (IBD) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/16-19\">",
"     16-19",
"    </a>",
"    ], possibly via activation of the enteric nervous system and the elaboration of proinflammatory cytokines. Appropriate pharmacological",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behavioral interventions may be useful in the management of their disease or improving symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=see_link&amp;anchor=H186033080#H186033080\">",
"     \"Definition, epidemiology, and risk factors in inflammatory bowel disease\", section on 'Psychosocial factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An assessment of medication compliance is also necessary in patients with steroid-dependent ulcerative colitis. Only 40 percent of colitis patients with IBD are adherent to their medication regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/20\">",
"     20",
"    </a>",
"    ]. Simplifying prescribed therapies to fewer medications with fewer daily applications can be helpful in improving compliance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526356962\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several adjunctive therapies exist that, when used alone or in combination with systemic steroids, can reduce or eliminate the need for systemic glucocorticoids and limit systemic steroid use (",
"    <a class=\"graphic graphic_algorithm graphicRef65085 \" href=\"UTD.htm?14/60/15311\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/5\">",
"     5",
"    </a>",
"    ]. The choice among options depends in part upon the patient's willingness to remain on glucocorticoids while new therapies are started.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Adding a slow-acting second medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main options for patients who are well on glucocorticoids, and able",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    willing) to remain on glucocorticoids while a second slow-acting maintenance medication is introduced, are 6-mercaptopurine (6-MP) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA). The therapeutic effect of 6-MP or AZA can take three to six months during which attempts can be made to taper glucocorticoids. The administration, safety, and monitoring of AZA and 6-MP are discussed in detail separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link\">",
"     \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AZA or 6-MP are not good options for patients who are unlikely to comply with regular monitoring, are unwilling to accept the risk of toxicity, or have dysplasia or other indications for colectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link\">",
"     \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link&amp;anchor=H9#H9\">",
"     \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Available evidence suggests that 6-MP and AZA improve the likelihood that remission will be maintained in patients with ulcerative colitis that is refractory to steroids and 5-ASA from approximately 40 to 70 percent in patients, and that these drugs will decrease glucocorticoid requirements in approximately 70 percent of patients with glucocorticoid-dependent disease. A number of small controlled trials and two meta-analyses have demonstrated that AZA is superior to placebo in maintenance of remission [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/21-27\">",
"     21-27",
"    </a>",
"    ]. A 2011 meta-analysis found that AZA was superior to placebo for preventing relapse (RR of relapse 0.60, 95% CI 0.37-0.95) and estimated that approximately four patients would need to be treated to prevent one relapse in patients with ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/28\">",
"     28",
"    </a>",
"    ]. A 2008 meta-analysis of 286 patients in four randomized trials that had at least 12 months of follow-up concluded that AZA was superior to placebo for maintenance of remission (OR for failure to maintain remission 0.41, 95% CI 0.24-0.70) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AZA has also been demonstrated to be superior to 5-aminosalicylate (ASA) medications in the maintenance of remission in glucocorticoid-dependent ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/26\">",
"     26",
"    </a>",
"    ]. In a randomized trial in which glucocorticoid-dependent patients with active ulcerative colitis were randomized to receive AZA 2",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    or oral 5-ASA 3.2",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    for a six-month follow-up period, the proportion of patients with glucocorticoid-free remission was significantly higher with AZA as compared with 5-ASA medications (53 versus 21 percent).",
"   </p>",
"   <p>",
"    There is no evidence that addition of 5-ASA medications reduces relapses in patients on AZA. A systemic review identified two small controlled trials that compared AZA alone to AZA combined with 5-ASA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/30\">",
"     30",
"    </a>",
"    ]. There was no evidence of benefit from combined therapy, but both trials had methodologic limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Adding a fast-acting second medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are either not well on glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are unable or unwilling to continue them require adjunctive therapy that has a rapid onset of action. Some options are effective for induction of remission (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) while others can be used both for induction of remission and for maintenance therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    has a role in induction of remission in patients with refractory colitis but is not effective",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    safe for long-term use. Cyclosporine is used as a short-term \"bridge\" to therapy with the slower onset, longer acting medications (AZA or 6-MP) (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Adding a slow-acting second medication'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    an option in patients who were intolerant to AZA or 6-MP, and in patients who have previously failed AZA or 6-MP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In addition, using cyclosporine after recent treatment with another immunosuppressant such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    has not been shown to be effective or safe [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=see_link\">",
"     \"Anti-tumor necrosis factor therapy in ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a controlled trial, for example, 20 steroid-resistant patients with severe colitis were randomly assigned to placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    given at a dose of 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day as a continuous infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/33\">",
"     33",
"    </a>",
"    ]. Response within a mean of seven days occurred in 9 of 11 patients given cyclosporine versus none of those given placebo. Furthermore, all five placebo-treated patients who were then given cyclosporine had a response.",
"   </p>",
"   <p>",
"    Although 70 to 80 percent of patients with severe ulcerative colitis respond to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , some of these responders ultimately require a colectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/33,36,37\">",
"     33,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      permitted the avoidance of colectomy for up to 5.5 years in 62 percent of 42 patients who initially had severe steroid-refractory ulcerative colitis; patients who also received treatment with 6-MP or AZA were more likely to retain their colons (80 versus 55 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/37\">",
"       37",
"      </a>",
"      ]. The benefit of cyclosporine was further underscored in another study, in which the quality of life of patients who were treated with cyclosporine was superior to those who had undergone colectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a retrospective cohort study of 142 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , 118 (83 percent) had an initial response and avoided colectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/33\">",
"       33",
"      </a>",
"      ]. However, 41 (35 percent) of these patients ultimately required a colectomy. The rate of colectomy was significantly higher in patients already taking AZA&nbsp;when cyclosporine was started compared with those who started AZA concurrently with cyclosporine (59 versus 31 percent). Life table analysis suggested that 88 percent of responding patients will require a colectomy by seven years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    administered it as a continuous infusion at a dose of 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/39\">",
"     39",
"    </a>",
"    ]. Lower doses (2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    may have similar efficacy and less toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .) We initially dose in the 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    range, using the lower dose in patients who have low serum cholesterol. Intravenous corticosteroids are maintained, and nightly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    enemas encouraged. We recommend prophylaxis against Pneumocystis pneumonia (PCP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    should be checked every one to two days after each dose change, and every two to three days when on stable doses. Goal levels for a dose of 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    are 300 to 400",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Patients dosed at 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    should have levels no less than 200",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Dose adjustments are based upon efficacy, side effects, and blood levels of cyclosporine. Doses should be rounded to the nearest 25 mg, to aid in subsequent conversion to oral cyclosporine.",
"   </p>",
"   <p>",
"    Patients should show an initial response to cyclosporin within 48 to 72 hours; the goal is a complete resolution of symptoms, along with normalization of blood tests. Specifically, patients should have a reasonable number of formed stools, without associated blood, no abdominal pain, and should be able to eat, prior to converting IV to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    microemulsion. Patients who relapse or fail to improve within 72 hours should undergo stool tests to exclude an infection with Clostridium difficile, and proceed to surgery (see",
"    <a class=\"local\" href=\"#H527391152\">",
"     'Surgery'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Conversion to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is calculated by doubling the intravenous dose that had led to adequate levels, administered in divided doses 12 hours apart. For example, patients who had good response at levels of 4",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of intravenous cyclosporine would be converted to 8",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of oral cyclosporine microemulsion, delivered as 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours. Steady state is achieved after the third dose; trough levels are checked immediately prior to fourth dose, with a goal level of 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    to 300",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Levels below 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    have been associated with loss of response [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be discharged on oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    microemulsion, oral glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    enemas, and PCP prophylaxis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    or 6-mercaptopurine is started and the doses optimized over the ensuing weeks. We often first taper off the glucocorticoids over the first four to six weeks, and then taper off the oral cyclosporine microemulsion over the next six to eight weeks. Some patients may require shorter or longer durations of therapy. Patients who cannot stay well or get off of glucocorticoids should be evaluated for surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link&amp;anchor=H3#H3\">",
"     \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\", section on 'Dosage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link&amp;anchor=H165136853#H165136853\">",
"     \"Surgical management of ulcerative colitis\", section on 'Types of surgical procedures based upon clinical setting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Side effects and drug interactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are common, and some may be life-threatening. Thus, patients receiving therapy must be carefully monitored for electrolyte abnormalities, nephrotoxicity, hypertension, neurotoxicity, and infections. Prophylaxis against Pneumocystis pneumonia (PCP) during therapy is required. The side effects of cyclosporine, drug interactions, and strategies to minimize toxicity are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2190907126\">",
"    <span class=\"h4\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    has been used in patients with refractory ulcerative colitis, but its role has not yet been determined, especially when compared with alternative approaches such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . In one randomized trial, tacrolimus use was examined in 62 hospitalized patients with steroid-refractory ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients were assigned to either tacrolimus or placebo for two weeks. Patients treated with tacrolimus had a higher clinical response rate (50 versus 13 percent), mucosal healing rate (44 versus 13 percent), and clinical remission rate (9 versus 0 percent). Most experience with tacrolimus has been as a bridging agent to the purine analogues, similar to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. However, a least one study suggests that it may be effective for the maintenance of remission [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Anti-tumor necrosis factor therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-tumor necrosis factor (anti-TNF) therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    has been shown to induce and maintain remission in patients with moderate to severe ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Anti-TNF medication (eg, infliximab, adalimumab) can be used both for induction of remission and for maintenance and should be considered in patients who have failed or have an allergy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or 6-mercaptopurine. The safety, efficacy, and administration of these agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=see_link\">",
"     \"Anti-tumor necrosis factor therapy in ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527391152\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is indicated in patients with steroid-dependent ulcerative colitis who fail medical therapy, have intolerable side effects, or for colorectal dysplasia or cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     STEROID-REFRACTORY ULCERATIVE COLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not have a meaningful clinical response to glucocorticoids up to doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40 to 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (or equivalent) within 30 days for oral therapy or 7 to 10 days for IV therapy are considered to have steroid-refractory ulcerative colitis. Such patients should undergo careful re-evaluation to rule out the presence of an underlying infection, an alternate diagnosis including Crohn&rsquo;s disease and complications of ulcerative colitis. (See",
"    <a class=\"local\" href=\"#H89942021\">",
"     'Evaluation of a patient with steroid-dependent or steroid-refractory ulcerative colitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A subset of patients with steroid refractory ulcerative colitis who are on oral glucocorticoids can achieve a clinical response when switching to intravenous glucocorticoids (typically given as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    40 to 60 mg daily in single or divided doses, or equivalent) (",
"    <a class=\"graphic graphic_algorithm graphicRef75726 \" href=\"UTD.htm?23/19/23871\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/3,50-52\">",
"     3,50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who do not respond to IV glucocorticoids after three to seven days should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/53\">",
"     53",
"    </a>",
"    ]. Cyclosporine and infliximab have similar safety and efficacy in patients with acute severe colitis refractory to IV steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=see_link\">",
"     \"Anti-tumor necrosis factor therapy in ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to choose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in hospitalized patients with steroid refractory ulcerative colitis depends upon several factors. We use cyclosporine in those who are refractory to IV glucocorticoids as a short-term \"bridge\" to therapy with the slower onset, longer acting medications (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or 6-mercaptopurine). We use infliximab in patients who respond to glucocorticoids but who cannot transition to oral steroids or stay well on oral steroids (relapses within 12 weeks after steroid tapering), patients who cannot tolerate",
"    <span class=\"nowrap\">",
"     azathioprine/6-mercaptopurine",
"    </span>",
"    or who have failed",
"    <span class=\"nowrap\">",
"     azathioprine/6-mercaptopurine",
"    </span>",
"    (fails a taper in corticosteroids after 12 to 24 weeks of full dose",
"    <span class=\"nowrap\">",
"     azathioprine/6-mercaptopurine).",
"    </span>",
"    We also use infliximab in patients with hypertension, renal disease, seizure disorders, or other major comorbidities who are poor candidates for cyclosporine and in patients who are not able or willing to comply with strict dosing and monitoring requirements while on cyclosporine. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Adding a fast-acting second medication'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If a response is not seen in 7 to 10 days, we recommend surgery. Composite indices also appear to be reliable in predicting which patients will respond poorly to intensive medical treatment and will require colectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. For example, using the Oxford index, colectomy is likely to be necessary in a patient with ulcerative colitis if the C-reactive protein level is above 45",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    and a stool frequency of three to eight stools per day, or stool frequency greater than eight stools per day on day 3 after the initiation of treatment with intravenous glucocorticoids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/57,59\">",
"     57,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of the patients who respond, many of these patients will eventually require surgery within a year and thus it is important to discuss surgery as an option so that patients can undergo appropriate evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Investigations into dosing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    in succession (in either order) have shown mixed efficacy data and concerning adverse event rates arguing against trying both agents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/35,63\">",
"     35,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple experimental approaches have been tried in patients with ulcerative colitis. Some of these agents may have a role in refractory colitis, although many have not been studied in these patients. None of these agents can be recommended for routine use based on available data but they may be an option in the setting of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526355695\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled studies have suggested a benefit of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in patients with ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. No benefit was found in the only controlled trial. However, this study employed oral dosing and lower doses than demonstrated to be effective in Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/64\">",
"     64",
"    </a>",
"    ]. Retrospective studies of methotrexate in pediatric ulcerative colitis have had mixed results as well [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Until further data are available, the role of methotrexate in the treatment of ulcerative colitis remains unclear. A randomized placebo-controlled trial of methotrexate will be critical to evaluate the efficacy of methotrexate in ulcerative colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526355702\">",
"    <span class=\"h2\">",
"     Anti-integrin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integrins are proteins involved in regulating cellular movement including migration of leukocytes to the gut. A humanized monoclonal antibody to alpha4 beta7 integrin, vedolizumab, was more effective than placebo in achieving clinical and endoscopic remission in a short-term randomized controlled trial in patients with ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/69\">",
"     69",
"    </a>",
"    ]. In another randomized controlled trial of patients with active ulcerative colitis in which 374 patients were randomized to vedolizumab or placebo, a significantly greater proportion of vedolizumab-treated patients achieved clinical response (47 versus 25 percent), remission (17 versus 5 percent), and mucosal healing (41 versus 25 percent) at six weeks compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/70\">",
"     70",
"    </a>",
"    ]. In patients with prior anti-TNF-alpha failure (39 percent of the intention to treat population), the clinical response and remission rates were also higher in vedolizumab-treated than in placebo patients. Other molecules blocking the interaction between alpha4 beta7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM) have demonstrated a favorable short-term safety profile and preliminary efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526355709\">",
"    <span class=\"h2\">",
"     Budesonide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two phase 3 trials of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    with multi matrix release that can deliver budesonide through the colon demonstrated significantly lower eight-week remission rates in patients treated with 9 mg versus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. The rates of adverse events were similar between the two groups. Budesonide-MMX can be substituted to systemic steroids in patients with steroid-dependent ulcerative colitis to decrease the rate of steroid side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526355716\">",
"    <span class=\"h2\">",
"     Phosphatidylcholine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral phosphatidylcholine (believed to have a mucosal protective effect in colonic mucus) was more effective than placebo in a small controlled trial of patients with steroid-refractory ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/74\">",
"     74",
"    </a>",
"    ]. Additional trials with long-term follow-up are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526355723\">",
"    <span class=\"h2\">",
"     Tofactinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;A promising agent to treat refractory ulcerative colitis is the oral Janus kinase 3 (JAK3) inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/49/18198?source=see_link\">",
"     tofacitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/75\">",
"     75",
"    </a>",
"    ]. In a double-blind, placebo-controlled, phase 2 dose-ranging trial in 194 adults with moderately to severely active ulcerative colitis, patients treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/76\">",
"     76",
"    </a>",
"    ]. This agent is now undergoing phase 3 testing in refractory ulcerative colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526355730\">",
"    <span class=\"h2\">",
"     Anti-interleukin-2 receptor antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daclizumab is humanized antibody to the interleukin-2 receptor (CD25). Daclizumab showed initial success in a pilot study [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/77\">",
"     77",
"    </a>",
"    ] but not in a larger placebo-controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     Basiliximab",
"    </a>",
"    is a chimeric antibody to the interleukin-2 receptor (CD25). A small open-label study of a single infusion in patients with steroid-refractory ulcerative colitis showed remission in 9 of the 10 patients at eight weeks, although all but one patient relapsed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/79\">",
"     79",
"    </a>",
"    ]. Another uncontrolled study reported remission rates of 50 and 65 percent at 8 and 24 weeks, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/80\">",
"     80",
"    </a>",
"    ]. However, in a subsequent randomized controlled trial in which 149 patients on glucocorticoids for moderate to severe steroid-refractory ulcerative colitis were treated with basiliximab (20 or 40 mg) or placebo, remission rates were not significantly higher in the basiliximab group [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526355744\">",
"    <span class=\"h2\">",
"     Alicaforsen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alicaforsen is an inhibitor of intracellular adhesion molecule-1. Alicaforsen enemas showed efficacy in the treatment of distal ulcerative colitis and pouchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/82-85\">",
"     82-85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526355751\">",
"    <span class=\"h2\">",
"     Visilizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visilizumab",
"    <strong>",
"    </strong>",
"    is a humanized anti-CD3 monoclonal antibody. A pilot study in patients with severe ulcerative colitis that was refractory to intravenous glucocorticoids found 30-day response and remission rates of 84 and 41 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/86\">",
"     86",
"    </a>",
"    ]. However, subsequent studies have failed to show a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. In a randomized trial with 127 patients with steroid-refractory ulcerative colitis, there was no difference between patients who received visilizumab and those who received placebo with regard to mucosal healing (29 versus 26 percent), symptomatic response (82 versus 74 percent), or need for colectomy (18 versus 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/88\">",
"     88",
"    </a>",
"    ]. In addition, visilizumab has been associated with cytokine-release syndrome and there are concerns over reactivation of Epstein-Barr virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H526355765\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one placebo-controlled trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , a B-cell depleting agent (anti-CD 20), showed no benefit in steroid-refractory ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/89\">",
"     89",
"    </a>",
"    ]. In addition, exacerbation of ulcerative colitis has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2190907279\">",
"    <span class=\"h2\">",
"     Probiotics and fecal microbiota transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pathogenic role for enteric flora has been suggested in patients with ulcerative colitis since colitis does not develop in animal models raised in a germ-free environment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=see_link\">",
"     \"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This observation provided the rationale for controlled trials of probiotic therapy in patients with ulcerative colitis. However, probiotics have demonstrated variable efficacy in the treatment of ulcerative colitis and more studies are required before they can be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although available evidence is limited to case reports which have demonstrated variable results, it suggests that fecal microbiota transplantation (FMT) has the potential to be an effective and safe treatment for ulcerative colitis when standard treatments have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. In a 2012 systematic review of nine small observational studies of patients treated with FMT for inflammatory bowel disease, a significant proportion of patients experienced a reduction of symptoms (19 of 25) and remission (15 of 24) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/92\">",
"     92",
"    </a>",
"    ]. However, randomized controlled trials are required to establish the role of FMT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2190907372\">",
"    <span class=\"h2\">",
"     Fish oil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eicosapentaenoic acid (EPA) derived from fish oil is an inhibitor of leukotriene activity. In a placebo-controlled trial, EPA was effective as an adjunctive therapy in ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/94\">",
"     94",
"    </a>",
"    ]. Another placebo-controlled trial found that among 18 patients with active colitis, four months of fish oil was associated with decreased leukotriene B4 levels in the rectal dialysate, improvement in the histology index, weight gain, and a reduction in the steroid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/95\">",
"     95",
"    </a>",
"    ]. None of these benefits was seen during a placebo period in which vegetable oil capsules were given. An oral supplement enriched with fish oil, soluble fiber, and antioxidants was associated with a clinical response in another controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/96\">",
"     96",
"    </a>",
"    ]. By contrast, a meta-analysis of three trials found no evidence of benefit in maintenance of remission in UC [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2190907477\">",
"    <span class=\"h2\">",
"     Trichuris suis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease is common in industrialized countries and rare in regions of the developing world. A potential explanation is the relatively high rate of helminth colonization in less developed countries. Infection with helminths may reduce the risk of inflammatory bowel disease by modulating the mucosal immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential therapeutic aspect to this association was evaluated in a study involving 54 patients with active ulcerative colitis who were randomly assigned to ingestion of Trichuris suis ova or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/99\">",
"     99",
"    </a>",
"    ]. Improvement in disease activity was observed significantly more often in patients receiving active treatment (43 versus 17 percent). There were no side effects. Additional studies are needed before this approach can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9823814\">",
"    <span class=\"h2\">",
"     Curcumin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Curcumin may have a protective role in ulcerative colitis through modulation of the release of TNF-alpha and nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/100\">",
"     100",
"    </a>",
"    ]. However, there are limited data to support the use of curcumin in ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/101\">",
"     101",
"    </a>",
"    ]. In one randomized trial, 89 patients with quiescent ulcerative colitis on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    were treated with curcumin (2 grams daily) or placebo for six months for maintenance of remission [",
"    <a class=\"abstract\" href=\"UTD.htm?23/43/24250/abstract/102\">",
"     102",
"    </a>",
"    ]. Patients treated with curcumin had lower relapse rates at six months (4 versus 32 percent), but not at 12 months, as compared with placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182997134\">",
"    <span class=\"h2\">",
"     Steroid-dependent ulcerative colitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcerative colitis is defined as steroid-dependent if glucocorticoids cannot be tapered to less than 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      within three months of starting steroids without recurrent disease, or if relapse occurs within three months of stopping glucocorticoids.",
"     </li>",
"     <li>",
"      In patients with steroid-dependent ulcerative colitis, it is important to rule out the presence of an underlying infection (eg, cytomegalovirus [CMV]), alternative diagnosis (eg, Crohn&rsquo;s disease), concomitant conditions (irritable bowel syndrome, lactose intolerance, or stress), and assess medication compliance. (See",
"      <a class=\"local\" href=\"#H89942021\">",
"       'Evaluation of a patient with steroid-dependent or steroid-refractory ulcerative colitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H527391245\">",
"       'Avoidance of contributing factors and assessment of compliance'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with steroid-dependent ulcerative colitis, who are well on glucocorticoids, and able",
"      <span class=\"nowrap\">",
"       (and/or",
"      </span>",
"      willing) to remain on glucocorticoids while a second slow-acting maintenance medication is introduced, we recommend treatment with 6-mercaptopurine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The therapeutic effect of 6-mercaptopurine or azathioprine can take three to six months during which periodic attempts can be made to taper glucocorticoids. (",
"      <a class=\"graphic graphic_algorithm graphicRef65085 \" href=\"UTD.htm?14/60/15311\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H526355188\">",
"       'Steroid-dependent ulcerative colitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with steroid-dependent ulcerative colitis who are either not well on glucocorticoids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      are unable or unwilling to continue them, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or an anti-tumor necrosis factor (anti-TNF) agent, both of which have a rapid onset of action (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Cyclosporine is effective for induction of remission and can be used as a short-term \"bridge\" to therapy with the slower onset medications (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or 6-mercaptopurine). Anti-TNF medication (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ) can be used both for induction of remission and for maintenance and should be considered in patients who have failed or have an allergy to azathioprine or 6-mercaptopurine. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Adding a fast-acting second medication'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182997142\">",
"    <span class=\"h2\">",
"     Steroid-refractory ulcerative colitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Steroid-refractory ulcerative colitis is defined as ulcerative colitis that lacks of a meaningful clinical response to glucocorticoids up to doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      40 to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (or equivalent) within 30 days for oral therapy or 7 to 10 days for IV therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with steroid-refractory ulcerative colitis should undergo careful re-evaluation to rule out the presence of an underlying infection (eg, CMV) and alternative diagnosis (eg, Crohn&rsquo;s disease). (See",
"      <a class=\"local\" href=\"#H89942021\">",
"       'Evaluation of a patient with steroid-dependent or steroid-refractory ulcerative colitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend switching from oral to intravenous glucocorticoids as the first step in managing patients with steroid-refractory ulcerative colitis (",
"      <a class=\"graphic graphic_algorithm graphicRef75726 \" href=\"UTD.htm?23/19/23871\">",
"       algorithm 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). In patients who do not respond to intravenous glucocorticoids after three to seven days, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Patients who continue to be refractory to treatment will require surgery. (See",
"      <a class=\"local\" href=\"#H89942021\">",
"       'Evaluation of a patient with steroid-dependent or steroid-refractory ulcerative colitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Steroid-refractory ulcerative colitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/1\">",
"      Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/2\">",
"      Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/3\">",
"      Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/4\">",
"      Cohen JL, Strong SA, Hyman NH, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 2005; 48:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/5\">",
"      Bianchi Porro G, Cassinotti A, Ferrara E, et al. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 2007; 26:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/6\">",
"      Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995; 73:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/7\">",
"      Shine B, Berghouse L, Jones JE, Landon J. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985; 148:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/8\">",
"      Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002; 14:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/9\">",
"      Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/10\">",
"      Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/11\">",
"      Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008; 46:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/12\">",
"      Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006; 101:2857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/13\">",
"      Siddiki HA, Fidler JL, Fletcher JG, et al. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol 2009; 193:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/14\">",
"      Fletcher JG, Huprich J, Loftus EV Jr, et al. Computerized tomography enterography and its role in small-bowel imaging. Clin Gastroenterol Hepatol 2008; 6:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/15\">",
"      Fern&aacute;ndez-Ba&ntilde;ares F, Hinojosa J, S&aacute;nchez-Lombra&ntilde;a JL, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/16\">",
"      Levenstein S, Prantera C, Varvo V, et al. Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study. Am J Gastroenterol 1994; 89:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/17\">",
"      Levenstein S, Prantera C, Varvo V, et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 2000; 95:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/18\">",
"      Lerebours E, Gower-Rousseau C, Merle V, et al. Stressful life events as a risk factor for inflammatory bowel disease onset: A population-based case-control study. Am J Gastroenterol 2007; 102:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/19\">",
"      Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol 2009; 104:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/20\">",
"      Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96:2929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/21\">",
"      Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/22\">",
"      Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/23\">",
"      Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000; 19:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/24\">",
"      Sood A, Kaushal V, Midha V, et al. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002; 37:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/25\">",
"      Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/26\">",
"      Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/27\">",
"      Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/28\">",
"      Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/29\">",
"      Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; :CD000478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/30\">",
"      Andrews JM, Travis SP, Gibson PR, Gasche C. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther 2009; 29:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/31\">",
"      Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001; 13:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/32\">",
"      Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004; 99:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/33\">",
"      Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/34\">",
"      Cohen RD. How should we treat severe acute steroid-refractory ulcerative colitis? Inflamm Bowel Dis 2009; 15:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/35\">",
"      Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008; 6:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/36\">",
"      Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/37\">",
"      Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/38\">",
"      Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis 1999; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/39\">",
"      Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol 1997; 92:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/40\">",
"      Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/41\">",
"      Rayner CK, McCormack G, Emmanuel AV, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/42\">",
"      Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012; 18:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/43\">",
"      Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/44\">",
"      Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci 2006; 51:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/45\">",
"      Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 2008; :CD007216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/46\">",
"      Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol 2006; 101:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/47\">",
"      Yamamoto S, Nakase H, Matsuura M, et al. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol 2011; 45:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/48\">",
"      Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/49\">",
"      Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/50\">",
"      Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/51\">",
"      Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/52\">",
"      J&auml;rnerot G, Rolny P, Sandberg-Gertz&eacute;n H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/53\">",
"      J&auml;rnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/54\">",
"      Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/55\">",
"      Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/56\">",
"      Seo M, Okada M, Yao T, et al. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002; 37:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/57\">",
"      Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/58\">",
"      Saito K, Katsuno T, Nakagawa T, et al. Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula. Aliment Pharmacol Ther 2012; 36:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/59\">",
"      Travis S, Satsangi J, L&eacute;mann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut 2011; 60:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/60\">",
"      Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/61\">",
"      Baudet A, Rahmi G, Bretagne AL, et al. Severe ulcerative colitis: present medical treatment strategies. Expert Opin Pharmacother 2008; 9:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/62\">",
"      Gustavsson A, J&auml;rnerot G, Hertervig E, et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010; 32:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/63\">",
"      Chaparro M, Burgue&ntilde;o P, Iglesias E, et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther 2012; 35:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/64\">",
"      Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/65\">",
"      Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993; 38:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/66\">",
"      Cummings JR, Herrlinger KR, Travis SP, et al. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005; 21:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/67\">",
"      Aloi M, Di Nardo G, Conte F, et al. Methotrexate in paediatric ulcerative colitis: a retrospective survey at a single tertiary referral centre. Aliment Pharmacol Ther 2010; 32:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/68\">",
"      Willot S, Noble A, Deslandres C. Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center. Inflamm Bowel Dis 2011; 17:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/69\">",
"      Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352:2499.",
"     </a>",
"    </li>",
"    <li>",
"     Feagan B, Rutgeerts P, Sands B, et al. Vedolizumab induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial. DDW abstract, San Diego 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/71\">",
"      Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011; 60:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/72\">",
"      Sandborn WJ, Travis S, Moro L, et al. Budesonide MMX&reg; 9 mg for the induction of remission of mild-to-moderate ulcerative colitis (UC): Data from a multicenter, randomized, double-blind placebo-controlled study in North America and India. Gastroenterology 2011; 140:S124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/73\">",
"      Sandborn WJ, Travis S, Danese S, et al. Budesonide-MMX&reg; 9 mg for induction of remission of mild-to-moderate ulcerative colitis (UC): Data from a multicenter, randomized, double-blind placebo-controlled study in the Europe, Russia, Israel and Australia. Gastroenterology 2011; 140:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/74\">",
"      Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 2007; 147:603.",
"     </a>",
"    </li>",
"    <li>",
"     Sandborn W, Ghosh S, Panes J, et al. Phase 2 study of CP-690,550, an oral janus kinase inhibitor, in active ulcerative colitis. DDW abstract 594, Chicago, IL 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/76\">",
"      Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/77\">",
"      Van Assche G, Dalle I, Noman M, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003; 98:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/78\">",
"      Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006; 55:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/79\">",
"      Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003; 18:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/80\">",
"      Creed TJ, Probert CS, Norman MN, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006; 23:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/81\">",
"      Sands BE, Sandborn WJ, Creed TJ, et al. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology 2012; 143:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/82\">",
"      Miner PB Jr, Geary RS, Matson J, et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 2006; 23:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/83\">",
"      Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 2006; 23:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/84\">",
"      van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004; 53:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/85\">",
"      van Deventer SJ, Wedel MK, Baker BF, et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006; 23:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/86\">",
"      Plevy S, Salzberg B, Van Assche G, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007; 133:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/87\">",
"      Sparrow M. Visilizumab in severe ulcerative colitis: good vision but blurry results. Inflamm Bowel Dis 2008; 14:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/88\">",
"      Sandborn WJ, Colombel JF, Frankel M, et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 2010; 59:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/89\">",
"      Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011; 60:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/90\">",
"      El Fassi D, Nielsen CH, Kjeldsen J, et al. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008; 57:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/91\">",
"      Goetz M, Atreya R, Ghalibafian M, et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007; 13:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/92\">",
"      Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/93\">",
"      Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/94\">",
"      Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol 1992; 87:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/95\">",
"      Stenson WF, Cort D, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 1992; 116:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/96\">",
"      Seidner DL, Lashner BA, Brzezinski A, et al. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005; 3:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/97\">",
"      Turner D, Steinhart AH, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; :CD006443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/98\">",
"      Elliott DE, Summers RW, Weinstock JV. Helminths and the modulation of mucosal inflammation. Curr Opin Gastroenterol 2005; 21:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/99\">",
"      Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005; 128:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/100\">",
"      Arafa HM, Hemeida RA, El-Bahrawy AI, Hamada FM. Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model. Food Chem Toxicol 2009; 47:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/101\">",
"      Kumar S, Ahuja V, Sankar MJ, et al. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10:CD008424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/43/24250/abstract/102\">",
"      Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4:1502.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4060 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24250=[""].join("\n");
var outline_f23_43_24250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89942021\">",
"      EVALUATION OF A PATIENT WITH STEROID-DEPENDENT OR STEROID-REFRACTORY ULCERATIVE COLITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89940863\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89940949\">",
"      Stool studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3946366\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H526355188\">",
"      STEROID-DEPENDENT ULCERATIVE COLITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H527391245\">",
"      Avoidance of contributing factors and assessment of compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526356962\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Adding a slow-acting second medication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Adding a fast-acting second medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2190907126\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anti-tumor necrosis factor therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H527391152\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      STEROID-REFRACTORY ULCERATIVE COLITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EXPERIMENTAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526355695\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526355702\">",
"      Anti-integrin antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526355709\">",
"      Budesonide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526355716\">",
"      Phosphatidylcholine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526355723\">",
"      Tofactinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526355730\">",
"      Anti-interleukin-2 receptor antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526355744\">",
"      Alicaforsen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526355751\">",
"      Visilizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H526355765\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2190907279\">",
"      Probiotics and fecal microbiota transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2190907372\">",
"      Fish oil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2190907477\">",
"      Trichuris suis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9823814\">",
"      Curcumin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182997134\">",
"      Steroid-dependent ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182997142\">",
"      Steroid-refractory ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4060\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4060|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/60/15311\" title=\"algorithm 1\">",
"      Steroid dependent UC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/19/23871\" title=\"algorithm 2\">",
"      Steroid refractory UC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=related_link\">",
"      Anti-tumor necrosis factor therapy in ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=related_link\">",
"      Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=related_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13722?source=related_link\">",
"      Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=related_link\">",
"      Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8279?source=related_link\">",
"      Irritable bowel syndrome in patients with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=related_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=related_link\">",
"      Nutrition and dietary interventions in adults with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_43_24251="Vasopressors in septic shock";
var content_f23_43_24251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vasoactive agents in septic shock",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect on heart rate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect on contractility",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arterial constriction effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dobutamine",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        - (dilates)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dopamine",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epinephrine",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norepinephrine",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenylephrine",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amrinone",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -- (dilates)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24251=[""].join("\n");
var outline_f23_43_24251=null;
var title_f23_43_24252="Congen dyseryth anemias";
var content_f23_43_24252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Congenital dyserythropoietic anemias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bone Marrow",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anemia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acidified serum test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene localization",
"       </td>",
"       <td class=\"subtitle1\">",
"        MCV",
"       </td>",
"       <td class=\"subtitle1\">",
"        i antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Megaloblastoid erythroid hyperplasia; Nuclear chromatin bridges between erythroblasts",
"       </td>",
"       <td>",
"        Mild- moderate",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        15q15.1-15.3",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II (HEMPAS*)",
"       </td>",
"       <td>",
"        Erythroblastic multinuclearity",
"       </td>",
"       <td>",
"        Mild- severe",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        20q11.1",
"       </td>",
"       <td>",
"        Normal or increased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Erythroblastic multinuclearity (up to 12 nuclei) with gigantoblasts",
"       </td>",
"       <td>",
"        Mild- moderate",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        AD, sporadic cases",
"       </td>",
"       <td>",
"        15q22",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Erythroblastic multinuclearity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Normal or increased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AR: autosomal recessive; AD: autosomal dominant.",
"     <br>",
"      * HEMPAS: Hereditary Erythroblastic Multinuclearity with Positive Acidified Serum test.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <ol>",
"      <li>",
"       Alter BP, Young NS. The bone marrow failure syndromes. In: Nathan and Oski's Hematology of Infancy and Childhood, Nathan DG, Orkin SH (Eds), W.B. Saunders Company, 1998, p.237",
"      </li>",
"      <li>",
"       Wickramasinghe SN. Congenital dyserythropoietic anaemias: clinical features, haematological morphology and new biochemical data. Blood Rev 1998; 12:178",
"      </li>",
"      <li>",
"       Gasparini P, Miraglia del Giudice E, Delaunay, J, et al. Localization of the congenital dyserythropoietic anemia II locus to chromosome 20q11.2 by genomewide search. Am J Hum Genet 1997; 61:1112&nbsp;",
"      </li>",
"      <li>",
"       Benjamin JT, Rosse WF, Daldorf FG, McMillan CW. Congenital dyserythropoietic anemia - type IV. J Pediatr 1975; 87:210.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24252=[""].join("\n");
var outline_f23_43_24252=null;
var title_f23_43_24253="Neurologic deficits in spinal injury";
var content_f23_43_24253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neurologic deficits in spinal cord injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Level of Lesion",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Loss of Function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Motor*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sensory level",
"       </td>",
"       <td class=\"subtitle2\">",
"        Reflex*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Cervical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Occiput",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Thyroid cartilage",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        C4",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Spontaneous breathing",
"       </td>",
"       <td>",
"        Suprasternal notch",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        C5",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Shrugging and external rotation of shoulders",
"       </td>",
"       <td>",
"        Below clavicle",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Biceps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Middle deltoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C6",
"       </td>",
"       <td>",
"        Elbow flexion Wrist extension",
"       </td>",
"       <td>",
"        Thumb",
"       </td>",
"       <td>",
"        Brachioradialis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        C7",
"       </td>",
"       <td>",
"        Elbow extension",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Index and middle&nbsp;fingers",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Triceps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wrist flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C8",
"       </td>",
"       <td>",
"        Finger flexion",
"       </td>",
"       <td>",
"        Small finger and ulnar side of hand",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Thoracic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T1 - T12",
"       </td>",
"       <td>",
"        Intercostal and abdominal muscles",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Nipple line",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Umbilicus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Lumbar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Femoral pulse",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L1 - L2",
"       </td>",
"       <td>",
"        Hip flexion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L2 - L3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Medial thigh",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L3&nbsp;",
"       </td>",
"       <td>",
"        Hip adduction",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L4",
"       </td>",
"       <td>",
"        Hip abduction",
"       </td>",
"       <td>",
"        Knee",
"       </td>",
"       <td>",
"        Patellar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L5",
"       </td>",
"       <td>",
"        Foot dorsiflexion",
"       </td>",
"       <td>",
"        Lateral calf",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Sacral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        S1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Lateral foot",
"       </td>",
"       <td>",
"        Achilles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        S1 - S2",
"       </td>",
"       <td>",
"        Foot plantar flexion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        S2 - S4",
"       </td>",
"       <td>",
"        Rectal sphincter tone",
"       </td>",
"       <td>",
"        Perianal region",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Level of injury is at or above the given location.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Rosen, P, Barkin, R, Danzl, DF, et al. Emergency Medicine: Concepts and Clinical Practice, 4th ed, Mosby-Year Book, St. Louis 1998. p.481 and Tachdjian, MO. The neck and upper limb. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management. Appleton and Lange, Stamford, CT 1997. p.263.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24253=[""].join("\n");
var outline_f23_43_24253=null;
var title_f23_43_24254="Contents: Skin soft tissue bone infection";
var content_f23_43_24254=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Skin soft tissue bone infection",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Skin soft tissue bone infection",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Myositis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/19/22839\">",
"           Psoas abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32950\">",
"           Pyomyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/41/9879\">",
"           Viral myositis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteomyelitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/50/12071\">",
"           Approach to imaging modalities in the setting of suspected osteomyelitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/33/538\">",
"           Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/46/42726\">",
"           Hematogenous osteomyelitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/34/4649\">",
"           Overview of osteomyelitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/22/39269\">",
"           Pathogenesis of osteomyelitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/20/23876\">",
"           Pelvic osteomyelitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/49/37656\">",
"           Skeletal tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/25/10646\">",
"           Treatment and prevention of osteomyelitis following trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/28/22985\">",
"           Vertebral osteomyelitis and discitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Septic arthritis/bursitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/43/42680\">",
"           Clinical manifestations and diagnosis of prosthetic joint infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/56/3976\">",
"           Disseminated gonococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/4/20550\">",
"           Infectious tenosynovitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/34/28198\">",
"           Prevention of prosthetic joint infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/50/11049\">",
"           Septic arthritis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/30/33256\">",
"           Septic bursitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/56/20360\">",
"           Synovial fluid analysis and the diagnosis of septic arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/19/6457\">",
"           Treatment of prosthetic joint infections",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12825\">",
"           Cellulitis and erysipelas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14803\">",
"           Cellulitis following pelvic lymph node dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/55/22387\">",
"           Folliculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21846\">",
"           Impetigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/44/24262\">",
"           Recurrent cellulitis after saphenous venectomy for coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43831\">",
"           Skin abscesses, furuncles, and carbuncles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Soft tissue infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/37/33365\">",
"           Botryomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30648\">",
"           Candidal intertrigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/33/538\">",
"           Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/62/12264\">",
"           Clostridial myonecrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/35/36406\">",
"           Epidemiology and pathogenesis of and risk factors for surgical site infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/0/11268\">",
"           Infection in mesh graft following hernia repair: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/39/31350\">",
"           Infectious complications of pressure ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/362\">",
"           Necrotizing soft tissue infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31290\">",
"           Overview of control measures to prevent surgical site infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/36/25158\">",
"           Overview of puncture wounds",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/48/1800\">",
"           Postoperative mediastinitis after cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/8/43142\">",
"           Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28038\">",
"           Soft tissue infections due to dog and cat bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31013\">",
"           Soft tissue infections due to human bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31687\">",
"           Soft tissue infections following water exposure",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-44966F735A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f23_43_24254=[""].join("\n");
var outline_f23_43_24254=null;
var title_f23_43_24255="Gallstone in gallbladder US";
var content_f23_43_24255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cholelithiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound of the gallbladder shows posterior acoustic shadowing (arrowhead) produced by a stone in the lumen of the gallbladder (arrow). There is no gallbladder wall thickening, a finding that may be seen with cholecystitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_43_24255=[""].join("\n");
var outline_f23_43_24255=null;
